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Abstract 
Development of a Multi-Functional Biopolymer Scaffold for Neural Tissue Engineering 
Nicola Louise Francis 
Margaret A. Wheatley, Ph.D. 
 
 
 
 
Spinal cord injury (SCI) affects approximately 270,000 people in the U.S., with 
approximately 12,000 new cases occurring every year. Several strategies have been 
investigated to enhance axonal regeneration after SCI, however, the resulting growth can 
be random and disorganized. Bioengineered scaffolds provide a physical substrate for the 
guidance of regenerating axons towards their targets, and can be produced by freeze 
casting. This technique involves the controlled directional solidification of an aqueous 
solution or suspension, resulting in a linearly aligned porous structure caused by ice 
templating. In this thesis, freeze casting was used to create novel porous chitosan-alginate 
(C/A) scaffolds with longitudinally aligned channels and a compressive modulus (5.08 ± 
0.61 kPa) comparable to that of native spinal cord tissue. These C/A scaffolds supported 
the viability, attachment, and directionally oriented growth of chick dorsal root ganglia 
(DRG) neurites in vitro, with surface adsorptions of polycations and laminin promoting 
significantly longer neurite growth than the uncoated scaffolds (p<0.001). 
In order to integrate therapeutic biomolecules within the scaffolds for sustained 
release, alginate and chitosan microcapsules produced by spray drying were used to 
encapsulate brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), and 
the enzyme chondroitinase ABC (chABC) prior to scaffold incorporation. BDNF and 
NT-3 were released from the C/A scaffolds in a sustained manner for 8 weeks in vitro, 
while chABC was released for up to 35 days. However, up to 85% of biomolecules 
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remained entrapped within the scaffold walls, due to limitation of diffusion by the 
scaffold wall mesh size. Release of bioactive chABC and neurotrophins from the multi-
functional scaffolds promoted the growth of DRG neurites through an in vitro barrier of 
chondroitin sulfate proteoglycans, a main inhibitory component of the growth-inhibiting 
glial scar in the injured spinal cord. The present data suggest these multi-functional 
scaffolds are suitable for use and future testing in vivo as a combination strategy for 
spinal cord repair due to their ability to promote the directionally oriented growth of 
neurites and their ability to provide the sustained release of therapeutic bioactive 
molecules for the stimulation of axonal growth through the glial scar. 
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1. INTRODUCTION 
1.1 Statement of the Problem 
An estimated 270,000 people are affected by spinal cord injury (SCI) in the 
United States, with approximately 12,000 new cases reported each year [1]. Since 2005, 
the most prevalent cause of SCI is vehicular accidents, followed by falls, acts of violence, 
and sports injuries. The effects of SCI depend on the level and type of injury and include 
complications such as loss of sensation and/or motor function, bowel, bladder, and sexual 
dysfunction, and chronic pain [2]. Average expenses for the first year after injury vary 
according to the severity of the injury, but can reach approximately $1 million, with 
estimated lifetime costs up to $4.5 million [1]. After the initial traumatic injury to the 
spinal cord, several secondary injury mechanisms exacerbate the injury by triggering a 
damaging cascade of cellular and molecular responses. In addition to necrosis caused by 
the primary injury, these secondary responses lead to the formation of a cystic cavity at 
the site of injury surrounded by growth-inhibiting glial scar tissue[3]. 
Regeneration in the injured spinal cord is inhibited by the formation of glial scar 
tissue, the presence of inhibitory molecules contained within this scar, the failure to 
produce molecules necessary to promote axon growth, and the poor regenerative ability 
of most CNS neurons [4]. Several strategies have been investigated to promote SCI 
repair, including cell transplantation, application of neurotrophic factors, administration 
of enzymes to remove growth inhibiting molecules, implantation of nerve guidance 
channels, and combinations of these treatments. Currently, there is no treatment available 
that is capable of completely restoring function after SCI. Since there are various barriers 
to regeneration in the injured spinal cord, several investigators agree that a combination 
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approach is best suited to promote axonal growth across a spinal cord lesion and promote 
functional recovery. Providing a growth permissive substrate in the form of a biomaterial 
scaffold while delivering molecules that can degrade the inhibitory glial scar and/or 
promote axon growth will encourage axons to bridge the lesion at the site of injury. 
 
1.2 Specific Aims 
The overall goal of this research was to create a multi-functional natural polymer 
scaffold in order to provide a combination of strategies for regeneration in the injured 
spinal cord. A three-dimensional, directionally solidified natural polymer matrix will 
provide a growth permissive physical substrate for neuronal cell adhesion and growth, 
acting as a nerve guidance channel to facilitate neuronal regeneration across spinal cord 
lesions. The scaffold can also provide spatial localization for the incorporation of a 
variety of encapsulated biomolecules, such as extracellular matrix (ECM) proteins and 
neurotrophic factors, enhancing neuronal cell attachment and growth throughout the 
porous scaffold. Further, incorporating the enzyme chondroitinase ABC (chABC) into the 
scaffold will facilitate the degradation of a growth-inhibiting glial scar at the injury site. 
Sustained release of these biomolecules from the scaffold will promote axonal 
regeneration in the injured spinal cord. In this study, the components of this multi-
functional scaffold were developed individually and collectively in order to determine 
effects on neurite growth in vitro and prepare for future in vivo work.  
Specifically, the aims of this project were: 
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1)  To develop a linearly aligned, porous chitosan-alginate (C/A) scaffold for use as an 
aid for spinal cord repair  
a) Use a freeze casting method to fabricate a linearly aligned, porous scaffold from a 
chitosan-alginate polyelectrolyte complex (PEC) mixture  
b) Incorporate laminin into the scaffold in order to promote neuronal cell attachment 
and growth 
Hypothesis: Directional solidification of a chitosan-alginate PEC mixture will produce a 
linearly aligned, porous scaffold that will support the directionally oriented growth of 
DRG neurites in vitro. The chitosan-alginate scaffold will be fabricated at a physiological 
pH of 7.4, permitting the future incorporation of bioactive molecules without the risk of 
denaturation due to pH extremes or organic solvents.  
 
2)  To incorporate bioactive molecules within the C/A scaffold in order to provide their 
sustained release  
a) Develop a method for encapsulating bioactive molecules for inclusion within the 
scaffold 
b) Incorporate neurotrophic factors (i.e. brain-derived neurotrophic factor (BDNF); 
neurotrophin-3 (NT-3)) within the scaffold in order to promote axon growth 
c) Incorporate chABC within the scaffold in order to degrade growth inhibitory 
molecules present in the glial scar 
d) Determine the release profiles of incorporated biomolecules from the C/A 
scaffolds 
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Hypothesis: Neurotrophic factors such as BDNF and NT-3 enhance the survival and 
growth of neurons in the injured spinal cord. Encapsulating these neurotrophins within 
the C/A scaffold will result in their sustained release, thereby demonstrating the efficacy 
of the C/A scaffold as a neurotrophin delivery vehicle for spinal cord repair. Applying 
chABC to a spinal cord injury site degrades growth-inhibiting chondroitin sulfate 
proteoglycans (CSPGs) and promotes axonal regeneration, however, this enzyme has a 
half-life of only a few hours. Providing sustained delivery of thermostabilized chABC via 
its controlled release from a C/A scaffold will effectively degrade CSPGs in vitro. 
 
3)  To determine the effects of the multi-functional scaffold on neurite growth in vitro 
a) Determine the bioactivity of the biomolecules released from the scaffold (BDNF, 
NT-3, chABC) 
b) Evaluate the effects of a combination of biomolecules released from the C/A 
scaffold on in vitro neurite growth 
Hypothesis: Neurotrophic factors released from the scaffold will maintain bioactivity and 
promote significantly longer neurite growth than the scaffold without these factors. A 
combination of incorporated chABC and neurotrophic factors released from the C/A 
scaffold will have a synergistic effect on neurite growth promoting penetration of an in 
vitro glial scar. Studies have demonstrated the synergistic effects of injections of chABC 
and neurotrophic factors (BDNF) on nerve growth in the injured rat brain. The constant, 
localized supply of neurotrophic factors and stabilized presentation of chABC from the 
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C/A scaffold can provide a similar beneficial effect, without the need for re-application or 
surgical implantation of pumps.  
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2. BACKGROUND 
2.1 Spinal Cord Injury 
2.1.1 Anatomy of the Spinal Cord 
The human spinal cord extends from the foramen magnum, a large opening in the 
occipital bone of the skull, down to the first or second lumbar vertebrae. The cord 
transmits sensory and motor information between the brain and the peripheral nervous 
system. A cross-section of the spinal cord reveals a central butterfly-shaped region of 
grey matter, surrounded by white matter (Figure 2.1). The grey matter contains the cell 
bodies of neurons and glia, dendrites and axons, while the white matter is composed 
mostly of ascending and descending tracts of myelinated axons and glia. The spinal cord 
is divided into 31 segments, each of which has a pair of spinal nerves and a dorsal and 
ventral root, except the first cervical segment which only has a ventral root. Each dorsal 
root has a nodule known as a dorsal root ganglion, containing the cell bodies of sensory 
neurons[5]. 
Both the brain and spinal cord are protected by the meninges, which consists of 
three layers: the dura mater (tough outer sheath), the arachnoid mater (middle protective 
layer), and the pia mater (delicate innermost protective membrane). The pia mater, which 
is adherent to the surface of the spinal cord, has 20-22 pairs of laterally extending 
denticulate ligaments which connect to the dura mater to stabilize the spinal cord. The 
subarachnoid space, located between the arachnoid mater and the pia mater, the ventricles 
of the brain, and the central canal of the spinal cord contain cerebrospinal fluid (CSF). 
This fluid aids in the protection of the central nervous system (CNS) by cushioning the 
brain and spinal cord from impact [6, 7]. 
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Figure 2.1 Cross-sectional anatomy of the spinal cord [8]  
 
 
 
 
2.1.2 Cellular and Molecular Responses After SCI 
 There are two mechanisms of damage to the spinal cord after acute spinal cord 
injury. The pathophysiology of acute spinal cord injury is divided into two main phases: 
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primary injury and secondary injury. The primary injury consists of the focal destruction 
of neural tissue caused by direct mechanical trauma [9]. Mechanical forces applied at the 
primary injury site can shear neuronal and endothelial cell membranes, leading to 
immediate necrosis and hemorrhage. This initial trauma then instigates a progressive 
wave of secondary injury, an interdependent cascade of cellular and systemic events 
which can last for days to weeks and exacerbates injury to the spinal cord[10]. Secondary 
injury mechanisms include hemorrhage, ischemia and reperfusion injury, excitotoxicity, 
calcium-mediated secondary injury, disturbances in mitochondrial function, immunologic 
injury, apoptosis and axonal degeneration[11]. Several of these secondary injury 
mechanisms cause the formation of a large cystic cavity at the injury site, which often 
expands beyond the site of initial impact [9].  
 Damage to the spinal cord produces an injury response known as reactive gliosis, 
or glial scarring. Within hours of injury, macrophages from the bloodstream and 
microglia from the surrounding tissue migrate to the site of injury and are joined by 
oligodendrocyte precursors after 3-5 days. If the injury penetrates the meninges, 
meningeal cells migrate to re-form the disrupted glia limitans that surrounds the CNS. 
Finally, reactive astrocytes slowly penetrate into the injury site and proliferate, forming 
the bulk of the glial scar along with these other cells. In its final form, the glial scar 
consists mostly of a meshwork of tightly interwoven astrocyte processes, bound together 
by tight and gap junctions, which surrounds the large cystic cavity at the area of 
injury[3].  
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Figure 2.2: Illustration of spinal cord injury site [12] 
 
 
 
 The rigid structure of the glial scar and associated growth inhibitory molecules 
present a mechanical and molecular barrier to axonal regeneration[9]. The dense glial 
scar network can block advancement of the growth cone, while growth inhibitory 
molecules can actively inhibit axon growth[13]. The inhibitory molecules upregulated 
after SCI consist of molecules produced by cells present in the glial scar and myelin-
associated inhibitory molecules. Most of the cell types present in the glial scar produce 
molecules that have been shown to inhibit axon regeneration. Reactive astrocytes at the 
injury site release inhibitory extracellular (ECM) matrix molecules known as chondroitin 
sulfate proteoglycans (CSPGs), which are one of the main growth inhibitory molecules in 
the injured CNS. CSPGs are composed of several core proteins (versican, neurocan, 
NG2, phosphacan, brevican, aggrecan, and biglycan) containing varying numbers of 
large, highly sulfated glycosaminoglycan (GAG) side chains[14]. Neurocan, brevican, 
and versican were shown to be upregulated within days of SCI and peaked at 2 weeks 
post-injury [15]. CSPGs have been shown to be inhibitory to axon growth in vitro and in 
vivo [16, 17]. Inhibitory glycoproteins such as tenascins are also produced by astrocytes 
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and oligodendrocytes. Activated microglia produce nitric oxide, free radicals, and 
arachidonic acid derivatives, contributing to the growth inhibitory environment [3]. 
Myelin inhibitory molecules such as Nogo, myelin-associated glycoprotein 
(MAG) and oligodendrocyte myelin glycoprotein (OMgp), are present in the glial scar 
due to mature oligodendrocytes and myelin debris[18]. MAG and OMgp were shown to 
inhibit neurite outgrowth in vitro, with OMgp also inducing growth cone collapse [19, 
20]. Investigated methods to promote axonal regeneration through the glial scar include 
blocking or removing these growth inhibitory molecules. 
 
2.1.3 Current Clinical Treatments 
 There are very few current clinical treatment options available for acute SCI in 
humans. The first step in medical treatment is to immobilize the spine of the patient to 
maintain spinal alignment and prevent further damage and/or recompression of the injury 
site. Surgical intervention to stabilize and decompress the spinal cord can be safely 
performed within the first 24 hours after injury [21]. After the initial treatment and 
stabilization of patients with SCI, most of the treatment is focused on physical 
rehabilitation and treatment of symptoms. 
 Methylprednisolone, a synthetic corticosteroid typically used to treat 
inflammation, is a drug used in high doses for acute SCI treatment in humans. Treatment 
with methylprednisolone can help to lessen the severity of the injury by reducing 
inflammation, but this treatment must start within no more than eight hours after injury 
and continue for 24-48 hours [22]. However, the use of methylprednisolone is debated, 
since high doses of the steroid can cause significant side effects and there is no 
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convincing evidence that it improves neurological outcome [23]. Several clinical studies 
have reported the efficacy of therapeutic hypothermia in improving long term functional 
recovery in patients with severe cervical SCI [24]. However, this treatment remains an 
experimental clinical approach. The current clinical treatments available serve as 
measures to prevent further damage and to treat the symptoms of SCI, rather than 
promote SCI repair. 
 
2.2 Spinal Cord Repair Strategies 
2.2.1 Delivery of Neurotrophic Factors 
 Neurotrophic factors are proteins that enhance neuronal survival, proliferation, 
differentiation, migration, axon growth, and synaptic plasticity[25]. In addition to 
contributing to neuronal survival and differentiation during development, they promote 
repair and recovery after CNS injury[25]. These growth factors include nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), 
neurotrophin-4/5, glial cell-line derived neurotrophic factor (GDNF), and ciliary 
neurotrophic factor (CNTF), among others. The term neurotrophin refers to NGF, BDNF, 
NT-3 and NT-4/5, a family of structurally related growth factors. Neurotrophins bind to 
two types of transmembrane receptors, trk (high affinity receptors) and p75 (low affinity 
receptors). NGF binds with high affinity to trkA, while BDNF and NT-4/5 bind to trkB, 
and NT-3 binds to trkC. The activated ligand-receptor complex is internalized and 
transported to the neuronal cell body, where it can activate transcriptional mechanisms, 
leading to appropriate changes in gene expression and local signals acting at the growth 
cone for axon extension[26, 27]. 
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 Application of these neurotrophic factors alone or in combination has been shown 
to promote axonal regeneration in the injured spinal cord and recovery of function [28-
32]. BDNF displays a wider trophic activity for CNS neurons than NGF, supporting the 
growth of axons in several motor and sensory axon tracts within the spinal cord [26, 33]. 
NT-3 promotes the growth of corticospinal axons, the most important upper motor 
neuron population in humans [30]. These two neurotrophins are the most frequently 
investigated for SCI repair strategies because of their ability to promote the growth of 
motor axons[33]. Conversely, NGF and GDNF promote the growth of nociceptive (pain 
receptive) axons, which may risk dysfunctional axon sprouting and increased sensations 
of pain after SCI treatment[33].   
Neurotrophic factors have been delivered to the spinal cord via direct injection, 
continuous infusion using osmotic pumps, genetically modified cells, and insertion of 
saturated scaffolds[30, 34-36]. Systemic administration is not possible for the 
administration of neurotrophic factors to the spinal cord, since they cannot cross the 
blood-brain barrier or blood-CSF barrier. Although an effective method of prolonged, 
local delivery of neurotrophic factors is the use of genetically modified cells, the resulting 
long-term expression of neurotrophic factors can lead to excessive axon sprouting and 
failure of axons to leave the graft site and reinnervate the distal spinal cord [37]. . 
However, if a neurotrophic factor source is established beyond the site of injury, axons 
can bridge the lesion site and extend into the distal spinal cord [38, 39]. 
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2.2.2 Removing Growth Inhibitory Molecules 
As described above, there are several growth inhibitory molecules present in the 
glial scar. There has been some success in promoting axonal growth by degrading 
CSPGs, the predominant inhibitory molecule found at the injury site [17, 40].  The 
molecular mechanisms by which CSPGs inhibit axonal growth are not well known, and 
these inhibitory actions are dependent on the sulfation pattern and amount of GAG 
chains[41]. Investigators have identified various mechanisms of CSPG inhibition: 
interference with ECM-integrin signaling [42-44], binding of various cell surface 
receptors, [45-47] ; and activation of downstream signaling cascades [48, 49] . 
Regardless of the particular mechanism of action, removing CSPG glycosaminoglycan 
(GAG) chains lessens these growth inhibitory effects [17]. These GAG chains can be 
degraded through the application of chondroitinase ABC (chABC), an enzyme produced 
by the bacteria Proteus vulgaris.  
Two distinct chondroitinase ABC lyases have been identified in Proteus vulgaris, 
chABC (endolyase) I and chABC II (exolyase)[50]. ChABC I degrades chondroitin 
sulfate and related polysaccharides to produce tetrasaccharides and disaccharides, while 
chABC II degrades chondroitin sulfate tetra- and hexasaccharides, yielding respective 
disaccharides [50, 51]. These lyases degrade their substrates via a β-elimination reaction 
that generates products with an unsaturated 4,5-bond on the uronic acid at the cleavage 
site[52]. ChABC (commercially available as a combination of the two lyases, unless 
highly purified) has a broad substrate specificity, degrading a variety of GAG substrates 
such as chondroitin-6-sulfate, chondroitin-4-sulfate, dermatan sulfate, and hyaluronic 
acid[51]. Application of chABC to lesioned dorsal columns of adult rats has been shown 
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to degrade GAG chains at the injury site, upregulate a regeneration-associated protein in 
injured neurons, and promote axonal regeneration[17]. Many investigators have reported 
axonal regeneration and functional recovery after the application of chABC alone to 
various rat or cat spinal cord injury models ranging from contusion to full transection[17, 
53-56]. In addition, combination treatments of chondroitinase ABC and the following 
have been used to enhance axonal regeneration: peripheral nerve grafts[57-59], Schwann 
cell-seeded guidance channels[60], Schwann cell bridges and olfactory ensheathing 
glia[61], adult olfactory mucosa progenitor cells[62], neural stem/progenitor cells[63], 
neurotrophin-3[64, 65], brain-derived neurotrophic factor[66], and rehabilitation training 
[67]. 
 
2.2.3 Scaffolds for CNS Repair 
 After SCI, implantation of substrates such as cellular grafts can promote axonal 
regeneration. However this axonal growth is usually highly random and rarely extends 
past the cellular graft site to extend into the host spinal cord [37]. Bioengineered 
scaffolds provide mechanical support at the site of injury by serving as a physical 
substrate for the support and guidance of axonal growth across the lesion cavity from the 
proximal to the distal host spinal cord, while also preventing the ingrowth of fibrous scar 
tissue [68]. Such scaffolds can also potentially serve as local delivery systems for 
neurotrophic factors and/or as carriers for cells that may promote repair[69]. Several 
fabrication techniques have been employed to fabricate scaffolds for SCI repair such as 
hydrogel formation, gas foaming, mold casting, solvent evaporation, freeze drying, phase 
separation, electrospinning, and heat compression[69, 70]. 
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 A wide variety of materials, both synthetic and natural, have been used as 
scaffolds for CNS repair. Non-degradable scaffolds are made of synthetic polymers that 
can be modified using uniform and controlled fabrication techniques to achieve desired 
material properties [68, 69]. Drawbacks of these materials are that the permanent 
implantation of a scaffold leads to a higher risk of inflammation and nerve compression 
over time, and may prompt the need for a second surgery to remove the scaffold[25, 71]. 
Common non-biodegradable synthetic polymers in use include poly(2-hydroxyethyl 
methacrylate) (pHEMA), poly[N-(2-hydroxypropyl) methacrylamide] (pHPMA), and 
poly(acrylonitrile-co-vinylchloride) (PAN/PVC) [72].  
The use of degradable materials eliminates the need for a second surgery to 
remove the scaffold and leads to a lower risk of nerve compression since they degrade as 
the axons regenerate. Degradation byproducts must be non-toxic and the rate of scaffold 
degradation should be matched to the rate of axon regeneration, which can range from 
weeks to months depending on the type of injury and the specific methods employed to 
promote regeneration [68]. The majority of biodegradable scaffolds are fabricated from 
natural materials such as collagen, alginate, agarose, chitosan, hyaluronic acid, 
fibronectin, and fibrin[72]. Natural materials are generally biocompatible and well 
tolerated in vivo, less toxic than synthetic materials, and can provide a support structure 
that promotes cell adhesion and migration [73, 74]. However, many natural materials are 
difficult to isolate, purify, and scale-up in a controlled manner, and insufficient 
purification can result in an immune response in vivo [68, 74]. Synthetic biodegradable 
scaffolds are also fabricated from materials such as poly(D,L lactic acid) (PLA), 
poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), poly-ε-caprolactone 
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(PCL), and polyethylene glycol (PEG) [72]. Although synthetic materials benefit from 
chemical and physical properties that can be optimized for a particular application, some 
of these materials are incompatible with cell adhesion and nerve repair[74]. The synthetic 
polymers PLA, PGA, and PLGA are widely used for tissue engineering purposes since 
their degradation byproducts (lactic acid and/or glycolic acid) are also byproducts of 
various metabolic pathways in the body. 
 
2.2.4 Combination Approach 
 Since there are several barriers to regeneration in the injured spinal cord, it is 
likely that effective treatment will require a combination of repair strategies. Providing a 
growth permissive substrate while delivering bioactive molecules that can degrade the 
inhibitory glial scar and/or stimulate axon growth will allow axons to bridge the lesion at 
the site of injury. Scaffolds with combinations of neurotrophic factors may promote more 
growth than those with only one factor, due to synergistic effects [75]. Synergistic effects 
between physical and chemical guidance cues have also been demonstrated to promote 
directional neurite outgrowth in vitro [76]. In addition to the combination strategies 
described above in section 2.2.2, several investigators have successfully applied multi-
functional scaffolds to animal models of SCI to promote axon growth and functional 
recovery [61, 77-79]. 
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2.3 Biomaterials for Spinal Cord Repair 
2.3.1 Biomaterial Design Strategies 
It is generally accepted that the ideal SCI repair scaffold should possess certain 
properties: biocompatibility, biodegradability/porosity, the ability to deliver bioactive 
factors, an internal oriented matrix to support cell migration and mimic the structure of 
nerve fascicles, incorporation of support cells, and electrical activity [68, 70, 80]. 
Biocompatibility is defined as the ability of a biomaterial to perform with an appropriate 
host response in a specific application[81]. In the application of a scaffold for SCI repair, 
the biomaterial should elicit a minimal inflammatory response, minimize or at least not 
cause additional glial scar tissue formation, allow neural cell adhesion and growth, and 
degrade in a nontoxic manner. 
Minimal swelling is required to maintain appropriate scaffold alignment and 
avoid compression of regenerating nerves [72]. It is important for the scaffold to maintain 
its structure in vivo, since structural collapse can lead to obstruction of axon regeneration 
through the length of the scaffold. The biomaterial should be sufficiently soft so that it 
does not physically damage the spinal cord as the patient moves. It is believed that 
mismatch in mechanical properties between the implant and native tissue can have 
negative consequences, impeding cell migration or axon extension across the implant-
tissue interface[68, 82]. Reported elastic modulus values of the spinal cord vary from 
approximately 3kPa to 300kPa, depending on the presence or absence of meninges during 
testing. Ozawa et al. report a compressive modulus of approximately 3-5kPa for gray and 
white matter alone[83]. 
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Cell attachment and axon regeneration can be aided by incorporating ECM 
molecules, neurotrophic factors, and cell adhesion molecules into the scaffold. As 
described in section 2.2.1, neurotrophic factors promote survival, repair and recovery 
after CNS injury. Neurotrophic factors have a short half-life in vivo (hours) and factors 
delivered via injection diffuse away from the injury site. Implanting a scaffold to provide 
sustained delivery of these bioactive molecules can overcome these challenges. 
Incorporating cells into a scaffold is also an effective manner of supplying bioactive 
molecules to the injury site. Cells such as Schwann cells, olfactory ensheathing cells 
(OECs), bone marrow stromal cells (BMSCs), genetically engineered fibroblasts, and 
neural stem or progenitor cells have been loaded into scaffolds for delivery to the spinal 
cord [61, 77, 84, 85]. Transplanted cells provide a permissive substrate for axon growth, 
while also producing cell adhesion molecules and neurotrophic factors that promote 
regeneration. Other bioactive molecules, such as glial scar-degrading chondroitinase 
ABC can be incorporated into scaffolds for sustained release [86, 87].  
Micro- and nanostructured topography of a scaffold, such as grooves, ridges, 
pores, and channels can provide physical cues to influence cell growth. Longitudinally 
aligned fibers or channels provide physical guidance for cell migration and oriented 
direction of axonal growth, leading to enhanced axon regeneration [79, 88, 89]. 
Compared to tubular scaffolds with a single lumen, multi-channel scaffolds provide more 
surface area for cell attachment and for release of incorporated bioactive molecules[69]. 
The internal matrix of a multi-channel scaffold also helps to prevent scaffold 
collapse[68]. 
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2.3.2 Hydrogels 
Hydrogels are hydrophilic polymer networks that have the capacity to absorb and 
retain large volumes of water [90, 91]. These insoluble networks can be formed through a 
variety of mechanisms, including chemical (covalent bonding) and physical gelation 
(ionic or hydrogen bonding) [92]. Covalently crosslinked networks are known as 
permanent or chemical gels. Physical/reversible hydrogels are crosslinked via molecular 
entanglements and/or secondary forces including hydrogen bonding, ionic bonding, 
hydrophobic forces, or microcrystallite formation[93]. These bonds can be reversed by 
changes in physical condition such as pH, temperature, ionic strength of the surrounding 
media, application of stress, or addition of specific solutes [90]. Neither ionically 
crosslinked nor covalently crosslinked hydrogels are homogeneous structures. The 
inhomogeneity of ionically crosslinked gels can be caused by the presence of clusters of 
ionic or hydrophobic associated domains or molecular entanglements. Covalently 
crosslinked gels usually contain clusters of low swelling and high crosslink density 
dispersed within regions of high swelling and low crosslink density[90]. 
Physical and chemical hydrogels can have several possible macromolecular 
structures, including: crosslinked networks of homopolymers or copolymers; polyion-
multivalent ion, polyion-polyion, or hydrogen bonded complexes; hydrophilic networks 
stabilized by hydrophobic domains; and interpenetrating polymer networks (IPNs) or 
physical blends[90]. Hydrogels can also be classified by their ionic charge (cationic, 
anionic, amphipathic, or neutral) or structure (amorphous, semicrystalline, and hydrogen 
bonded) [90, 93]. Four main parameters have been used to define the network structure of 
hydrogels: the polymer volume fraction in the swollen state (ν2,s); the number average 
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molecular weight between crosslinks (?̅?𝑐), and the network mesh (or pore) size (ξ), and 
the swelling ratio (Q) [94-96]. Q and ν2,s can be measured from swelling experiments, 
while ?̅?𝑐 and ξ can be calculated by the equilibrium swelling equations [94]. These 
parameters can be defined by the following equations: 
The equilibrium polymer volume fraction in the gel (ν2,s) describes the amount of 
liquid that can be held within a hydrogel. It is a ratio of the polymer volume (Vp) to the 
swollen gel volume (Vgel), and the reciprocal of the volume swelling ratio (Q) as 
described by equation 2.1, where ρ1 is the solvent density, ρ2 is the polymer density, and 
Qm is the mass swelling ratio [95, 96]. Qm is described by equation (2), where Wg is the 
weight of the equilibrium swollen gel and Wp is the weight of the polymer [94].  
 
𝜐2,𝑠 =  
𝑉𝑝
𝑉𝑔𝑒𝑙
=  𝑄−1 =  
1 𝜌2⁄
𝑄𝑚 𝜌1 ⁄ + 1 𝜌2⁄
                                            (2.1) 
 
𝑄𝑚 =  
𝑊𝑔− 𝑊𝑝
𝑊𝑝
                                                                          (2.2) 
 
?̅?𝑐, the number average molecular weight between two adjacent crosslinks, can be 
described by equation (3) where M0 is the polymer density and X is the degree of 
crosslinking [96]. 
 
?̅?𝑐 =  
𝑀0
2Χ
                                                                 (2.3) 
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The network mesh size (ξ) can be described by equation 2.4, where (?̅?𝑜
2)
1
2 is the root-
mean-squared end-to-end distance of network chains between two adjacent crosslinks in 
the equilibrium state [94, 95].  
 
𝜉 =  𝜐2,𝑠
−
1
3 (?̅?𝑜
2)
1
2  =  𝑄1/3(?̅?𝑜
2)
1
2                                              (2.4) 
 
There are several benefits to using hydrogels as scaffolds for SCI repair. The soft, 
flexible, three-dimensional structure of hydrogel networks can mimic the in vivo ECM 
environment while the porous structure supports the exchange of nutrients with the 
surrounding tissue and allows cell attachment and growth into the scaffold [68, 97]. 
Hydrogels can be modified using proteins or peptides derived from the ECM in order to 
promote cell attachment and axon growth [98, 99]. They can be easily cast into different 
shapes and can also be injected directly into sites of CNS injury, gelling in situ and 
conforming to the shape of the defect[100]. Bioactive molecules can also be incorporated 
within hydrogel scaffolds under mild crosslinking conditions for delivery to the injury 
site. Natural hydrogels, formed from proteins or polysaccharides, already have an 
intrinsic function such as structural support or ECM, nontoxic degradation products, and 
inherent adhesiveness to neural cells [68, 72]. Previously investigated natural hydrogels 
for spinal cord repair include alginate, collagen, hyaluronic acid, agarose, alginate, and 
chitosan [88, 101-104]. 
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2.3.3 Alginate 
Alginate is a linear anionic polysaccharide commonly derived from brown 
seaweed, consisting of 1,4-linked α-L-guluronic acid (G) and β-D-mannuronic acid (M) 
monomers [105]. These uronic acid monomers can be arranged in homopolymeric G 
blocks, M blocks, or blocks with random combinations of M and G monomers (MG-
blocks), which vary in distribution and proportion depending on the alginate source 
[106]. The physical properties of alginate depend on its chemical composition, more 
specifically the M/G ratio, the sequential order of the G-, M-, and MG-blocks, and the 
overall molecular weight[107]. 
 
 
 
 
Figure 2.3: Structure of alginate illustrating guluronic acid (G) and mannuronic acid (M) 
monomers[108] 
 
 
 
 Gelation of alginate occurs in the presence of multivalent cations, such as divalent 
Ca2+, Ba2+, or Sr2+, by the ionic interaction of these cations with blocks of G monomers. 
The resulting three-dimensional network is best described by the “egg-box model”, since 
cations are bound between adjacent G block regions like eggs in an egg box [109].  
 
 
 
23 
 
 
Figure 2.4: Schematic of the “egg-box model” for calcium-crosslinked alginate 
gel and the interaction between calcium cations and oxygen atoms (dark circles) on the 
guluronic acid monomers[110].  
 
 
 
The overall stiffness of the gel is affected by the molecular weight of the alginate, 
cation concentration at the time of gelation and the M/G ratio, particularly the frequency 
and length of adjacent G-blocks[107]. Gels prepared from alginates with higher G 
residues exhibit increased mechanical rigidity and strength, due to the increased 
proportion of ionic bonding[111]. Proteins also diffuse out of high G gels at higher rates. 
This results from the short elastic segments of long G-blocks forming more of a stiff open 
and static network, as compared to the relatively long elastic segments of high M gels 
which form more dynamic and entangled networks[112].  
One of the drawbacks of ionically crosslinked alginate gels is limited long term 
stability under physiological conditions, sine these gels can dissolve quickly due to 
release of the crosslinking divalent cations through exchange reactions with monovalent 
cations such as sodium or chelating compounds such as phosphates[111]. In addition to 
ionic gels, alginates can form acid gels at a pH below the pKa value of the uronic acid 
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residues, which are 3.38 and 3.65 for mannuronic acid and guluronic acid respectively 
[112, 113]. Alginates can also be covalently crosslinked via their carboxyl and/or 
hydroxyl functional groups, and chemically modified alginate can also be 
photocrosslinked [114-116]. 
There are several advantages for the use of alginate as a biomaterial for in vivo 
implantation. It is nontoxic, easily processed into any desired shape by the introduction of 
non-cytotoxic divalent cations, and is capable of immobilizing biomolecules and cells 
while allowing them to retain their structure and full biological activity[117, 118]. The 
diffusion rate of biomolecules out of an alginate gel can be controlled by coating the gel 
with polycations such as poly-L-lysine, poly-L-ornithine, or polyethylenemine [119-121], 
or cationic polymers such as chitosan [122]. 
 Alginate gels have been investigated for use in CNS and peripheral nervous 
system (PNS) repair. An alginate sponge covalently crosslinked using ethylenediamine 
was shown to promote axon regeneration and astrocyte process extension at the stump of 
transected spinal cords in rats[101], and also regeneration across a 50 mm gap in a cat 
sciatic nerve[123, 124]. In adult rat acute cervical spinal cord lesions, alginate-based 
anisotropic capillary gels integrated into the spinal cord parenchyma without major 
inflammatory responses and directed axonal regrowth across the gel[125]. Implanting 
alginate-encapsulated BDNF-producing fibroblasts into a rat cervical hemisection in the 
absence of immune suppression promoted axon growth and partial recovery of function 
[85, 119].  
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2.3.4 Chitosan 
 Chitosan is a linear copolymer of N-acetyl-D-glucosamine and D-glucosamine 
units linked by β(1-4) glycosidic bonds [126]. It is obtained through the N-deacetylation 
of chitin, the second most abundant natural polysaccharide, which is harvested from the 
exoskeletons of crustaceans and insects and the cell walls of fungi [127]. Chitosan is 
insoluble in neutral or basic pH solutions, but soluble in acidic solutions (< pH 6.5), due 
to the presence of primary amine groups which make chitosan a cationic polyelectrolyte 
(pKa ~ 6.5) and allow it to be covalently coupled to various biomolecules, along with its 
other primary and secondary hydroxyl functional groups [127, 128]. Depending on the 
source and preparation procedure, the molecular weight of chitosan can range from 300 
to over 1000 kDa with a degree of deacetylation ranging from 30-95% [126]. 
 
 
 
 
Figure 2.5: Chemical structure of chitosan[129] 
 
 
 
Gels can be formed from chitosan using various methods, such as solvent 
evaporation, neutralization, crosslinking, or ionotropic gelation [128]. Chitosan’s 
beneficial biological properties include biocompatibility, non-toxicity, biodegradability, 
affinity to proteins, and its antibacterial, antiviral, antifungal, antitumoral, and 
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anticholesteremic activity [126-128, 130]. The main disadvantages of using chitosan as a 
scaffold are possible lack of mechanical stability and highly pH-sensitive swelling, which 
can lead to dissolution of the system[131].  
Used as a neural tissue engineering scaffold, chitosan has been shown to support 
the attachment and growth of neural cells. In the injured spinal cord, implantation of a 
chitosan tube led to the regeneration of axons and recovery of function [132]. GDNF and 
laminin have been incorporated into chitosan nerve guides by simply blending into the 
chitosan prior to gelation using a neutralization method, leading to enhanced nerve 
regeneration and functional recovery [133, 134]. NT-3-chitosan carriers maintain the 
viability of neural stem cells and increase their differentiation percentage into neurons 
[135]. Mixing chitosan with peptides that have been shown to improve cell attachment 
also has beneficial effects on neural cell behavior. Nerve cells grown on chitosan-
polylysine mixtures show improved attachment, differentiation, and growth as compared 
to chitosan membranes alone [136]. Chitosan in solution has been shown to seal 
compromised neuronal membranes, thereby acting as a neuroprotector after spinal cord 
injury [104].  
 
2.3.5 Polyelectrolyte Complexes 
In aqueous solutions, oppositely charged polymers spontaneously interact to form 
polyelectrolyte complexes (PECs) due to the formation of strong but reversible 
electrostatic links [137]. Bonding takes place between oppositely charged ionizable 
functional groups, primarily through electrostatic or dipole-dipole interactions as well as 
secondary bonding via hydrogen bonding or covalent bonding [138, 139]. The formation 
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and stability of PECs depends on several factors: the degree of ionization of the 
oppositely charged polymers, charge distribution and position of the ionic groups on the 
polymer chains, polymer chain flexibility, concentration and molecular weight of the 
polymers, mixing ratio and order, duration of the electrostatic interaction, and 
temperature, ionic strength and pH of the reaction solution [137, 139-141]. 
 PEC formation occurs under mild reaction conditions, leading to biocompatible 
PEC systems that can encapsulate proteins or drugs without denaturation. PEC hydrogels 
demonstrate highly pH-sensitive swelling due to alterations in the global charge densities 
of the two complexed polymers if the pH changes after formation[142].  They can 
therefore be used for pH-controlled drug delivery under acidic and basic conditions. It is 
possible to enhance the swelling capacity, permeability, and mechanical strength of a 
PEC hydrogel via ionic crosslinking [142-144].  A wide variety of PECs have been used 
for controlled release systems, enzyme and cell encapsulation, wound healing membranes 
and tissue engineering scaffolds.  
PECs formed from chitosan and alginate are widely studied because these 
complexes remains biocompatible and biodegradable, but are mechanically stronger at 
lower pH values where chitosan dissolves [137]. Chitosan and alginate form PECs 
through interaction of the negatively charged carboxyl groups in alginate and the 
positively charged amine groups in chitosan. These PECs can be formed using various 
methods: one polymer solution can be slowly added to the other drop by drop; a two-step 
process can be used, fabricating Ca2+-crosslinked alginate capsules and then forming a 
PEC membrane on the surface with a chitosan solution; or the two polymer solutions can 
be mixed in various proportions and homogenized or blended at high speed[141, 145]. 
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Properties of chitosan-alginate PECs such as particle size, surface charge, and stability 
are affected by the net charge ratio, molecular weight, mixing order, ionic strength, and 
pH [146]. 
While chitosan scaffolds are fabricated in acidic solutions, chitosan-alginate PEC 
scaffolds can be prepared over a wide pH range [138, 144]. Chitosan-alginate 
microcapsules have been shown to be superior to chitosan as well as alginate 
microcapsules for sustained protein and drug release, making these PECs beneficial for 
sustained delivery of therapeutic biomolecules to the injured spinal cord [147, 148]. 
Chitosan-alginate PECs display a low rate of enzymatic degradation by lysozyme and 
partial degradation by hydrolysis, due to the strong interaction between the polymer 
chains[149]. For use in tissue engineering, chitosan-alginate PECs have been used to 
fabricate scaffolds for bone[144], cartilage[145], liver[150], intervertebral disc[151], 
tendon and ligament tissue engineering [152], and for in vitro cancer cell culture[153, 
154]. These scaffolds have also been investigated for the controlled release of growth 
factors, including nerve growth factor (NGF) and basic fibroblast growth factor (bFGF) 
[155, 156]. 
 
2.4 Controlled Release of Bioactive Molecules 
2.4.1 Hydrogels for Drug Delivery in the CNS 
As described above, there are several methods that have been explored for 
neurotrophin and drug delivery to the nervous system, such as direct injection, osmotic 
mini-pumps, genetically modified cells, and biomaterial delivery vehicles. The effects of 
a bolus injection are short-lived since the therapeutic agent is washed away by the 
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continuous flow of CSF. The average flow rate of CSF is 0.35 mL/min, ranging from 0.4 
mL/min in young humans to 0.19 mL/min in elderly humans, with the entire CSF volume 
being produced and cleared approximately every 5 hours[157-159]. Effective delivery of 
bioactive molecules via injection can therefore require repeated injections and higher 
concentrations. Delivery via osmotic mini-pump can be used for sustained delivery of 
bioactive molecules. However, implantation of the device is invasive and can lead to scar 
formation at the catheter tip, infection, or catheter complications which can cause 
infusion failure[160].  
 Implantation of a biomaterial scaffold at the injury site can provide a source for 
sustained local neurotrophin delivery, while simultaneously providing a physical 
substrate for axon growth. Hydrogels are well suited for biomolecule delivery due to their 
porous nature, with release being dependent on the rate of diffusion through the hydrogel 
matrix [161]. Delivery of biomolecules using hydrogel scaffolds is accomplished by 
encapsulating the molecules during gelation or soaking a dry hydrogel in the biomolecule 
of interest. The loaded biomolecules are subsequently released from the scaffold via 
diffusion and degradation mechanisms [92].  
A downside of the high water content of hydrogels is that hydrophilic 
biomolecules such as proteins are soluble and can diffuse out of the gel quickly, over a 
few hours to a few days[162]. Charge interactions between ionic polymers and charged 
biomolecules can enhance the duration of biomolecule release. At physiological pH, 
anionic polymers such as alginate will interact electrostatically with cationic drugs or 
proteins, leading to prolonged release. IPNs and semi-IPNs (a blend of two or more 
polymers in which only one polymer in the network is crosslinked) have relatively dense 
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hydrogel networks, and can moderate the effects of burst drug release because of their 
ability to restrict equilibrium swelling of either or both of the interpenetrating phases 
according to the crosslinking density of either or both gel phases[162]. Surface 
modifications can be made to the hydrogel to generate a perm-selective layer at the 
hydrogel surface, such as by coating with a polyelectrolyte film layer [85]. Delivery time 
of incorporated molecules can also be prolonged by covalently binding biomolecules to 
the gel with a cleavable crosslinker, or by incorporating microparticles such as polymeric 
microspheres or lipid microtubules within the hydrogel [87, 156, 163]. The hydrogel 
keeps these secondary delivery vehicles in place and limits burst release commonly seen 
with microsphere systems [162].  
 
2.4.2 Mechanisms of Controlled Release 
 Biomolecule release mechanisms from hydrogels are very different from 
hydrophobic polymers. Models of hydrogel release can be categorized as diffusion-
controlled, swelling-controlled, and chemically-controlled. In addition to modeling the 
release of biomolecules, the mesh size (ξ) of a hydrogel network can be calculated using 
the equations described in section 2.3.2 and compared with the hydrodynamic radius of 
an encapsulated biomolecule. Theoretically no biomolecule diffusion can take place from 
the hydrogel when the mesh size is close to or smaller than the size of the biomolecule 
[95].  
The theoretical hydrodynamic radii of NT-3 and BDNF can be calculated using 
the following equation, where MW = molecular weight of the solute (neurotrophin), NA = 
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Avogadro’s number, and ρ = density of the solute (1 g/cm3), and assuming that the solute 
is a sphere [164]: 
𝑎 = (
3𝑀𝑊
4𝜋𝜌𝑁𝐴
)
1
3⁄                                                (2.5) 
 Using this equation and the molecular weights of 29,355 Da (NT-3), 27,818 Da 
(BDNF), and approximately 100,000 Da (chABC) the theoretical hydrodynamic radii of 
NT-3, BDNF, and chABC were calculated to be 2.27 nm, 2.23 nm, and 3.41 nm 
respectively.  
The equations used to calculate hydrogel mesh size described in section 2.3.2 
usually apply to isotropic single polymer hydrogels. Since our scaffolds are anisotropic 
IPNs composed of two polymers (chitosan and alginate), calculating the hydrogel 
network mesh size involves more than simple swelling experiments. Pescosolido et al. 
determined the mesh size of IPNs based on calcium alginate/dextran methacrylate using a 
combination of rheological and low field NMR characterization, and also through 
cryoporosimetry, developing mathematical models to interpret the experimental data 
[165]. Using their data, they express crosslink density ρx using the following equation, 
where G = shear modulus of the hydrogel, R = gas constant, and T = absolute 
temperature:   
𝜌𝑥 = 𝐺 𝑅𝑇⁄                                                       (2.6) 
 This crosslink density, along with the equivalent network theory, can be used to 
calculate the average network mesh size ξa. This theory implies that making a detailed 
description of a polymeric network is difficult, if not impossible, and suggests the 
replacement of the actual network with an idealized infinite network of a collection of 
spheres with a diameter that coincides with the average network mesh size, termed the 
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“equivalent network” [165, 166]. Crosslinking density can then be inserted into an 
equation to solve for ξa, where NA = Avogadro’s number [165]: 
𝜉𝑎 = (
6
𝜋𝜌𝑥𝑁𝐴
)
1
3⁄                                                      (2.7) 
 In order to determine a hypothetical value of ρx, G (shear modulus) must first be 
calculated. The compressive (Young’s) modulus for the C/A scaffolds is 5.08 ± 0.61 kPa. 
In isotropic materials, G can be calculated from E (Young’s modulus) using the following 
relationship: 𝐺 =
𝐸
2(𝜐+1)
, where υ = Poisson’s ratio. Without rheological data on our 
anisotropic scaffolds, this equation was used to obtain a hypothetical value for G, with 
the assumption that υ = 0.5. The resulting hypothetical value of G = 1.693 kPa was 
inserted into the crosslink density equation (T = 310.1 K = 37oC) to yield ρx = 0.657 
mol/m3. Using this value, the average network mesh size ξa was calculated to be 1.69 x 
10-8 m, or 16.9 nm. This hypothetical value of ξa is larger than the theoretical values of 
the hydrodynamic radii of NT-3 and BDNF (2.27 and 2.23 nm respectively), indicating 
that these neurotrophins will be able to exit the scaffold via diffusion. However, these 
values are not exact, especially that of the average network mesh size, and therefore 
actual release may differ from that predicted using these equations.  
Diffusion-controlled release is the most widely applicable mechanism for 
describing biomolecule release from hydrogels, using Fick’s law of diffusion [95, 167]. 
Release from a reservoir system where the biomolecule core is surrounded by a 
polymeric membrane can be described by Fick’s first law of diffusion in dilute solutions, 
where JA is the flux of the biomolecule, D is the biomolecule diffusion coefficient, and 
CA is the biomolecule concentration [95, 168]. 
33 
 
𝐽𝐴 =  −𝐷
𝑑𝐶𝐴
𝑑𝑥
                                                                    (2.8) 
For a matrix system where the biomolecule is uniformly dispersed throughout the 
hydrogel matrix, unsteady-state release from a one-dimensional slab matrix can be 
described by Fick’s second law of diffusion, where the diffusion coefficient is assumed to 
be a constant and sink conditions are also assumed (equation 2.6). If diffusivity is 
concentration dependent, equation 2.7 can be used [95, 168]. 
 
𝑑𝐶𝐴
𝑑𝑡
=  𝐷
𝑑2𝐶𝐴
𝑑𝑥2
                                                                    (2.9) 
 
𝜕𝐶𝐴
𝜕𝑡
=  
𝜕
𝜕𝑥
(𝐷(𝐶𝐴)
𝜕𝐶𝐴
𝜕𝑥
)                                                             (2.10) 
 
Swelling-controlled release occurs when biomolecule diffusion is faster than the 
swelling of the hydrogel. In this type of release, a hydrogel matrix begins to swells upon 
contact with aqueous media and a dry glassy phase and a swollen rubbery phase can be 
observed within the polymer. Entrapped biomolecules remain immobilized within the 
glassy phase, while biomolecules rapidly diffuse into the surrounding media from the 
rubbery phase [167]. In swelling-controlled release, biomolecule diffusion time and 
polymer chain relaxation time are two main parameters that determine release from a 
matrix, and release rate depends on the swelling rate of hydrogel network[95].  
Chemically-controlled release describes biomolecule release that is determined by 
reactions occurring within a drug delivery matrix, such as hydrolytic or enzymatic 
degradation of polymer chains. This type of release can be further classified as kinetic-
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controlled release, where polymer degradation is the rate limiting step via surface erosion 
or cleavage of crosslinkers that covalently crosslink the biomolecules to the gel; or 
reaction-diffusion-controlled release (bulk degradation), where both polymer degradation 
and diffusion contribute to the modeling of biomolecule release [95].  
 
2.5 Freeze Casting 
 Freeze casting, also referred to as directional/unidirectional solidification or ice 
templating, is the directional freezing of aqueous solutions or slurries. A mold with a 
copper bottom plate is filled with an aqueous solution or slurry and placed in contact with 
a cold source, such as a copper cold finger extending into a bath of liquid nitrogen. The 
temperature of the cold source is reduced at a constant rate, by controlling the heating of 
the cold finger with a band heater and thermocouple, creating a directional temperature 
gradient within the sample. Once the temperature of the cold source is lower than the 
freezing point of the solution or slurry, a freezing front (the interface between solid and 
liquid phases) is formed and begins to travel through the sample [169]. As this freezing 
front travels through the sample, the solutes are concentrated in the spaces between ice 
crystals. After the entire sample is frozen, ice is sublimated by lyophilization (freeze 
drying), resulting in a scaffold possessing a pore structure that is a negative template of 
the ice crystals[170]. The scaffold structure is comprised of aligned channels that run 
continuously from the bottom to the top of the sample, originating from the steady state 
freezing front and previously continuous ice crystals[171]. 
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Figure 2.6: Schematic of the freeze casting process. Particles and polymer molecules are 
excluded from the ice and aggregate between the growing ice crystals; adapted from 
[172]. 
 
 
 
The size of the ice crystals, and therefore pore size, can be controlled by varying 
the freezing temperature and rate[172]. The form in which the solvent crystallizes will 
also affect sample microstructure and mechanical properties. Under ambient temperature 
and pressure, water solidifies into anisotropic hexagonal ice crystals with a growth 
velocity that is approximately 100 times faster in the a-direction of the hexagonal base 
than the perpendicular c-direction, therefore leading to ice crystal growth parallel to the 
a-direction during freeze casting  [169]. Channel spacing is inversely proportional to the 
freezing front velocity: 𝜆 ∝  
1
𝜈𝑛
, where λ is the channel spacing, ν is the freezing front 
velocity, and n depends on particle size in the sample (e.g. ~1 for 400nm particles; ~2/3 
for 100nm particles)[171]. 
Freeze casting can be used to fabricate scaffolds with a highly aligned, porous 
structure while easily controlling pore size and geometry[169]. For neural tissue 
engineering applications, freeze casting has been used to process scaffolds from collagen 
[173, 174], agarose [175], chitosan [176], and a collagen-chitosan blend[177]. The 
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resulting scaffolds have varying architecture, but all possess longitudinally aligned 
pores/channels due to templating by ice. In addition to modifying the scaffold 
microstructure and properties by altering the freezing rate, these properties are also 
affected by changing the composition of the sample (i.e. concentration) or by gelling or 
crosslinking before or after the freezing process [178, 179]. Since processing occurs at 
low temperatures, polymer scaffolds can be functionalized or biomolecules can be 
incorporated into the scaffolds without compromising their function during manufacture 
[178].  
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3. MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Chemicals 
Alginate (Protanal LF200M, MW approx. 270-325 kDa; lot number S21721) was 
obtained as a sample from FMC Biopolymer (Philadelphia, PA). Chitosan (MW approx. 
50-190kDa, 85% deacetylated), calcium chloride, sodium chloride, sodium hydroxide, 
sodium citrate, epichlorohydrin, D-(+)-gluconic acid δ-lactone (GDL), D-(+)-trehalose 
dehydrate, 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid sodium salt, 
dimethylmethylene blue, sodium formate, and formic acid were purchased from Sigma-
Aldrich (St. Louis, MO). Chondroitinase ABC and chondroitin sulfate C were purchased 
from Seikagaku USA (Associates of Cape Cod, Inc., East Falmouth, MA). Additional 
chondroitinase ABC was also purchased from Sigma-Aldrich. Absolute ethanol and 
Pierce Silver Stain Kit were purchased from Fisher Scientific (Fair Lawn, NJ). NuPAGE 
LDS Sample Buffer, Invitrogen Reducing Agent, Novex Sharp Unstained Protein 
Standard, NuPAGE 4-12% Bis-Tris gradient gel (1.0 mm), NuPAGE MOPS SDS 
Running Buffer, and tetramethylrhodamine-5-(and-6)-isothiocyanate (5(6)-TRITC) 
mixed isomers were purchased from Invitrogen (Carlsbad, CA). 
 
3.1.2 Cells and Cell Culture Materials 
Fertilized white Leghorn chicken eggs were purchased from Charles River 
Laboratories (Wilmington, MA). Dulbecco’s Modified Eagle Medium (DMEM with 4.5 
g/l glucose, L-glutamine, and sodium pyruvate), Hank’s Buffered Salt Solution (HBSS), 
0.25% trypsin EDTA, antibiotic/antimycotic solution,  were purchased from Mediatech 
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(Herndon, VA). Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT-3), poly-L-ornithine hydrobromide (MW 30-70 kDa), poly-L-lysine 
hydrobromide (MW 30-70kDa), laminin from Englebreth-Holm-Swarm murine sarcoma 
basement membrane, decorin, and mouse monoclonal anti-neurofilament 200 (Phos. and 
Non-Phos.) clone N52 were purchased from Sigma-Aldrich (St. Louis, MO). Fetal bovine 
serum (FBS) was purchased from HyClone (Logan, UT). B-27 supplement, Live/Dead 
Cell Viability/Cytotoxicity Kit for mammalian cells, and AlexaFluor 488 goat anti-mouse 
IgG secondary antibodywere purchased from Invitrogen (Carlsbad, CA). Polystyrene 
culture plates (100 mm, 6 well, 12 well, 24 well, 48 well, 96 well) were purchased from 
Falcon, Becton Dickinson Labware (Franklin Lakes, NJ).  
 
3.2 Fabrication and Characterization of Scaffolds 
3.2.1 Fabrication of 3D Chitosan Scaffolds 
A 2.4% (w/v) chitosan solution (MW approx. 50-190kDa, 85% deacetylated) was 
prepared in 1% (v/v) acetic acid, mixing using an overhead stirrer (Caframo Stirrer 
BDC6015, ON, Canada). In collaboration with the laboratory of Dr. Ulrike Wegst, the 
chitosan solution was freeze cast into a scaffold, using the freeze casting system and 
method previously described by Wegst et al. [169, 178]. A schematic of the freeze 
casting system is shown in Figure 1. Entrapped bubbles in the chitosan solution were 
removed by spinning at 2500 rpm for 1 minute in a shear mixer (SpeedMixer, DAC 1510 
FVZ‐K, FlackTek). The mixture was pipetted into a custom-built cylindrical 
polytetrafluoroethylene (PTFE) mold (25 mm O.D. x 50 mm tall) fitted with a copper 
bottom plate and secured onto the temperature-controlled copper cold finger of the freeze 
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casting system. The temperature of the system was controlled using a band heater and 
thermocouple in contact with the copper cold finger, which was partially submerged into 
a liquid nitrogen bath. The cold finger temperature was lowered at a constant cooling rate 
of 6oC/min to a final temperature of -150oC, resulting in the directional solidification of 
the chitosan solution. Samples were kept on the freeze caster until frozen solid, which 
was determined by the appearance of ice crystals at the top surface of the frozen sample. 
The samples were removed from the molds using a Teflon punch attached to an Arbor 
press and lyophilized for 72 hours using a VirTis Benchtop freeze dryer (SP Industries, 
Warminster, PA). Dried chitosan scaffolds were stored in a desiccator at room 
temperature until use. 
 
 
 
 
Figure 3.1: Schematic of freeze casting system [169] 
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3.2.2 Neutralization of Chitosan Scaffolds 
Chitosan is highly charged (+) below its pKa of 6.5. Prior to use in an aqueous 
environment, the chitosan scaffolds were neutralized by soaking for 15 minutes in a 0.4% 
NaOH in 95% ethanol solution, followed by rinsing in phosphate buffered saline (PBS). 
Alternative methods of neutralizing scaffolds were: 
 Soaking for 15 minutes in 50 mM sodium bicarbonate in 70% ethanol 
 Soaking for 15 minutes in 95% ethanol 
 Briefly rinsing in 95% ethanol before soaking for 15 minutes in 50 mM sodium 
bicarbonate in 70% ethanol 
 
All alternative scaffold neutralization methods were followed by rinsing in PBS 
before use in an aqueous environment. In order to evaluate the effects of scaffold 
neutralization methods on encapsulated protein activity, alginate fibers containing 1 
mg/ml β-galactosidase were crosslinked using a calcium chloride solution for 10 minutes, 
before placing in a waterproofing solution for 15 minutes, and then rinsing in HEPES-
buffered saline. β-galactosidase activity was assayed using a β-Galactosidase Reporter 
Gene Activity Detection Kit (Sigma-Aldrich). Note: alginate was used for β-
galactosidase testing due to chitosan interference with the assay. 
 
3.2.3 Initial Testing of Chitosan-Alginate PEC Mixtures for Scaffold Fabrication 
A 2.4% (w/v) chitosan solution was prepared in 1% (v/v) acetic acid, and 2.4% 
(w/v) alginate solutions were prepared in deionized (DI) water and 0.174 M sodium 
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hydroxide. In a 50 ml beaker, a total volume of 20 ml of chitosan and alginate solutions 
were mixed by homogenizing at 11,000 rpm for 5 minutes using a Brinkmann PT 3100 
homogenizer with a Polytron PT-DA 3020/2 probe (Brinkmann Instruments, Westbury, 
NY). The following chitosan-alginate compositions were fabricated: 
 
 
 
Table 3.1: Composition of chitosan-alginate PEC mixtures for scaffold fabrication 
Chitosan : alginate ratio Composition of mixture 
90:10 18 ml chitosan, 2 ml alginate (in DI water) 
90:10 18 ml chitosan, 2 ml alginate (in NaOH) 
75:25 15 ml chitosan, 5 ml alginate (in DI water) 
75:25 15 ml chitosan, 5 ml alginate (in DI water) 
50:50 10 ml chitosan, 10 ml alginate (in DI water) 
50:50 10 ml chitosan, 10 ml alginate (in DI water) 
 
 
 
Chitosan-alginate scaffolds (50:50 ratio) were also prepared using 2%, 1.5%, 1%, 
and 0.5% (w/v) chitosan and alginate solutions. Homogeneous chitosan-alginate mixtures 
were also produced by sonicating in an ice bath with 90W applied power using a 20kHz 
sonicator probe (CL4 tapped horn probe with 0.5” tip; Misonix Inc.) set to pulse for 2 
minutes at 15 second intervals with a 3 second pause. 
Entrapped bubbles in the chitosan-alginate mixtures were removed by spinning at 
2500 rpm for 1 minute in a shear mixer (SpeedMixer, DAC 1510 FVZ‐K, FlackTek). The 
mixtures were pipetted into a custom-built cylindrical PTFE mold (25 mm O.D. x 50 mm 
tall) fitted with a copper bottom plate and secured onto the temperature-controlled copper 
cold finger of the freeze casting system. The cold finger temperature was lowered at a 
constant cooling rate of 6oC/min to a final temperature of -150oC, resulting in the 
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directional solidification of the chitosan-alginate mixtures. Samples were kept on the 
freeze caster until frozen solid, which was determined by the appearance of ice crystals at 
the top surface of the frozen sample (approximately 1-2 hours). The samples were 
removed from the molds using a Teflon punch attached to an Arbor press and lyophilized 
for 72 hours as described above. Dried chitosan-alginate scaffolds were stored in a 
desiccator at room temperature until use. 
 
3.2.4 Fabrication of Bulk 3D C/A Scaffolds (Final Protocol) 
Chitosan (MW approx. 50-190kDa, 85% deacetylated) and alginate (MW approx. 
270-325 kDa) were dissolved in 1% acetic acid and DI water, respectively, to produce 
separate 1.5% (w/v) solutions. Equal volumes (10 mL each) of the chitosan and alginate 
solutions were added to a 50 mL beaker (1.5% total polymer content) and 225 µL 6M 
sodium hydroxide was added in order to adjust the pH to 7.4. A homogeneous C/A PEC 
mixture was produced by sonicating in an ice bath with 90W applied power using a 
20kHz sonicator probe (CL4 tapped horn probe with 0.5” tip; Misonix Inc.) set to pulse 
for 2 minutes at 15 second intervals with a 3 second pause. The C/A PEC mixture was 
degassed, freeze cast (at a constant cooling rate of 1oC/min or 6oC/min to a final 
temperature of -150oC), and lyophilized as described above. 
 
3.2.5 Preparation of Bulk C/A Scaffolds for In vitro Cell Culture  
The dried scaffolds were cut into cube shaped samples (3mm x 3mm 
longitudinally, 1 mm depth cross-section) using a sterile scalpel blade. The samples were 
then crosslinked with a 0.25% calcium chloride (CaCl2) solution for 10 minutes and 
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washed in PBS three times prior to surface adsorption of polycations or laminin. For 
polycation adsorption, C/A scaffolds were submerged in 3 ml of a 0.5mg/mL solution of 
poly-L-lysine (PLL, MW 30-70 kDa) or poly-L-ornithine (PLO, MW 30-70 kDa) for 6 
minutes at room temperature with gentle shaking and then washed 3 times in 3 ml PBS. 
This was followed by adsorption of laminin overnight at 37oC (200 µl of 100 µg/mL 
solution in PBS) and further washing with PBS (3x) before in vitro cell culture (see 
Section 3.5). 
 
3.2.6 Mechanical Testing 
Dry C/A scaffolds were mounted on ceramic discs with Crystalbond 509 (Aremco 
Products, Inc) and sectioned with a 220 µm diameter diamond-decorated steel wire on a 
Well 4240 saw (WELL Diamond Wire Saws, Inc) at a wire speed of 0.7 m/s. Sample 
cubes (5mm x 5mm x 5mm) were sectioned from each scaffold, cutting four cubes from 
three different heights within the scaffold. Mechanical testing of the scaffolds (n = 3) was 
performed on an Instron Model 4442 single‐column bench‐top machine using a 5 N load 
cell at a strain rate of 0.01 s-1 in unconfined compression (testing performed on 
crosslinked samples saturated in PBS). The sample cubes were compressed in the axial 
direction with a cross‐head speed of 0.05 mm/s, with the load parallel to the linearly 
oriented channels. The data obtained were used to generate stress‐strain curves and derive 
the elastic modulus of the samples. 
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3.2.7 Assessment of Scaffold Swelling 
For swelling testing, C/A scaffolds were prepared in the cylindrical molds as 
described above, and then cut into discs of approximately 2mm thickness (cylindrical 
scaffold diameter approximately 18.5 mm). After crosslinking, the scaffold samples were 
incubated in PBS for 24 hours. The change in scaffold diameter over time as compared to 
the dry scaffold diameter (t=0) was measured using digital calipers (n = 3 scaffolds for 
each sample group).  
 
3.2.8 Scanning Electron Microscopy (SEM) 
Dry, uncrosslinked C/A scaffolds were thinly sliced with a scalpel blade in both 
cross-sectional and longitudinal directions and were directly mounted onto aluminum 
stubs. Crosslinked C/A scaffolds were washed thoroughly in DI water, then frozen at -
80oC and lyophilized, before mounting on stubs. All specimens were sputter coated with 
a 3 nm thick layer of platinum-palladium and loaded into a Zeiss Supra 50VP SEM (Carl 
Zeiss SMT Inc.). Imaging was performed with an accelerating voltage of 6 kV at a 
working distance of 5 mm. 
 
3.2.9 Light Microscopy 
For optical analysis, a stereo microscope (Leica M205, Leica Microsystems Inc., 
Buffalo Grove, IL, USA) with a resolution of 480 nm was used. Digital images were 
taken with an attached digital camera (Leica DFC400, Leica Microsystems Inc., Buffalo 
Grove, IL, USA) and captured with the manufacturer’s LAS software. 
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3.2.10 Measurements and Statistical Analysis 
All image analysis and measurements were performed using ImageJ software 
(NIH, Bethesda, MD). Power analysis was performed using GPower 3.1 software. 
Statistical analysis was performed with GraphPad Prism 5 (GraphPad Software) software. 
One-way analysis of variance (ANOVA) and Tukey–Kramer post-tests were performed 
for quantitative analysis of DRG neurite elongation. A priori confidence intervals of 95% 
were used for the post hoc test results.  
 
3.3 Loading Protein into C/A Scaffolds 
3.3.1 Fabrication of Alginate Microcapsules 
Alginate (300 ml of a 1.5% w/v solution) was spray dried with a Büchi-190 Mini 
Spray Dryer (Büchi Corporation, New Castle, DE) using the parameter settings displayed 
below in Table 3.2, modified from Coppi et al. [180]. 
 
 
 
Table 3.2: Settings for spray drying alginate microcapsules in Büchi-190 Mini Spray 
Dryer 
Spray dryer parameter Setting 
Nozzle diameter 0.5 mm 
Inlet temperature 160oC (heat setting ~9.5) 
Outlet temperature 90-95oC 
Pump flow rate 5 ml min-1 (pump setting: 1) 
Air spray flow 700 N l h-1 
Aspirator setting 17 
 
 
 
Spray dried alginate microcapsules were collected in approximately 90 ml of a 
1.3% calcium chloride solution in the product collection vessel. The CaCl2-crosslinked 
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alginate microcapsules were transferred into four 50 ml polypropylene tubes and 
centrifuged at 5000xg for 2 minutes in an Allegra™ 21 Centrifuge (Beckman Coulter, 
Brea, CA). The microcapsules were then washed with DI water followed by 100% 
ethanol. After washing with ethanol, each tube of microcapsules was resuspended in 
approximately 35 ml 100% ethanol. This mixture was vortexed briefly before pipetting 
30 ml of the microcapsule suspension into a 100 ml beaker.  
Alginate microcapsules were crosslinked with epichlorohydrin by modifying a 
protocol described by Sharma et al., 2001 [181]. In order to covalently crosslink the 
microcapsules, epichlorohydrin (6 ml) was added to the microcapsule suspension (30 ml), 
and this mixture was homogenized on ice at ~6000 rpm (Brinkmann Instruments, 
Westbury, NY) while slowly adding 10 ml 5M NaOH. The mixture was homogenized on 
ice at 9500 rpm for approximately 1 minute, and this process was repeated for each tube 
of microcapsules. These epichlorohydrin-microcapsule mixtures were stirred for 24 hours 
at room temperature on a stir plate at approximately 400 rpm. After 24 hours, the pH of 
the mixture was adjusted to 7 using 1M hydrochloric acid. The microcapsules were 
centrifuged at 5000xg for 2 minutes, and then washed in 100% ethanol (1x), 75% ethanol 
(1x), 50% ethanol (1x), 25% ethanol (1x), and DI water (3x). After washing in water, 
remaining calcium chloride was removed from the alginate microcapsules by 
resuspending in 55mM sodium citrate and stirring for 10 minutes at room temperature. 
The microcapsules were then washed several times in DI water, until the microcapsule 
pellet was firmly settled at the bottom of the tube after centrifugation (~5-6 washes). The 
diameter of the hydrated microcapsules was measured using ImageJ. 
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3.3.2 Fabrication of Chitosan Microcapsules 
Chitosan (300 ml of a 1.5% w/v solution) was spray dried with a Büchi-190 Mini 
Spray Dryer using the parameter settings displayed above in Table 3.2 and collected in a 
dry product collection vessel. Spray dried chitosan microcapsules (approximately 4.5 g) 
(weight?) were neutralized in 500 ml absolute ethanol (undenatured) containing 12.5 ml 
6M NaOH, stirring for 2 hours at 400 rpm at room temperature. The neutralized 
microcapsules were transferred into four 50 ml polypropylene tubes (microcapsules were 
evenly divided among the tubes) and centrifuged at 5000xg for 2 minutes, decanting the 
supernatant and repeating as necessary until all of the microcapsules were contained in 
the polypropylene tubes. The microcapsules were then washed in 50 ml 100% ethanol 
(1x), 75% ethanol (1x), 50% ethanol (1x), 25% ethanol (1x), and DI water (3x). For the 
wash steps, the microcapsules were vortexed in the wash solution, centrifuged at 5000xg 
in an Allegra™ 21 Centrifuge (Beckman Coulter, Brea, CA) for 2 minutes, and the wash 
solution was decanted before continuing with the next wash solution in the series. After 
the last wash with DI water, the tubes were filled with approximately 20 ml water, frozen 
in liquid nitrogen, and lyophilized for approximately 72 hours. Dried chitosan 
microcapsules were stored in a desiccator at room temperature until further use. The 
diameter of the dry or hydrated microcapsules was measured using ImageJ. 
 
3.3.3 Quantification of Chymotrypsinogen Loading in Microcapsules 
Chymotrypsinogen was used as a model protein for BDNF and NT-3 to determine 
the loading efficiency of the alginate and chitosan microcapsules. The molecular weights 
and isoelectric points are approximately 25 kDa and 9.1 for chymotrypsinogen; 27 kDa 
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and 9.01for BDNF; and 29 kDa and 9.46 for NT-3.  ChABC loading for the alginate and 
chitosan microcapsules was also quantified. Microcapsules (20 mg) were soaked (either 
from a dry state or pre-hydrated in PBS) in 200 µl of a 400 µg/ml chymotrypsinogen 
solution (in PBS, or 500mM trehalose in PBS). Note: 500mM trehalose was used because 
concentrations higher than this interfered with the Quant-it protein assay. At t=10, 60, 
and 120 minutes, the microcapsules were briefly centrifuged and the supernatant was 
assayed using a Quant-it Protein Assay Kit (Invitrogen) according to the manufacturer’s 
instructions. Briefly, 10 µl of each protein sample was added to a 96-well plate 
containing 200 µl of the Quant-it working solution (samples read in duplicate). 
Fluorescence was measured using a plate reader (Tecan infinite M200; i-control 1.3 
software) at excitation/emission wavelengths of 470/570 nm. A standard curve was used 
to quantify the amount of protein remaining in the supernatant in order to determine the 
amount of protein loaded into the microcapsules. 
 
3.3.4 Fabrication of Custom Molds for Mini C/A Scaffolds 
The C/A scaffolds were also fabricated in smaller molds custom made to fit the 
diameter of rat spinal cords (Sprague Dawley rats, approximately 275 g) for future in vivo 
studies. Molds were designed using AutoCAD and fabricated in the Drexel University 
Machine Shop with the specifications shown below (Figure 3.2). 
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Figure 3.2: Specifications and 3D images of custom molds 
 
 
 
3.3.5 Fabrication of 3D Mini C/A Scaffolds  
The two halves of each rat model mold were joined together, fitted with a copper 
bottom plate, and tightened with screws. BDNF and/or NT-3 (10 µg total) was 
resuspended in 26.5 µl cold PBS (4oC). ChABC (normal (Seikagaku) or protease-free 
(Sigma)) was resuspended in cold PBS to a concentration of 754 Units/ml. 20 µl of the 
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desired protein solution was added to a 1.5 ml microcentrifuge tube containing 2 mg of 
dry alginate or chitosan microcapsules (or no capsules). 
The tube of protein solution and microcapsules was briefly vortexed to ensure that 
all of the microcapsules were hydrated, and then kept at 4oC while preparing the C/A 
PEC mixture (prepared as described above). Entrapped bubbles in the C/A PEC mixture 
were removed by spinning at 2500 rpm for 1 minute in a shear mixer (SpeedMixer, DAC 
1510 FVZ‐K, FlackTek). The C/A PEC mixture was added to the hydrated microcapsules 
(total final volume of 667 µl) and gently pipetted to mix. A 5 ml syringe with a 25G 
needle was used to transfer the C/A PEC mixture into the rat model molds before 
securing onto the temperature-controlled copper cold finger of the freeze casting system. 
The scaffolds were freeze cast at a constant cooling rate of 1oC/min to a final temperature 
of -150oC as described above. After the samples were completely frozen, the screws and 
copper bottom plates were removed from the molds, and the molds containing the frozen 
C/A mixture were lyophilized for 24 hours. Dried C/A scaffolds were removed from the 
molds using dissecting forceps and stored in a desiccator at -20oC until use. For 
BDNF/NT-3, each C/A scaffold contained 1µg of protein. For chABC, each C/A scaffold 
contained 2 Units of the enzyme (total mass depending on chABC lot number and 
specific activity). 
 
3.4 Quantification of Protein Release from C/A Scaffolds 
3.4.1 Quantification of Neurotrophin Release from Mini C/A Scaffolds 
Calcium chloride solution (0.25% w/v) was prepared in 1M trehalose (in water, 
0.2 µm filtered), and a separate 1M trehalose solution was prepared in PBS (0.2 µm 
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filtered). A PLO solution (0.5 mg/ml) was also prepared (in 1M trehalose prepared in 
PBS, 0.2 µm filtered). Eight microcentrifuge tubes were filled with 0.5 ml of the 
following solutions, and the mini C/A scaffolds were crosslinked, rinsed, and PLO-coated 
by incubating in the tubes with gentle agitation, in the following order: 
 
 
 
Table 3.4: Crosslinking, polycation/laminin coating, and wash steps 
Tube Solution (0.5 ml) Incubation time 
1 0.25% CaCl2 (in 1M trehalose, water) 10 minutes 
2 1M trehalose, PBS 30 seconds (wash step) 
3 1M trehalose, PBS 30 seconds (wash step) 
4 1M trehalose, PBS 30 seconds (wash step) 
5 0.5mg/ml PLO (in 1M trehalose, PBS) 6 minutes 
6 1M trehalose, PBS 30 seconds (wash step) 
7 1M trehalose, PBS 30 seconds (wash step) 
8 1M trehalose, PBS 30 seconds (wash step) 
9 0.1 mg/ml laminin (in 1M trehalose, PBS) 1 hour 
 
 
 
After the last step, the mini C/A scaffolds were placed into a 1.5 ml 
microcentrifuge tube with an attached cap + O-ring seal (Corning), containing 0.5 ml 1M 
trehalose (PBS, 0.2 µm filtered). These microcentrifuge tubes were secured onto an end-
over-end shaker in a 37oC incubator. At designated time points, all of the supernatant was 
removed (0.5 ml) and replaced with a fresh 0.5 ml of 1M trehalose, before returning the 
tubes to the 37oC incubator. The removed supernatant was saved in separate 
microcentrifuge tubes and kept at -20oC until further use. To quantify the mass of BDNF 
or NT-3 present in the collected supernatant, DuoSet ELISA Development Kits (R&D 
Systems) were used according to the manufacturer’s protocol. Two-way ANOVA with 
repeated measures was performed for statistical analysis of neurotrophin release. 
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3.4.2 Dimethylmethylene Blue (DMMB) Assay  
A modified DMMB assay, as according to Enobakhare et al., 1996, was used to 
characterize the release profile and activity of chABC released from the C/A scaffolds 
[182]. The DMMB assay quantifies the amount of chondroitin sulfate 
glycosaminoglycans (CS-GAGs) remaining after digestion with chABC. The DMMB dye 
solution was prepared by mixing 10.5 g of dimethylmethylene blue with 2.5 ml absolute 
ethanol and 1g sodium formate. This mixture was added to 400 ml DI water and the pH 
was adjusted to 1.5 using formic acid. The final volume was made up to 500 ml using DI 
water and the DMMB dye solution was stored in dark bottles at room temperature for up 
to 3 months. A standard curve from 0-20 µg chondroitin sulfate C (Seikagaku) was 
prepared by making 1:2 serial dilutions of a 1 mg/ml chondroitin sulfate C solution 
(prepared in PBS). Twenty µl of each dilution was added to a 48 well plate (Corning) 
along with 5 µl of 1 M trehalose. Release samples were assayed by pipetting 5 µl of 
release supernatant collected from the scaffolds into the 48 well plate and adding 20 µl of 
the 1 mg/ml chondroitin sulfate C solution. The plates were sealed with plate sealers, 
placed on an orbital shaker for approximately 15 seconds to mix the solutions and 
incubated at 37oC for 20 minutes. After the incubation, 1 ml of DMMB solution was 
added to each well and A595nm was measured immediately using a plate reader. Two-way 
ANOVA with repeated measures was performed for statistical analysis of chABC release. 
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3.4.3 A232nm Kinetic Assay 
An additional spectrophotometric assay was performed to quantify the activity of 
chABC released from the scaffolds. A 4 mg/ml substrate solution of chondroitin sulfate C 
(Seikagaku) was prepared in a Tris-sodium acetate buffer (250 mM Tris HCl, 300 mM 
Sodium Acetate, 0.05% (w/v) BSA, pH 8.0). Release medium taken from the C/A 
scaffolds (50 µl) was added to a 96 well plate (Corning) and 50 µl of the substrate 
solution was also added to the plate using a multichannel pipette. The plate was placed on 
an orbital shaker for approximately 15 seconds to mix the solutions before inserting into 
the plate reader. A kinetic assay was performed at 37oC, measuring A232nm of each of the 
wells at 1 minute intervals for a total of 21 minutes. Beer-Lambert’s law was used to 
calculate the concentration of chABC, where c = concentration, A = absorbance at 
232nm, ε = molar extinction coefficient of chondroitin sulfate C (5500 L mol-1 cm-1), and 
ℓ = path length of 0.29 cm corresponding to 100 µl in a 96 well plate: 
 
𝑐 =  
𝐴
𝜀ℓ
   →    
∆𝐴 𝑚𝑖𝑛⁄
(𝐿 𝑚𝑜𝑙−1𝑐𝑚−1)(𝑐𝑚)
=  
𝑚𝑜𝑙
𝑚𝑖𝑛∙𝐿
                                           (3.1) 
 
One unit of chABC hydrolyzes chondroitin sulfate C to produce 1 µmole of 2-acetamido-
2-deoxy-3-O-(β-D-gluc-4-ene-pyranosyluronic acid)-6-O-sulfo-D-galactose per minute at 
pH 8.0 at 37°C. Continuing from equation 3.1, the concentration of product formed per 
minute was used to calculate the concentration of chABC: 
 
𝜇𝑚𝑜𝑙
𝑚𝑖𝑛∙𝐿
=  
𝑢𝑛𝑖𝑡𝑠
𝐿
 𝑜𝑓 𝑐ℎ𝐴𝐵𝐶                                                         (3.2) 
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Two-way ANOVA with repeated measures was performed for statistical analysis of 
chABC release. 
 
3.4.4 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
To further characterize the release of chABC from the scaffolds, SDS-PAGE was 
performed to analyze the degradation of decorin, a specific CSPG. Decorin (10 µl of 0.5 
mg/ml in PBS) was added to 250 µl of release substrate collected from the scaffolds and 
this mixture was incubated in a 37oC water bath for 4 hours. Samples were then removed 
and stored at -20oC until ready for SDS-PAGE analysis. The samples were further diluted 
(24 µl + 36 µl PBS) before mixing 13 µl with 5 µl NuPAGE LDS Sample Buffer and 2 µl 
Invitrogen Reducing Agent and heating at 70oC for 10 minutes. Novex Sharp Unstained 
Protein Standard was diluted 1:10 in Sample Buffer without heating. A 4-12% Bis-Tris 
gradient gel (1.0 mm) was placed in an electrophoresis chamber and filled with NuPAGE 
MOPS SDS Running Buffer. 20 µl of the sample (5 µl protein standard) was loaded into 
each lane, and the gel was run at 200V for 1 hour. Silver staining was performed using a 
Pierce Silver Stain Kit according to the manufacturer’s instructions. Images were taken 
with an Alpha Innotech FluorChem SP MultiImage Light Cabinet and AlphaEase FC 
software version 6.0.0 (Santa Clara, CA). 
 
3.5 In vitro Evaluation of C/A Scaffolds 
3.5.1 Dorsal Root Ganglia Isolation and Culture 
Fertilized white Leghorn eggs were kept in an egg incubator at 37oC with an 
automatic egg turner for 10 days (E10) before being removed for dissection. Eggs were 
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sprayed with 70% reagent alcohol and then cracked open to remove the chick embryo. 
The heads of the embryos were removed with dissecting forceps and the bodies placed in 
sterile culture dishes to dissect under a dissecting microscope. The thoracic cavity of the 
embryo was opened dissecting forceps and the organs removed to expose the spine and 
DRGs. The DRGs were removed with dissecting forceps and placed into a culture dish 
containing Hank’s Buffered Saline Solution (Mediatech).  
DRGs were dissociated by incubating the whole DRG explants in PBS for 10 
minutes at 37oC, followed by incubating in 0.25% trypsin-EDTA for 12 minutes at 37oC. 
DRG growth medium (Dulbecco’s modified Eagle medium (DMEM) + 10% FBS + 1% 
antibiotic/antimycotic) was added and the DRGs were triturated using a flame polished 
glass Pasteur pipette. Dissociated DRGs were plated in a tissue culture plate with DMEM 
+ 10% FBS + 1% antibiotic/antimycotic for up to 2 hours in order to allow non-neuronal 
cells (Schwann cells and fibroblasts) to attach. The neuronal cells were then harvested 
from the tissue culture plate and centrifuged to collect the pellet. 
Whole DRG explants or dissociated DRGs were seeded onto a cross-sectional 
surface of the scaffold and incubated in growth medium (DMEM, 10% fetal bovine 
serum (FBS), 1% antibiotic/antimycotic, and 100 ng/ml nerve growth factor (NGF)) at 
37oC and 5% CO2. DRGs were cultured for 72 hours in vitro prior to 
immunocytochemical analysis. 
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Figure 3.3: Schematic of DRG explant seeded on the cross-sectional surface of a C/A 
scaffold (adapted from Riblett et al. [176]). 
 
 
 
3.5.2 Assessment of Cell Viability 
To assess cell viability of individual DRG neurons on the C/A scaffolds, a 
Live/Dead Viability/Cytotoxicity Kit (Invitrogen) was used according to the 
manufacturer’s instructions. Scaffolds were washed once with PBS and incubated in the 
dye solution containing 2 µM Calcein AM and 4 µM ethidium homodimer-1 for 30 
minutes at room temperature. The stained cells were visualized using an Olympus IX71 
fluorescence microscope and SPOT RT3 microscope camera. Three fields were imaged 
from each scaffold (n=4 scaffolds from each sample group) and ImageJ software (NIH) 
was used to count live cells (green fluorescence) and dead cells (red fluorescence).  
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3.5.3 Immunocytochemistry/Confocal Microscopy 
After removal of the medium, DRG-seeded scaffolds were fixed in 4% 
paraformaldehyde for 30 minutes at room temperature and washed three times in PBS. 
The fixed cells were blocked in 0.1% Triton X-100 with 10% normal goat serum in PBS 
for 1 hour at room temperature, followed by an overnight incubation at 4oC in blocking 
solution containing mouse monoclonal antibody anti-neurofilament 200 kDa (Sigma; 
1:500). The cells were washed three times in PBS and then incubated in secondary 
antibody Alexa Fluor 488 goat anti-mouse IgG (Invitrogen; 1:500 in blocking solution) 
for 1 hour at room temperature in the dark. DRG-seeded scaffolds were visualized and 
images were captured using an Olympus IX81 inverted confocal microscope. A z-stack 
over approximately 20 sections of 10 µm thickness was performed, and single layers 
were merged into one image using FluoView software version 1.7.  
 
3.5.4 Measurement of Neurite Orientation 
Confocal images of immunocytochemically stained DRGs and neurites were used 
to quantify the angle of neurite orientation on the C/A scaffolds. The angle of neurite 
orientation relative to the channel direction of the C/A scaffolds was measured from the 
point of origin at the DRG explant to the tip of the neurite, with the direction of the 
channels represented as 0o (determined by slight scaffold autofluorescence). Measured 
neurite angles were separated into bins consisting of 10o increments between -90o and 
+90o and the data were fit to a Gaussian distribution curve. 
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3.5.5 Determination of Neurotrophin Bioactivity After Release from C/A Scaffolds 
C/A scaffolds containing neurotrophins were crosslinked, washed, and coated as 
described in section 3.4.1. The neurotrophins were released into 0.5 ml of DMEM + 2% 
B-27 supplement + 1% antibiotic/antimycotic, removing and replacing 0.5 ml of this 
medium at similar designated time points. The removed medium was saved in separate 
microcentrifuge tubes and kept at -20oC until further use. 
Coverslips (12mm) were acid washed by soaking in a glass beaker containing 1N 
HCl at 50oC overnight and then cooled to room temperature. The coverslips were then 
washed 3 times with deionized water before sonicating in deionized water in a bath 
sonicator for 30 minutes. This sonication step was repeated again in deionized water, 
followed by sonication in a 50% ethanol solution, 70% ethanol solution, and 100% 
ethanol solution. The cleaned coverslips were then passed through the flame of an alcohol 
burner 10 times on each side before placing in a 24 well tissue culture plate and UV-
sterilizing for 15 minutes. Each cleaned, sterilized coverslip was coated with 0.5 ml of 
0.1 mg/ml PLO (diluted in water) overnight. The coverslips were washed 3 times with 
PBS to remove any excess, unadsorbed PLO.  
 Chick embryos were dissected and DRG explants were isolated as described in 
section 3.2.8. Collected release medium was diluted 1:1 with fresh culture medium 
(DMEM + 2% B-27 supplement + 1% antibiotic/antimycotic) and 200 µl of this diluted 
medium was added to the 24 well plates containing PLO-coated coverslips. DRG 
explants were placed into the wells using forceps and cultured at 37oC and 5% CO2 for 48 
hours. After 48 hours of culture, neurite outgrowth was observed using an Olympus IX71 
fluorescence microscope and SPOT RT3 microscope camera. To determine the average 
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neurite length, the distance from the edge of the explant to the tip of the neurite growth 
cone was measured in 4 places around the perimeter of the DRG, with each length 
measurement separated by 90o [183, 184]. These average neurite length measurements 
were compared to negative and positive controls of culture medium containing either no 
exogenous neurotrophin or 1 and 10 ng/ml neurotrophin (BDNF or NT-3). 
 
3.5.6 Assessment of Neurite Growth on Laminin/CSPG Striped Substrate 
An in vitro “glial scar” was fabricated on a flat culture surface by generating a 
striped pattern of adsorbed proteins as described by Snow et al. [16, 185, 186]: 
Coverslips were cleaned as described in section 3.5.5 before using silicone 
aquarium sealant to glue the coverslips to the underside of holes formed in the bottom of 
12 well tissue culture plates. The wells formed by this procedure were coated with 50 µl 
of a nitrocellulose solution (20 cm2 Whatman Protran BA85 nitrocellulose dissolved in 
24 mL reagent grade methanol) and the surfaces were then air dried and UV sterilized 
under a laminar flow hood. Filter paper (Whatman No. 1) was cut into strips of 1mm 
width and then soaked in a solution of CSPGs (50 µg/mL) and TRITC (4.4 µg/mL) in 
PBS. The soaked filter paper strips were laid onto the nitrocellulose substrate, air dried, 
and then removed, resulting in the transfer of CSPGs and TRITC to the nitrocellulose 
substrate. Laminin (100 µl of a 25 µg/mL solution in PBS) was then spread evenly over 
the entire dish to create alternating stripes of laminin and CSPG + laminin, allowing 
laminin to attach for 2 hours before washing twice with PBS. Dissociated DRG neurons 
were seeded on the laminin/CSPG striped substrate at a density of 10,000 cells per well in 
DMEM + B27 + antibiotic/antimycotic. Netwell inserts with 500 µm mesh size (Corning) 
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containing crosslinked scaffolds coated with PLO and laminin were inserted into the 12 
well plates and additional culture medium was added to raise the total volume to 1 ml per 
well. 
The dissociated DRG neurons were cultured at 37oC and 5% CO2 for 48 hours. 
After 48 hours of culture, DRG neurons were immunostained as described in section 
3.5.3, and images were captured using an Olympus IX71 fluorescence microscope and 
SPOT RT3 microscope camera. The density of neurites growing on the laminin/CSPG 
striped substrate was measured using ImageJ software (NIH). The threshold of the 
images was adjusted to white and black using the threshold adjustment controls in 
ImageJ. Neurite density was quantified by measuring the integrated density value within 
equal sized rectangular boxes drawn on either side of the CSPG/laminin border. Average 
integrated density values were calculated for each treatment group. 
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4. RESULTS AND DISCUSSION 
4.1 Fabrication and Development of a Chitosan-Alginate (C/A) Scaffold  
 Porous, linearly aligned scaffolds were produced by directionally freezing and 
subsequently lyophilizing a chitosan-alginate polyelectrolyte complex mixture. These 
scaffolds, with and without surface modifications, were evaluated for their ability to 
support neuronal survival and growth in vitro, in order to determine their suitability as a 
substrate for regeneration in the injured spinal cord. 
 
4.1.1 Effects of Charge Neutralization Solutions on Encapsulated Protein Activity 
 The initial scaffolds to be used in these studies were produced by directionally 
freezing a 2.4% (w/v) chitosan solution at a rate of 6oC/min. These particular parameters 
were selected because the resulting scaffold possessed a lamellar architecture with 
microridges that were capable of directionally aligning DRG neurite growth, and an 
elastic modulus (10 ± 0.18 kPa) close to that of native spinal cord tissue (3-5 kPa) [176]. 
In order to render it insoluble in aqueous media and maintain its structure, the chitosan 
scaffold required immersion in a charge neutralization solution, composed of 0.4% (w/v) 
NaOH in 95% ethanol. Since one of the aims of this thesis was to encapsulate proteins 
such as neurotrophic factors and chondroitinase ABC within the scaffold, it was 
necessary to determine if this charge neutralization solution or alternative neutralization 
solutions affected protein activity. The enzyme β-galactosidase (β-gal) was used to 
evaluate the effects of various charge neutralization solutions on the enzyme activity. 
 β-gal is a commonly used reporter molecule for analysis of gene expression, and 
can be easily detected through a colorimetric assay by measuring hydrolysis of the 
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chromogenic substrate, o-nitrophenyl-ß-D-galactoside (ONPG). Due to chitosan 
interference with the assay, β-gal was encapsulated within 1% alginate capsules 
crosslinked with CaCl2 and incubated in various charge neutralization solutions for 15 
minutes at room temperature. After washing with HEPES buffered saline, the capsules 
were incubated in an ONPG solution and the absorbance of this solution was measured in 
order to quantify β-gal activity. Trehalose, a sugar that has been shown to preserve the 
activity of proteins, was also incorporated into the alginate capsules to determine if its 
presence would prevent loss of β-gal activity due to the charge neutralization solutions.  
 
 
 
 
Figure 4.1: Effects of various charge neutralization solutions on β-galactosidase activity. 
*** indicates p < 0.001. 
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 As shown in Figure 4.1, all of the charge neutralization solutions tested in the 
absence of trehalose caused a significant loss in β-gal activity as compared to the HEPES 
buffered saline control; 83.7 ± 10.2% (0.4% NaOH in 95% ethanol), 71.4 ± 11.5% (95% 
ethanol), and 52.1 ± 9.02% loss in activity (50 mM NaHCO3 in 70% ethanol) compared 
to the β-gal activity in HEPES buffered saline (p<0.001). Although 95% ethanol and 
50mM sodium bicarbonate in 70% ethanol performed significantly better than the 
NaOH/ethanol mixture (p< 0.05 and p<0.01, respectively), β-gal activity levels under 
these conditions were still significantly lower than the control (p<0.001). The addition of 
trehalose did not sufficiently preserve the activity of β-gal under any conditions, as none 
of the activity levels were found to be significantly different for each charge neutralizing 
solution (p>0.05 for trehalose vs. no trehalose; all solutions). Protein denaturation is 
caused by the disruption of hydrogen bonding in secondary and tertiary protein 
structures, and can occur through exposure to organic solvents such as ethanol and strong 
bases. However, a basic solution is needed to neutralize chitosan scaffolds and organic 
solvents maintain the scaffold structure during neutralization. Since all of the charge 
neutralization solutions tested negatively affected β-gal activity, we decided to develop 
an alternative scaffold in order to avoid this protein-denaturing step. 
 
4.1.2 Fabrication of C/A Scaffolds 
 Although chitosan has many beneficial biomaterial characteristics such as 
biocompatibility, the use of a chitosan-alginate composite scaffold has certain advantages 
over a scaffold made only of chitosan. The charge interactions between chitosan and 
alginate in a composite scaffold maintain structural integrity and as a result chitosan-
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alginate composites do not need harsh treatments to prepare them for immersion in 
aqueous media, while chitosan scaffolds must be neutralized in a mixture of ethanol and 
NaOH, or other solutions described in section 4.1.1. Also, while chitosan scaffolds must 
be fabricated in acidic solutions due to their insolubility above ~pH 6 (pKa 6.3), chitosan-
alginate scaffolds can be prepared over a wide pH range, providing the ability to 
incorporate proteins at physiological pH and avoid potential denaturation [144]. Other 
investigators have shown that a chitosan-alginate scaffold produced by blending, non-
directional freezing, and lyophilizing is able to maintain its shape for transplantation due 
to minimal swelling in aqueous media, as compared to a similarly fabricated chitosan 
scaffold which swelled significantly more [144]. It has been demonstrated that C/A 
microcapsules are superior to chitosan as well as alginate microcapsules for sustained 
protein and drug release, which will be beneficial for the extended local delivery of 
growth factors to the injured spinal cord [147, 148]. We first intended to determine the 
suitability of a chitosan-alginate scaffold for use as a neural tissue engineering substrate 
prior to further scaffold development, including the incorporation of proteins for 
sustained release. 
 
4.1.3 Effects of Varying Chitosan:Alginate Ratio  
Chitosan and alginate solutions were mixed together in varying weight ratios 
(90:10, 75:25, and 50:50 chitosan:alginate) by homogenizing at 10,000 rpm to form a 
chitosan-alginate PEC (C/A PEC) mixture. The C/A PECs form due to strong 
electrostatic interactions between the oppositely charged polymers. This C/A PEC 
mixture was then processed by freeze casting at 6oC/min, the same freezing rate that was 
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successfully used to produce the chitosan scaffolds described in section 4.1.1, in order to 
determine the effects of alginate incorporation on scaffold structure. Figure 4.2 is a 
composition of SEM images of the plain chitosan scaffold, illustrating its lamellar 
architecture and ridges in order to highlight the differences in scaffold structure between 
chitosan and chitosan-alginate composites of varying ratios [176]. Figure 4.3 shows light 
micrographs of the cross-sections of the chitosan-alginate composite scaffolds and a 
100% alginate scaffold (2.4% w/v, freeze cast at 6oC/min). 
 
 
 
 
Figure 4.2: SEM images of the cross-section of chitosan scaffolds (2.4% w/v) produced 
by freeze casting at 6oC/min. Scale bars: (A) 200 µm, (B) 40 µm, (C) 200 µm, (D) 10 µm 
[176]. 
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Figure 4.3: Light micrographs of C/A scaffolds produced by mixing chitosan and alginate 
in different ratios; and 100% alginate scaffold. A) 90:10, B) 75:25, C) 50:50 
chitosan:alginate ratio; D) 100% alginate scaffold. All scaffolds had 2.4% w/v total 
polymer content and were freeze cast at 6oC/min. Scale bar = 500 µm. 
 
 
 
 The overall ridged lamellar structure seen in the plain chitosan scaffolds is also 
observed within the 90:10 scaffolds (see Appendix B for larger images). Large chunks of 
C/A PECs can also be seen dispersed throughout the scaffold. This was even more 
pronounced in the 75:25 scaffolds. These scaffolds possess smaller regions of chitosan 
lamellae broken up more frequently by C/A PECs, because of the higher ratio of alginate 
present in the mixture. The 50:50 scaffolds have a dense, porous structure with no clear 
regions of chitosan or alginate lamellae since mixing the polymers in this ratio produces 
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the highest yield of the insoluble PECs. The plain alginate scaffold has a similar ridged 
lamellar architecture to that of the plain chitosan scaffold, due to ice crystals forming in 
these solutions in a similar manner during directional freezing. The presence of insoluble 
C/A PECs in a mixture of the two polymer solutions affected the size and shape of the 
growing ice crystals, interfering with the formation of the continuous lamellae seen in 
both the plain chitosan and alginate scaffolds. 
 When these chitosan-alginate scaffolds were immersed in PBS without first 
soaking them in a charge neutralization solution, the 50:50 scaffolds were the only ones 
to maintain their structure in the aqueous solution. The 90:10 and 75:25 scaffolds quickly 
collapsed and dissolved, leaving only the portions of insoluble PECs intact. In these 
scaffolds, there is a predominance of chitosan which results in a high proportion of the 
scaffold that is dependent on charge neutralization to maintain its integrity when 
hydrated. The 50:50 scaffolds have the highest yield of insoluble PECs, which do not 
require charge neutralization for maintenance of scaffold integrity. Since the 50:50 
scaffolds were able to maintain their structure without the protein-denaturing charge 
neutralization step, this scaffold ratio was selected for further structural and chemical 
modifications. 
 
4.1.4 Effects of Varying C/A PEC Mixing Method 
 Early on in the study it was determined that the method of mixing the chitosan 
and alginate polymers had a considerable influence on the outcome of freeze casting. The 
C/A PEC mixing method was varied in order to determine if smaller PECs and a more 
homogeneous PEC mixture would improve the uniformity of the scaffold structure and 
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permit the formation of unimpeded longitudinal lamellae or channels. We investigated 
sonication using an ultrasonic probe as an alternative method of producing smaller C/A 
PECs in comparison to homogenization, which was used to produce the PECs for the 
scaffolds fabricated as described in Section 4.1.3. Sonication is the process of converting 
an electrical signal into mechanical vibration through a piezoelectric transducer in order 
to apply ultrasound energy to a sample. When immersed in liquid, rapid vibration of the 
probe tip causes the cavitation of microscopic bubbles which agitate particles within the 
cavitation field. Sonicating the mixture of chitosan and alginate solutions produced more 
uniform PEC particles than homogenization, as shown in Figure 4.4.  
 
 
 
 
Figure 4.4: Phase contrast images of PEC particles produced by A) homogenization; B) 
sonication. Scale bar = 100 µm. 
 
 
 
Homogenization produced a mixture of linear strands and smaller globular PEC 
particles, while sonication yielded only these uniform globular particles. Other 
investigators describe forming a C/A PEC mixture by blending at high speed for up to 1 
hour [144, 154]. Sonicating for only 2 minutes was a more effective and efficient manner 
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of producing a uniform C/A PEC mixture as compared to blending or homogenizing. 
Freeze casting this sonicated C/A PEC mixture produced a scaffold with a more 
homogeneous structure due to the absence of these larger PEC particles, shown below in 
Figure 4.5. The differences in structure were much more pronounced when the pH of the 
mixture was adjusted to 7.4 (Figure 4.5D), described in Section 4.1.5 below.  
 
 
 
 
Figure 4.5: Light micrographs of 50:50 C/A scaffolds freeze cast at 1oC/min after 
fabricating PECs using different methods. A) Homogenized, pH ~4.4; B) Homogenized, 
pH 7.4; C) Sonicated, pH ~4.4; D) Sonicated, pH 7.4. Scale bar = 500 µm. 
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4.1.5 Effects of pH Adjustment on Scaffold Structure 
Freeze casting the 50:50 C/A PEC mixture without adjusting the pH produced a 
porous, dense scaffold without any linearly aligned channels as shown in Figure 4.6A. 
This dense structure resulted from the high yield of insoluble C/A PECs formed at the 
unadjusted pH of 4.35, which interrupted the formation of continuous ice crystals 
extending through the entire length of the scaffold. This high yield of C/A PECs led to 
the formation of smaller ice crystals during freeze casting, which were unable to extend 
unimpeded through the C/A PEC mixture to form continuous channels. 
Adjusting the pH to 7.4 after sonication by mixing 6 N NaOH into the C/A PEC 
mixture immediately caused the formation of large clumps, due to the precipitation of 
chitosan. In contrast, adding sufficient 6 N NaOH to the chitosan and alginate solutions 
prior to sonicating facilitated the production of a homogeneous C/A PEC mixture with an 
overall pH of 7.4. Adding NaOH in this manner prevents the initial formation of a large 
amount of PECs, rather than first producing a high yield of PECs and subsequently 
dissociating some of them through the precipitation of chitosan. Concentrated NaOH (6 
M) was used in order to minimize the volume of water added, which would affect the 
final polymer concentration of the mixture. Freeze casting the pH-adjusted C/A PEC 
mixture resulted in a highly porous scaffold with linearly aligned channels extending 
longitudinally throughout its entire length (Figure 4.6B), as determined by pipetting a dye 
solution (saline dyed with food coloring) onto the top of the scaffold and observing its 
emanation from the opposite end. This structure is the result of a lower yield of C/A 
PECs formed at higher pH. A lower yield of these insoluble PECs permits the formation 
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of larger ice crystals during freeze casting, which were able to extend unimpeded through 
the mixture and template continuous channels. 
The mannuronic and guluronic acid groups of alginate have pKa values of 3.38 
and 3.65, respectively, while the pKa of chitosan is approximately 6.5. At a pH between 
approximately 3.65 to 6.5, there is a maximum yield of C/A PECs due to ionic bonding 
between the positively charged chitosan amine groups (-NH3
+) and the negatively 
charged alginate carboxyl groups (-COO-). At pH values outside this window, there is a 
lower yield of PEC formation due to chitosan precipitation above approximately pH 6.5, 
alginate precipitation below approximately pH 3.5, and a predominance of non-
protonated amine and carboxyl groups which do not interact ionically. In the preparations 
of C/A PECs for scaffold fabrication, it was observed that adjusting the pH of the PEC 
mixture to 7.4 greatly decreased the viscosity of the mixture, indicating a lower PEC 
yield.  
 
 
 
 
Figure 4.6: Light micrographs of 50:50 C/A scaffolds directionally frozen at 1oC/min, 
prior to crosslinking; effects of scaffold formation at different pH. A) Transverse section 
of C/A scaffold formed at unadjusted pH 4.35; B) Transverse section of C/A scaffold 
formed at pH adjusted to 7.4. Scale bar = 100 µm. 
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Fourier transformed infrared (FTIR) spectroscopy has previously been used to 
characterize the ionic interactions between chitosan and alginate in C/A PECs formed at 
different pH values [138, 144]. The presence of a peak attributed to the interaction of 
chitosan amine groups and alginate carboxyl groups can be seen at a wide range of pH 
values. The intensity of this peak increased from pH 2 to pH 6, and decreased a little at 
pH 9, indicating that there is still C/A PEC formation at pH values outside the optimum 
window for maximum yield [138]. Also, another change in the FTIR spectra was noted 
after the chitosan-alginate mixture was crosslinked with CaCl2, indicating the linking of 
adjacent residual alginate carboxyl groups into a network matrix [144]. Using the 
Henderson-Hasselbalch equation, we determined that at a pH of 7.4, the chitosan amine 
groups are approximately 11.2% protonated (NH3
+), while the alginate carboxyl groups 
are approximately 99.9% unprotonated (COO-), resulting in a polymer mix with a net 
negative charge. The chitosan charge is neutralized prior to freeze casting and 
lyophilization, and the remaining uncomplexed alginate present in the scaffold is 
available for crosslinking with CaCl2. The final scaffold structure is an interpenetrating 
network matrix of chitosan, alginate, and C/A PECs.  It would be beneficial to 
incorporate proteins into a scaffold at physiological pH rather than an acidic pH, and the 
presence of continuous channels is important for unobstructed axon regeneration through 
the length of the scaffold. Since the pH-adjusted C/A scaffolds possessed these 
characteristics, all further testing was performed with scaffolds produced under these 
conditions. 
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4.1.6 Mechanical Properties  
We aimed to produce a scaffold that has mechanical properties comparable to 
those of native spinal cord tissue, a characteristic that is important to prevent compression 
of the regenerating nerves when implanted into the injured spinal cord [83]. Compression 
tests were performed in order to determine the elastic modulus of the crosslinked, 
hydrated scaffolds prepared at different freezing rates. Since the original chitosan 
scaffolds described in Section 4.1.1 were freeze cast at 6oC/min, we first evaluated the 
mechanical properties of C/A scaffolds prepared at a similar freezing rate. Freeze casting 
the C/A PEC mixture at this freezing rate produced a scaffold with an elastic modulus of 
23.0 ± 6.82 kPa. In order to produce scaffolds with an elastic modulus closer to that of 
the spinal cord, the C/A PEC mixture was freeze cast at a slower rate, 1oC/min. The 
resulting scaffold had an elastic modulus within the desired range, measured at 5.08 ± 
0.61 kPa. These changes in elastic modulus are directly related to the effect of freezing 
rate on the mechanisms of ice-formation. A slower freezing rate causes the formation of 
larger ice crystals, which in turn template a scaffold with wider channels (69 ± 5.8 µm 
channel width for scaffolds frozen at 1oC/min compared to 33 ± 5.6 µm for scaffolds 
frozen at 6oC/min) and a less tightly packed structure of chitosan-alginate channel walls 
(Figure 4.7). This change in structure leads to lower scaffold stiffness and strength. The 
wider channels of the scaffolds frozen at 1oC/min provide less resistance against bending 
and buckling,  thereby decreasing the elastic modulus [178].  
Reported elastic modulus values for the spinal cord range widely from 
approximately 3 kPa to 300 kPa depending on the presence or absence of meninges on 
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the tested samples [68], but the modulus of the C/A scaffolds frozen at 1oC/min is 
comparable to the 3-5kPa reported for isolated white and grey matter (no meninges 
present). All further development was continued with C/A scaffolds frozen at 1oC/min, 
due to these closely aligning mechanical properties. 
 
 
 
 
Figure 4.7: Light micrographs of 50:50 C/A scaffolds frozen at A) 6oC/min; B) 1oC/min. 
Scale bar = 100 µm. 
 
 
 
4.1.7 Final Structure of C/A Scaffolds 
Freeze casting a 1.5% (w/v) total polymer concentration C/A PEC mixture (pH 
7.4) at 1oC/min produced three-dimensional C/A scaffolds with a linearly aligned, highly 
porous microstructure. Characterization of the dry scaffolds with SEM indicated that the 
average channel diameter was 69 ± 5.8 µm (ranging from approximately 60 to 80 µm), 
with channels extending longitudinally throughout the entire length of the scaffold. The 
smooth surface and channel walls were shown to be connected via discrete points of 
bridging (i.e. “pillars”) and small fenestrations throughout the scaffold, but these pillars 
did not block the longitudinal channels (Figure 4.8). The C/A scaffolds also maintained 
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their porous structure after crosslinking with CaCl2 and immersion in aqueous medium, 
visible in Figure 4.9. Slight distortions of the structure seen in Figure 4.9 are due to the 
re-freezing after hydration. The average channel width after crosslinking and dehydration 
was almost unchanged at 68 ± 5.7 µm (ranging from approximately 60 to 80 µm). 
Adsorption of polycations and/or laminin onto the scaffold surface did not visibly affect 
the structure.   
In comparison, a pure chitosan scaffold also directionally frozen at 1oC/min is 
described as having “highly elongated pores with relatively straight cell walls” with an 
approximate lamellar spacing of 100 µm [178]. Freeze casting the 1:1 C/A PEC mixture 
(pH 7.4) under the same conditions leads to a tighter channel structure with discrete 
pillars connecting the channel walls. This difference in structure is caused by the 
presence of the insoluble PECs, which change the manner in which water diffuses out 
from the polymer mixture, resulting in the templating of smaller, bridged channels 
throughout the scaffold [178]. The pillars bridging the channel walls do not block the 
channel openings, but will help to maintain patency of the scaffold in vitro or in vivo, 
allowing axons to grow throughout the open, porous structure. 
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Figure 4.8: Scanning electron micrographs of C/A scaffold directionally frozen at 
1oC/min, prior to crosslinking. A) Transverse section of scaffold; B) Longitudinal section 
of scaffold. Note the horizontal discrete pillars that connect the walls of the channels in 
B) do not extend across the entire channel.  Scale bar = 100 µm. 
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Figure 4.9: Scanning electron micrographs of C/A scaffold directionally frozen at 
1oC/min, after crosslinking. A) Transverse section of scaffold; B) Longitudinal section of 
scaffold. Scale bar = 100 µm. 
 
 
 
4.1.8 Scaffold Swelling Behavior 
 For spinal cord repair, it is important for porous scaffolds to maintain their 
structure after implantation, as swelling can compromise scaffold structure, leading to 
collapse and therefore obstruction of axon growth through the length of the implant. The 
swelling behavior of the C/A scaffolds was evaluated by measuring the change in 
scaffold diameter and length during incubation in PBS at 37oC over a 24 hour period, at 
which point swelling equilibrium had been reached. No significant change in length was 
observed between the uncrosslinked (2.14 ± 2.83% change) and crosslinked scaffolds  
(-1.19 ± 2.92% change) after 24 hours (p>0.05) (data not shown). 
 
 
 
 
Figure: 4.10: Change in scaffold diameter over time during immersion in PBS at 37oC. 
Chitosan scaffold: fabricated with original parameters, 2.4% w/v, freeze cast at 6oC/min. 
C/A scaffolds: 50:50 ratio, 1.5% w/v, freeze cast at 1oC/min. 
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The cross-sectional diameter of the uncrosslinked scaffolds increased by 11.7 ± 
2.7% (from 18.6 ± 0.23 mm to 20.8 ± 0.25 mm) after 24 hours of incubation in PBS 
(Figure 4.10). Crosslinking the scaffolds with a 0.25% CaCl2 solution significantly 
reduced swelling to 4.4 ± 1.4% (diameter increase from 18.7 ± 0.18 mm to 19.5 ± 0.12 
mm) (p<0.01) at 24 hours. Both the uncrosslinked and crosslinked C/A scaffolds (50:50 
ratio, 1.5% w/v concentration, freeze cast at 1oC/min) displayed significantly less 
swelling than the original chitosan scaffold described in Section 4.1.1. (16.6 ± 2.64% 
increase in diameter, p<0.05 compared to uncrosslinked C/A, p<0.001 compared to 
crosslinked C/A)  (Figure 4.10). After 24 hours of immersion in PBS, the average wall 
width of the uncrosslinked scaffolds was 9.03 ± 1.67 µm, significantly larger than the 
width of the scaffolds crosslinked with 0.25% CaCl2, which was measured to be 7.25 ± 
1.42 µm (p<0.001). Phase contrast images of the uncrosslinked and crosslinked scaffolds 
are shown below in Figure 4.11. 
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Figure 4.11: Phase contrast images of hydrated C/A scaffolds after 24 hours of immersion 
in PBS. A) Uncrosslinked scaffolds, B) Scaffolds crosslinked with 0.25% CaCl2. Scale 
bar = 100 µm. 
 
 
 
More concentrated CaCl2 solutions were tested for scaffold crosslinking (1% and 
2.5% CaCl2), however these solutions led to an initial sample shrinkage during the 
crosslinking step (-2.6 ± 1.3% and -3.4 ± 0.3% respectively) compared to shrinkage of  
-0.5 ± 1.4% for 0.25% CaCl2. Although differences in shrinkage during crosslinking were 
not found to be significantly different, 0.25% CaCl2 was chosen as the scaffold 
crosslinking solution in order to minimize potential distortion of the structure and channel 
constriction. Li et al. also report that a lyophilized, calcium crosslinked chitosan-alginate 
scaffold for bone tissue engineering maintains its structure during incubation in solutions 
with widely ranging pH values, as compared to a similarly fabricated chitosan scaffold 
which only maintained structural stability in solutions of physiological or higher pH 
[144]. This structural stability is attributed to the electrostatic interactions between 
chitosan and alginate which prevent the protonation of chitosan amine groups, and the 
buffering capacity of the alginate carboxyl groups which slow the degradation of chitosan 
[144]. 
 
4.1.9 Incorporation of Laminin into C/A Scaffolds 
Laminin, the major glycoprotein component of basement membranes, is widely 
used as a substrate for the culture of neural cells. This ECM protein modulates cell 
functions such as attachment, spreading, growth and motility, differentiation, and 
stimulation of neurite outgrowth by interacting with specific cell surface receptors [187]. 
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Various methods were investigated for incorporating laminin into the C/A scaffolds in 
order to enhance cell attachment and neurite outgrowth. 
Patel et al. have successfully incorporated laminin along with GDNF into chitosan 
scaffolds through blending, enhancing functional and sensory recovery in rats with sciatic 
nerve transection [134]. Blending laminin into the chitosan and alginate solutions prior to 
sonication produced an acrid odor during the sonication process, even though sonication 
took place with the sample on ice. This was likely due to the destruction of laminin 
molecules by the force of ultrasonic cavitation. This odor was also noted when C/A 
scaffolds were fabricated using alginate covalently modified with laminin. Laminin 
contains a relatively high proportion of cysteine (-SH) residues, with most clustered in 
repeats of approximately 50 amino acids [188]. These sulfur containing residues may 
account for the acrid smell of the breakdown products. Preliminary studies indicated that 
laminin-incorporated scaffolds fabricated using these methods did not promote any DRG 
neurite growth (Figure 4.12A and C). Laminin was also incorporated by blending it with 
the C/A PEC mixture after sonication (25 µg laminin per ml polymer mixture). 
Preliminary studies also demonstrated no neurite growth on these laminin-incorporated 
scaffolds (Figure 4.12B). Concentrations of laminin recommended for cell culture are 
approximately 1-10 µg/cm2. The volume of the cylindrical scaffolds produced was 
approximately 22 cm3 and its many channels give these scaffolds extensive surface area 
for neuron attachment and growth. In order to approach concentrations near those 
recommended for attachment in cell culture, large amounts of laminin would have to be 
mixed into the scaffold, making this method cost ineffective and wasteful.  
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Figure 4.12: Confocal microscope images (z-stack over approximately 20 sections of 10 
µm thickness each) of immunostained DRGs (neurofilament 200; Alexa Fluor 488) on 
scaffolds (not visible) with incorporated laminin after 72 hours of culture.  A) Laminin 
blended into C/A scaffolds before sonication; B) Laminin blended into C/A scaffolds 
after sonication; C) C/A scaffolds fabricated with laminin-modified alginate; D) C/A 
scaffolds coated with laminin. White dotted line indicates top border of scaffold. Scale 
bar = 100 µm. 
 
 
 
The most successful method of incorporating laminin into the scaffold was 
through surface adsorption. Preliminary studies indicated significantly more DRG neurite 
growth on scaffolds coated with laminin as compared to scaffolds blended or covalently 
modified with laminin (Figure 4.12D). At physiological pH in the scaffold, uncomplexed 
alginate and chitosan above their respective pKas lead to an overall negative surface 
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charge on the C/A scaffold. In order to enhance the adsorption of negatively charged 
laminin, the surface charge of the scaffold was first altered by coating it using a solution 
of poly-L-lysine (PLL) or poly-L-ornithine (PLO), two polycations which are frequently 
used in cell culture to support cell and protein surface attachment and neuron growth. 
Some studies have found that coating alginate microcapsules with PLL can lead to a host 
inflammatory and immune response [189, 190]. Poly-L-ornithine has been investigated as 
an alternative polycation coating with successful results [191]. The C/A scaffolds, with 
and without surface adsorption of polycations and/or laminin, were investigated further 
for their ability to support DRG viability and neurite extension. 
 
4.2 In vitro Characterization of DRG Viability and Growth on C/A Scaffolds 
DRG neurons, which synapse with dorsal horn neurons in the spinal cord and 
possess the general properties of nerve cells, are robust in culture and clinically 
applicable as an in vitro culture model for spinal cord repair [192, 193]. Embryonic chick 
DRGs have been widely used as cellular models for studying the effects of neurotrophic 
factors and glial scar-associated inhibitory molecules on neurite outgrowth [75, 185]. 
Throughout this study, embryonic chick DRGs were used to evaluate the ability of the 
C/A scaffolds to support the viability, outgrowth, and directional guidance of neurites. 
Viability of dissociated DRG neurons cultured in C/A scaffolds with and without 
various surface coatings was evaluated using a Live/Dead cell viability assay. After 72 
hours in culture, greater than 91% cell viability was observed for all C/A scaffold groups, 
as shown in Figure 4.13. Figure 4.14 shows fluorescent images of the dissociated DRG 
neurons cultured within C/A scaffolds. The fluorescent dye calcein is retained within live 
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cells, producing a green fluorescence, while ethidium homodimer enters cells with 
damaged membranes and binds to nucleic acids, causing dead cells to fluoresce red. 
There was no significant difference in cell viability between experimental groups (p 
>0.05), demonstrating that surface adsorption of polycations and/or laminin was not 
necessary for improving the survival of DRG neurons cultured on or within the C/A 
scaffolds. 
 
 
 
 
Figure 4.13: Quantification of DRG neuron viability within C/A scaffolds with various 
surface coatings. 
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Figure 4.14: Fluorescent images of DRG neuron viability in C/A scaffolds with various 
surface coatings. Green: live cells; Red: dead cells. A) uncoated scaffold; B) PLO-coated 
scaffold; C) PLL-coated scaffold; D) Laminin-coated scaffold; E) PLO and laminin-
coated scaffold; F) PLL and laminin-coated scaffold. Scale bar = 100 µm. 
 
 
 
The C/A scaffolds were evaluated for their ability to support neurite extension in 
vitro by culturing DRG explants on the scaffolds and measuring the resulting neurite 
growth. The explants were seeded directly onto the cross-sectional surface of the 
scaffolds, so that neurites would be able to penetrate into the longitudinal channels. Prior 
to seeding with DRGs, polycations (PLO or PLL) and/or laminin were adsorbed on the 
scaffold surface to determine their effects on the promotion of neurite outgrowth within 
the C/A scaffolds. DRGs adhered to the scaffold surfaces with or without polycation 
and/or laminin adsorption and extended neurites in parallel alignment with the channel 
direction. Since the C/A scaffolds were opaque, the DRGs were immunostained using a 
primary antibody for an intermediate neurofilament (neurofilament 200 kDa) and 
fluorescent secondary antibody in order to visualize neurite growth. 
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Neurite outgrowth on the scaffolds was quantified (Figure 4.15), revealing that 
the greatest average length of neurite penetration was achieved within C/A scaffolds that 
were coated with a combination of polycation and laminin (mean neurite length: 793.2 ± 
187.2 µm for PLO+laminin, 768.7 ± 241.2 µm for PLL+laminin). There was no 
significant difference in average neurite length between these two groups (p>0.05).  The 
combination of polycation and laminin surface adsorption promoted significantly longer 
neurite growth than the individual scaffold surface treatments investigated here 
(p<0.001).  Neurite growth on scaffolds coated with a polycation alone (mean neurite 
length: 36.92 ± 65.71 µm for PLO, 53.19 ± 92.13 µm for PLL), showed no statistical 
difference between polycation types (p>0.05). Neurite growth on scaffolds coated with 
laminin alone was significantly longer than that on the uncoated scaffolds (mean neurite 
length: 482.9 ± 170.3 µm for laminin alone, 22.52 ± 50.14 µm for uncoated scaffolds, 
p<0.001), but still significantly shorter than on scaffolds that received polycation + 
laminin surface adsorption. Representative confocal images of DRG-seeded scaffolds 
from each experimental group are shown in Figure 4.16. 
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Figure 4.15: Quantification of average DRG neurite length (total number of neurites in 
field of view) on scaffolds with various surface coatings. * indicates p < 0.001 compared 
to all other groups. n = 30 DRGs per group. 
 
 
 
Other investigators have quantified in vitro DRG neurite growth on and within 
various three-dimensional scaffolds, reporting a wide range of growth rates. In this study, 
we achieved a maximum mean neurite growth rate of approximately 265 µm per day on 
the PLO and laminin-coated C/A scaffolds. With regards to other directionally frozen 
scaffolds, Bozkurt et al. (2007) reported a mean in vitro DRG neurite growth rate of 
approximately 36 µm per day on their linearly oriented collagen scaffolds, though their 
culture medium did not contain exogenous growth factors [174]. Pearson et al. examined 
DRG neurite outgrowth within collagen-filled conduits under culture conditions that were 
closer to ours, as their medium also contained 100 ng/ml exogenous NGF [194]. After 72 
hours in culture, DRG neurites growing within the conduit reached lengths of 
approximately 800 µm (as determined from a graph quantifying neurite length), 
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corresponding to a growth rate of approximately 267 µm per day [194]. This growth rate 
is comparable to the mean neurite growth rate on our PLO and laminin-coated scaffolds. 
Due to differences in DRG culture conditions such as the exact medium and supplements 
used and the presence or absence of exogenous growth factors, it is difficult to make 
direct comparisons among the data here and that reported by others. Nevertheless, it is 
apparent that the C/A scaffolds support the growth of DRG neurites, indicated by neurite 
growth rates comparable to other successful neural tissue engineering scaffolds. 
 
 
 
 
Figure 4.16: Representative confocal microscope images (z-stack over approximately 20 
sections of 10 µm thickness each) of immunostained DRGs (neurofilament 200; Alexa 
Fluor 488) on scaffolds (not visible) with varying surface treatments: A) uncoated 
scaffold; B) PLO-coated scaffold; C) PLL-coated scaffold; D) Laminin-coated scaffold; 
E) PLO and laminin-coated scaffold; F) PLL and laminin-coated scaffold. Scale bar = 
100 µm. White dotted line indicates top border of scaffold. 
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 The ability of the C/A scaffolds to promote neurite growth aligned with the 
longitudinal channel directions was also evaluated. Due to the anisotropic architecture of 
the scaffold and its channels, DRGs extended neurites in alignment with the channel 
direction, rather than the random non-directional neurite growth seen in unaligned 
hydrogels. Neurite alignment was quantified by measuring the angle of orientation 
between the neurites and the channel direction (represented as 0oC; channel positioning 
was identified by slight scaffold autofluorescence) and separating these angles into bins 
in 10o increments. Alignment was quantified on the PLO and laminin-coated C/A 
scaffolds, the experimental group with the longest mean neurite length.  
 
 
 
 
Figure 4.17: Histogram of neurite orientation on C/A scaffolds. 0oC represents channel 
direction.  
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 Figure 4.17 shows that 62.0% of DRG neurites extending on the scaffolds were 
oriented within 20o relative to the channel direction. A Gaussian distribution fit to this 
data had a mean orientation angle of 1.84o ± 14.9o, quantitatively demonstrating that 
these C/A scaffolds can promote directionally oriented neurite growth in the absence of 
chemical or electrical gradients. The longitudinal channels direct the growth of neurites 
in parallel with the channel direction, and the open, porous scaffold structure and 
fenestrations connecting the channels do not confine elongation of neurites to individual 
channels. The C/A scaffolds produced by freeze casting were found to support the 
attachment, growth and directed orientation of DRG neurites in vitro, indicating their 
viability as a substrate for regeneration in the injured spinal cord. 
 
4.3 Incorporation of Bioactive Molecules into the C/A Scaffolds 
 The DRG neurite growth within the C/A scaffolds described above was 
stimulated by exogenous NGF in the culture medium. Application of neurotrophic factors 
has also been shown to promote the growth of regenerating axons in vivo. We intended to 
supply the controlled, prolonged release of neurotrophins from our C/A scaffolds in order 
to promote axon regeneration in addition to providing a substrate for growth. Hollow 
alginate and chitosan microcapsules were produced by spray drying and subsequently 
loaded with neurotrophic factors and/or chABC in order to localize reservoirs of protein 
within the C/A scaffolds without introducing new biomaterials that would degrade at a 
different rate and potentially introduce different characteristics into the scaffold. Also, 
incorporating biomolecules within synthetic microcapsules might lead to denaturation 
and loss of bioactivity during the encapsulation process, since such microcapsules are 
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frequently fabricated using organic solvents. Incorporating biomolecules within alginate 
or chitosan microcapsules via diffusion would allow the biomolecules to be kept in an 
aqueous solution at physiological pH, diminishing the risk of denaturing the proteins. 
Spray drying is a widely used method of producing dry particles by evaporating moisture 
from an atomized feed of liquid. The atomized feed and flow of heated air are 
concurrently injected into a spray drying cylinder, facilitating evaporation of moisture 
from the spray droplets. Aspiration of air flow through the spray dryer draws the dry 
product into a cyclone where it is separated from the air stream and collected in a vessel 
below the cyclone. The particle size, yield, and final humidity of the product are affected 
by various parameters such as aspirator rate, air humidity and flow rate, inlet temperature, 
feed spray rate, and concentration of the liquid feed, all of which have to be determined 
for the individual solution/slurry to be spray dried [195]. The resulting microcapsules 
were loaded with biomolecules and incorporated into the C/A scaffolds. Release profiles 
of these biomolecules from the scaffolds and post-release bioactivity were evaluated in 
vitro. 
 
4.3.1 Alginate Microcapsule Fabrication 
 Alginate microcapsules were fabricated by spray drying a 1.5% (w/v) solution of 
alginate using a method modified from Coppi et al [180]. When these microcapsules were 
collected in a dry product collection vessel and subsequently stirred into a CaCl2 solution 
for crosslinking, large amorphous clumps were formed (Figure 4.18A). Residual moisture 
caused the microcapsules to clump together while adding them to a crosslinking solution, 
leading to crosslinking of alginate polymer chains between microcapsules, rather than the 
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polymer chain crosslinking within individual microcapsules. In contrast, collecting the 
alginate microcapsules directly into a CaCl2 solution placed in the product collection 
vessel allowed immediate crosslinking and maintenance of individual particles (Figure 
4.18B). These microcapsules maintained their structure after freezing, lyophilizing and 
reconstitution in an aqueous solution (Figure 4.18C).  
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Figure 4.18: Phase contrast images of alginate microcapsules produced by spray drying 
and crosslinked with CaCl2. A) Microcapsules crosslinked after collection; B) 
Microcapsules crosslinked by collecting in CaCl2 at the end point of spray drying; C) 
Microcapsules produced as in 4.18B after freezing, lyophilization and reconstitution in 
water. Scale bar = 100 µm. 
 
 
 
 SEM images of these alginate microcapsules crosslinked by collection in CaCl2 
reveal a smooth outer shell. Some collapsed or broken microcapsules visible in Figure 
4.19 show that these microcapsules are hollow with a thin wall.  
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Figure 4.19: SEM image of alginate microcapsules produced by spray drying a 1.5% w/v 
aqueous solution and crosslinked by collecting in CaCl2. Arrows indicate microcapsule 
eruption hole created during spray drying process. Scale bar = 10 µm. 
   
 
 
Incorporating these CaCl2-crosslinked alginate microcapsules into the C/A PEC 
mixture resulted in changes in the scaffold structure that were seen after freeze casting 
and freeze drying, as shown in Figure 4.20. Disruption of the continuous channels seen in 
the original C/A scaffolds was most likely caused by residual CaCl2 in the microcapsules 
crosslinking alginate in the PEC mixture. The presence of ionically crosslinked alginate 
within the PEC mixture probably created areas of gelation, which would impede the 
formation of continuous ice crystals during freeze casting. 
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Figure 4.20: Cross-section of C/A scaffold: A) without incorporated microcapsules, B) 
with incorporated alginate microcapsules (crosslinked by collecting in CaCl2). Note the 
complete absence of defined channels in B. Scale bar = 500 µm.  
 
 
 
4.3.2 Covalent Crosslinking of Alginate Microcapsules 
 Since incorporation of the CaCl2-crosslinked alginate microcapsules into the C/A 
scaffold led to distortion of the structure, an alternative covalent method of crosslinking 
these alginate microcapsules after they were ionically crosslinked with Ca2+  was 
investigated. Covalent crosslinking of the alginate microcapsules would allow the 
removal of CaCl2 prior to scaffold incorporation, enabling the microcapsules to be mixed 
into the C/A PEC mixture without residual CaCl2 crosslinking alginate. Calcium alginate 
microcapsules were produced by spray drying and collecting in a solution of CaCl2 as 
previously described, and subsequently covalently crosslinked using epichlorohydrin. 
The crosslinking process was performed in ethanol due to the poor solubility of 
epichlorohydrin in water. Under alkaline conditions, epichlorohydrin undergoes a ring-
opening reaction with nucleophiles such as hydroxyl groups present in alginate (Figure 
4.21) [196-198].  
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Figure 4.21: Mechanism of alginate crosslinking using epichlorohydrin [198]. 
 
 
 
After epichlorohydrin crosslinking, Ca2+ was removed from the alginate 
microcapsules by using sodium citrate to chelate the calcium ions. Using epichlorohydrin 
to covalently crosslink these microcapsules without first ionically crosslinking them with 
CaCl2 in the product collection vessel as described above led to the formation of large 
amorphous clumps (Figure 4.22A), similar to those seen in Figure 4.18A. Initially 
crosslinking these microcapsules with CaCl2 and then removing that CaCl2 after the 
epichlorohydrin crosslinking process prevented clumping, resulting in the formation of 
individual microcapsules (Figure 4.22B). 
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Figure 4.22: Phase contrast images of alginate microcapsules produced by spray drying 
and crosslinked with epichlorohydrin. A) Epichlorohydrin-crosslinked microcapsules 
without initial CaCl2 crosslinking; B) Epichlorohydrin-crosslinked microcapsules with 
initial CaCl2 crosslinking. Scale bar = 100 µm. 
 
 
 
SEM images of these lyophilized epichlorohydrin-crosslinked alginate 
microcapsules reveal shriveled capsules with no apparent spherical structure (Figure 
4.23), in contrast to the smooth surface and spherical structure of the CaCl2-crosslinked 
microcapsules shown above in Figure 4.19. However, the shriveled dry microcapsules 
immediately swelled to a spherical state upon the introduction of water or saline. In 
Figure 4.24, dry microcapsules are seen on the right hand side of the air-liquid interface, 
and the swollen microcapsules immersed in water on the left hand side have regained the 
spherical morphology seen after the initial spray drying process. The thin, flexible shell 
of the alginate microcapsules causes them to contract and expand greatly during 
dehydration or rehydration. Crosslinking the alginate microcapsules with epichlorohydrin 
increased the distance between the alginate chains, leading to a more elastic microcapsule 
structure. This allows these microcapsules to completely collapse while dry and regain 
their spherical appearance when hydrated, in contrast to the microcapsules ionically 
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crosslinked with CaCl2 whose stiffer shell prevents total collapse in the dry state [114, 
199]. It was not possible to measure the diameter of the dry alginate microcapsule skins 
because of their severely shriveled appearance. After epichlorohydrin crosslinking, 
microcapsules were gradually rehydrated in a series of ethanol/water washes to prevent 
clumping. The diameter of the hydrated alginate microcapsules was calculated to be 5.23 
± 2.71 µm, with the size distribution of these hydrated microcapsules shown in Figure 
4.25. 
 
 
 
 
Figure 4.23: SEM image of epichlorohydrin-crosslinked alginate microcapsules. Scale 
bar = 20 µm. 
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Figure 4.24: Phase contrast image of dry vs. swollen epichlorohydrin-crosslinked alginate 
microcapsules in water. Scale bar = 20 µm. 
 
 
 
 
Figure 4.25: Size distribution histogram of hydrated alginate microcapsules. 
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4.3.3 Chitosan Microcapsule Fabrication 
 Chitosan microcapsules were fabricated by spray drying a 1.5% (w/v) solution of 
chitosan using the same spray dryer settings as those used to produce alginate 
microcapsules. These chitosan microcapsules were collected in a dry vessel and 
subsequently neutralized by stirring in a 150 mM NaOH in ethanol solution. After 
neutralization, the chitosan microcapsules were gradually rehydrated in a series of 
ethanol/water washes to prevent clumping. Figure 4.26 is a phase contrast image of these 
microcapsules suspended in water after neutralization and rehydration. Similar to the 
chitosan scaffolds described in section 4.1.1, charge neutralization allows the 
microcapsules to maintain their structure in aqueous media. The un-neutralized chitosan 
microcapsules dissolved when they were added to water or saline without charge 
neutralization.  
 
 
 
 
Figure 4.26: Phase contrast image of chitosan microcapsules produced by spray drying, 
after charge neutralization and suspension in water. Scale bar = 100 µm. 
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 Examining SEM images of the dry chitosan microcapsules reveals further details 
about their structure (Figure 4.27A). The shriveled spherical surface of the chitosan 
microcapsules is caused by dehydration of the microcapsule wall. The structure of these 
microcapsules is similar to that of all microcapsules formed by spray drying non-
crystalline organic products. The microcapsules obtain this structure through the 
evaporation of solvent (water in the case of chitosan or alginate microcapsules). Water 
first evaporates from the surface of the microcapsule, and moisture in the interior of the 
capsule forms a pocket of steam beneath the capsule shell. Upon further drying in the 
spray drying cylinder, the pressure of the enclosed steam pocket increases, causing the 
droplet to erupt at one spot in order to release the steam [195]. The resulting 
microcapsule structure is a hollow ball with one eruption hole, as shown in Figure 4.27B. 
 
 
 
 
103 
 
 
Figure 4.27: SEM images of chitosan microcapsules produced by spray drying. A) Scale 
bar = 10 µm; B) Scale bar = 2 µm. Arrows indicate microcapsule eruption hole created 
during spray drying process. 
 
 
 
 
Figure 4.28: Differential interference contrast images of rehydrated microcapsules 
produced by spray drying. A) Chitosan microcapsules, B) Epichlorohydrin-crosslinked 
alginate microcapsules. Scale bar = 10 µm. 
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 The alginate microcapsules have a similar structure since this is also a non-
crystalline organic product. The microcapsule eruption hole can be seen in the CaCl2-
crosslinked alginate microcapsules (Figure 4.19). However, it is difficult to see the 
structure of these epichlorohydrin-crosslinked alginate microcapsules in a SEM image 
because these alginate microcapsules do not maintain their spherical structure when 
dehydrated. In contrast to the epichlorohydrin-crosslinked alginate microcapsules, 
chitosan microcapsules retain their overall spherical shape when dry, due to a less elastic 
microcapsule shell. These dry chitosan microcapsules had a mean diameter of 1.36 ± 0.73 
µm, illustrated by the histogram of size distribution in Figure 4.29A. During immersion 
in aqueous media the hollow capsules increase approximately 130% in size to a mean 
diameter of 3.13 ± 1.39 µm (Figure 4.29B).  
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Figure 4.29: Size distribution histogram of chitosan microcapsules produced by spray 
drying. A) Dry chitosan microcapsules; B) Hydrated chitosan microcapsules. 
 
 
 
4.3.4 Incorporation of Microcapsules into C/A Scaffolds 
 Both the epichlorohydrin-crosslinked alginate and chitosan microcapsules (both 
added to the C/A PEC mixture in the hydrated state prior to freeze casting) could be 
incorporated into the C/A scaffolds without affecting the overall structure of the scaffold. 
Longitudinally aligned channels extending throughout the length of the scaffold were still 
present after the incorporation of microcapsules. Figure 4.30 shows SEM images (dry 
scaffolds) and phase contrast images (crosslinked, hydrated scaffolds) of the scaffolds 
with incorporated alginate and chitosan microcapsules respectively.  
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Figure 4.30: Cross-sectional images of C/A scaffolds with incorporated microcapsules. 
A) SEM image of dry C/A scaffold with incorporated alginate microcapsules; B) SEM 
image of dry C/A scaffold with incorporated chitosan microcapsules; C) Phase contrast 
image of crosslinked, hydrated C/A scaffold with incorporated alginate microcapsules; 
D) Phase contrast image of crosslinked, hydrated C/A scaffold with incorporated chitosan 
microcapsules. Scale bar = 100 µm. 
 
 
 
Figure 4.31 shows the incorporation of the microcapsules within the scaffold 
channel walls. The shriveled dry alginate microcapsules give the scaffold wall a rough 
appearance, while the larger dry chitosan microcapsules can be seen visibly embedded in 
the channel wall. During freeze casting as the freezing front travels through the sample, 
the microcapsules become concentrated in the spaces between ice crystals along with 
107 
 
particles from the C/A PEC mixture. This results in the microcapsules embedded within 
the interpenetrating network of chitosan, alginate and PECs. 
 
 
 
 
 
Figure 4.31: SEM images of microcapsules incorporated into the C/A scaffold walls. A) 
C/A scaffold with alginate microcapsules; B) C/A scaffold with chitosan microcapsules. 
Scale bar = 10 µm. 
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4.3.5 Loading Efficiency of Microcapsules (Chymotrypsinogen) 
 In order to evaluate the loading efficiency of the alginate and chitosan 
microcapsules with regards to BDNF or NT-3, the inactive enzyme precursor 
chymotrypsinogen A was used as a model protein. This proenzyme, secreted by the 
pancreas, is cleaved by trypsin in the small intestine to yield chymotrypsin. It has a 
molecular weight of 25,000 Da and an isoelectric point of 9.1, making it an ideal model 
protein for BDNF or NT-3, which have similar molecular weights in their active 
homodimer form of 27, 818 Da and 29,355 Da respectively, and isoelectric points of 9.01 
and 9.46 respectively [200, 201].  
 Typically, protein loading into hydrogel microspheres is performed by adding the 
protein to the hydrogel solution prior to crosslinking. Incorporating proteins into the 
chitosan or alginate solutions prior to spray drying would cause denaturation, since the 
spray drying process occurs at high temperature (inlet temperature 160oC, outlet 
temperature 90-95oC). Large amount of neurotrophins would also have to be incorporated 
into the feed solutions, since these solutions are sprayed at low polymer concentration 
because of viscosity limits within the spray dryer. During loading in this manner, protein 
loss may occur during gelation due to diffusion out of the microsphere/capsule into a 
large volume of crosslinking solution. Also, mixing a large mass of high pI proteins into 
an alginate solution may lead to gelation due to electrostatic interaction between 
negatively charged alginate molecules and the positively charged proteins. Proteins were 
therefore encapsulated into the chitosan or alginate microcapsules by loading them into 
the microcapsules post-fabrication. 
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A method of loading high pI proteins into alginate microspheres post-fabrication 
is described by Wells and Sheardown, 2007 [202]. Alginate microspheres were loaded by 
soaking them in a solution of chymotrypsin or lysozyme, which facilitated the prolonged 
release of these proteins [202]. Hollow alginate microcapsules and chitosan 
microcapsules produced by spray drying were similarly loaded by soaking them in a 
solution of chymotrypsinogen. Loading efficiency was determined by calculating the 
mass of remaining chymotrypsinogen in the supernatant after soaking pre-hydrated or dry 
alginate or chitosan microcapsules for a specific period of time. Since trehalose was to be 
incorporated into the scaffolds in order to stabilize proteins, loading was also performed 
in solutions of this sugar to determine its effects on loading efficiency and preservation of 
stability. 
 
 
 
 
Figure 4.32: Equilibrium chymotrypsinogen loading efficiency of pre-hydrated alginate 
and chitosan microcapsules. 
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 There was no significant difference in the percentage of chymotrypsinogen loaded 
into the pre-hydrated alginate or chitosan microcapsules at any time point (p>0.05) 
(Figure 4.32, loading time three hours). There was no significant difference in the amount 
of chymotrypsinogen loaded over time (23.5 ± 7.96% loading for alginate microcapsules, 
15.5 ± 3.95% loading for chitosan microcapsules at 180 minutes) (p>0.05). In 
comparison, loading dry microcapsules with chymotrypsinogen was significantly more 
effective than loading the swollen microcapsules (p<0.001) (Figure 4.33 compared to 
Figure 4.32). The mechanism of loading of pre-hydrated capsules was through diffusion 
of the protein from the high concentration in the supernatant into the interior core of the 
hollow microcapsules. The maximum amount of protein loading was dependent on the 
initial protein concentration and the volume of the capsules, as equilibrium would 
eventually be reached between the protein concentration inside and outside the 
microcapsules. The total amount would always be less than the starting concentration in 
the supernatant solution unless partitioning into the microcapsule shell occurred. In 
contrast, soaking dry microcapsules in a solution of chymotrypsinogen facilitated 
significantly higher loading from a solution with the same initial concentration, and in a 
shorter period of time. After only 10 minutes of loading, the alginate and chitosan 
microcapsules loaded 31.1 ± 4.64% and 18.7 ± 6.10% of the original mass of 
chymotrypsinogen present in the loading solution respectively, in comparison to 9.84 ± 
2.17% and 6.29 ± 4.44% loading for the hydrated capsules (p<0.001). However, in both 
cases the alginate microcapsules achieved a higher loading compared to the chitosan 
microcapsules (p<0.001). 
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Figure 4.33: Chymotrypsinogen loading efficiency of dry alginate and chitosan 
microcapsules. *** indicates p<0.001. 
 
 
 
Loading the dry microcapsules using a higher concentration of chymotrypsinogen 
(400 µg/ml) and lower volume (10 µl liquid per µg of microcapsule) led to even higher 
loading efficiencies (73.1 ± 1.89% for alginate microcapsules and 31.3 ± 5.28% for 
chitosan microcapsules after 10 minutes) (Figure 4.33). These loading efficiencies 
correspond to a total mass of 2.6 ± 0.1 µg chymotrypsinogen/mg dry alginate 
microcapsules and 1.2 ± 0.2 µg chymotrypsinogen/mg dry chitosan microcapsules. The 
concentration of chymotrypsinogen selected for microcapsule loading was calculated in 
order to load scaffolds with 1 µg of protein. Loading was performed using minimal 
volumes of protein solution, in order to both conserve the amount of neurotrophins used 
(for future incorporation into scaffolds) and to maximize loading efficiency. Maximum 
loading of the dry microcapsules was reached after 10 minutes, as compared to several 
hours for loading swollen microcapsules. Extending the time of protein soaking did not 
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significantly increase the amount loaded, as there was no significant difference seen in 
loading efficiency between 10, 60, and 120 minutes (p>0.05).  
 
 
 
 
Figure 4.34: Chymotrypsinogen loading efficiency of dry alginate and chitosan 
microcapsules using a minimal volume of liquid. *** indicates p<0.001. 
 
 
 
 The loading efficiency of alginate microcapsules was significantly higher than 
chitosan microcapsule loading at every time point examined (p<0.001). Also, the 
presence of trehalose had no significant effect on the loading of either type of 
microcapsule (p>0.05). The greater loading efficiency of alginate was largely due to the 
difference in pre and post swelling volume between the alginate and chitosan 
microcapsules, which had final volumes of 74.9 ± 10.4 µm3 and 16.1 ± 0.20 µm3 
respectively. In addition to loading through swelling, additional protein can be partitioned 
into the negatively charged alginate microcapsules through electrostatic interaction with 
the high pI proteins. 
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 The release profile of chymotrypsinogen from the alginate and chitosan 
microcapsules is shown below in Figure 4.35. The alginate microcapsules released 93.8 ± 
5.38% of the loaded chymotrypsinogen by day 7, compared to 80.8 ± 16.9% released 
from the chitosan microcapsules, though these values were not significantly different 
(p>0.05). Large variation was seen in the release values from the chitosan microcapsules 
due to some interference with the protein assay used to quantify chymotrypsinogen 
release (Fluoroprofile Protein Quantification Kit).  
 
 
 
 
Figure 4.35: Release of chymotrypsinogen from alginate and chitosan microcapsules. 
 
 
 
4.3.6 Loading Efficiency of Microcapsules (Chondroitinase ABC) 
 Chondroitinase ABC was loaded into the alginate and chitosan microcapsules in 
an identical manner to the loading of chymotrypsinogen. The concentration of the loading 
solution was calculated to load scaffolds with a total of 2 enzyme units, based on the 
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specific activity of the protein. A similar loading profile was seen as compared to 
chymotrypsinogen loading. The loading efficiency of alginate microcapsules was 
determined to be 75.2 ± 1.01%, significantly more than chitosan loading efficiency of 
33.6 ± 2.96%. For alginate, the effective concentration loaded was 6.9 ± 0.1 µg chABC 
per mg dry microcapsule and chitosan loading concentration was 3.3 ± 0.2 µg chABC per 
mg dry microcapsule. The similar loading efficiencies seen for both chymotrypsinogen 
and chABC indicate that loading was not affected by the molecular weight of the protein 
(25,000 Da for chymotrypsinogen vs. ~100,000 Da for chABC). 
 
 
 
 
Figure 4.36: Chondroitinase ABC loading efficiency of alginate and chitosan 
microcapsules. *** indicates p<0.001. 
 
 
 
4.3.7 Incorporation of Trehalose into C/A Scaffolds 
The presence of trehalose has previously been shown to maintain the activity of 
chABC for up to 4 weeks in vitro at a concentration of 1 M [87]. Since chABC and 
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neurotrophins both have short half-lives, incorporating trehalose into the C/A scaffolds 
would help stabilize these proteins for prolonged release. Loading the microcapsules with 
proteins dissolved in a 1 M trehalose solution and then incorporating the 
protein/microcapsules into the C/A PEC mixture led to an overall trehalose concentration 
of 29.85 mM in the scaffolds. Incorporating trehalose at this concentration had no 
significant effects on protein activity, as evidenced by preliminary tests with chABC 
released from the scaffolds (Figure 4.37). Mixing additional trehalose into the C/A PEC 
mixture prior to freeze casting in order to raise its overall concentration to 1 M produced 
brittle, fragile scaffolds that crumbled during handling. This occurred because the mass of 
trehalose in the scaffold at a concentration of 1 M was approximately 25 times higher 
than the polymer mass (3.8733 g trehalose vs. 0.15 g total polymer content in 10 ml of 
C/A PEC mixture).  
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Figure 4.37: Effects of trehalose loading into scaffolds on bioactivity of released 
chondroitinase ABC, determined using a DMMB assay. A) Scaffold + alginate capsules 
(SAC); B) Scaffold + chitosan capsules (SCC); C) Scaffold with direct incorporation of 
chABC (SDI) 
 
 
 
In order to incorporate sufficient trehalose into the C/A scaffolds for protein 
stabilization, the crosslinking, wash, and polycation/laminin coating solutions were made 
up in 1 M trehalose. Soaking the scaffolds in 1 M trehalose post-fabrication allowed them 
to be saturated with the protein-stabilizing sugar without negatively affecting the scaffold 
structure.  
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4.4 Evaluation of Biomolecule Release from C/A Scaffolds 
 C/A scaffolds were fabricated in small Teflon molds that were custom designed to 
fit the spinal cord of Sprague Dawley rats (approximately 275 g; spinal cord diameter 2.5 
mm). The neurotrophins NT-3 and BDNF were loaded into the C/A scaffolds through 
encapsulation in alginate or chitosan microcapsules or by mixing directly into the C/A 
PEC mixture without the presence of microcapsules. Scaffolds were crosslinked and 
coated with polycations and laminin as previously described and suspended in release 
buffer at 37oC. The release buffer contained 1 M trehalose in order to maintain protein 
activity and therefore more accurately determine the in vitro release profiles. Samples of 
buffer were collected to monitor neurotrophin release at designated time points by 
ELISA.  
 Initial ELISA analysis of the release buffer revealed that a very small amount of 
the encapsulated biomolecules was released from the scaffolds. There are several stages 
between the initial microcapsule/scaffold loading and release buffer collection at which 
protein could have been lost, such as during the scaffold crosslinking, PLO and/or 
laminin surface coating, and several wash steps. In addition to the release buffer, these 
crosslinking, coating, and wash steps were also analyzed by ELISA in order to determine 
protein release from the scaffold at all stages.  
 
4.4.1 Controlled Release of NT-3 from C/A Scaffolds 
 The in vitro release profiles of NT-3 released from the PLO and laminin-coated 
scaffolds (scaffold + alginate capsules (SAC), scaffold + chitosan capsules (SCC), and 
scaffold with direct incorporation of neurotrophin (SDI)) are shown in Figure 4.38. 
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Figure 4.37A illustrates release during the crosslinking, PLO/laminin coating, and wash 
steps, while Figure 4.37B shows the cumulative release taking place after these 
preliminary steps (crosslinking/coating/wash). During the crosslinking, coating, and wash 
steps, a total of 101 ± 33.4 ng, 223 ± 43.9 ng and 66.1 ± 12.2 ng NT-3 were released from 
SAC, SCC and SDI respectively. Release from SCC during these steps was significantly 
higher than release from SAC and SDI which was the lowest (p<0.001). This initial NT-3 
release was caused by swelling-mediated delivery, as water hydrates the scaffold and the 
embedded microcapsules, and dissolves the protein for release by diffusion [203]. 
Encapsulating NT-3 within the chitosan microcapsules prior to scaffold incorporation 
initially shielded some of the protein from electrostatic interaction with alginate present 
in the C/A PEC mixture during mixing and freeze casting. After lyophilization, during 
crosslinking, washing, and coating, this unbound NT-3 was free to diffuse out of the 
swollen microcapsules contained within the scaffolds. In contrast, a higher proportion of 
NT-3 loaded within SAC and SDI would electrostatically bond to alginate in the 
microcapsules and/or in the C/A PEC mixture prior to freeze casting. These electrostatic 
interactions lowered the availability of free NT-3 and reduced the extent of release from 
SAC and SDI during the subsequent crosslinking, washing, and coating steps. However, 
in all cases the crosslinking step suffered the greatest loss of NT-3 during scaffold 
preparation. 
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Figure 4.38: Release of NT-3 per C/A scaffold at various stages in preparation and into 
release buffer. A) Noncumulative release from crosslinking, coating, and wash steps; B) 
Cumulative release into 1M trehalose after crosslinking, coating, and wash steps; SAC = 
Scaffold + alginate capsules; SCC = Scaffold + chitosan capsules; SDI = Scaffold with 
direct incorporation of neurotrophin. 
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The three different scaffold constructs displayed a burst release of NT-3 on the 
order of only a few percent of the total loaded over the first three days after crosslinking, 
coating with PLO and laminin, and washing; 3.53 ± 1.17%, 5.15 ± 1.64%, and 4.64 ± 
1.81% of the original total 1 µg loaded into SAC, SCC, and SDI respectively. This initial 
overall release was probably caused by diffusion of NT-3 out of the scaffold. Wells and 
Sheardown report the total release of lysozyme (pI = 11.0) and chymotrypsin (pI = 9.1) 
from calcium alginate gels within 3 hours into PBS, and over 150 hours into Tris-
buffered saline, indicating that the release of high pI proteins via diffusion is not hindered 
by electrostatic interaction with alginate in the scaffold [202].  Therefore, the main 
parameter affecting the diffusion of NT-3 out of the scaffold would be the hydrogel mesh 
size. In this case, the hydrogel mesh size is probably closer to the hydrodynamic radius of 
NT-3 than the theoretical values calculated in section 2.4.2, leading to restriction of NT-3 
diffusion out of the scaffold wall. The slower release rates seen after day 3-5 are likely 
due to degradation-mediated delivery, in which erosion of the interpenetrating polymer 
network matrix was the rate limiting step.  
After 8 weeks of supernatant collection, the amount of NT-3 released from the 
scaffolds was 5.25 ± 1.70%, 7.09 ± 2.09%, and 8.24 ± 3.58% of the total amount loaded 
(1 µg) for SAC, SCC and SDI respectively (Figure 4.37B). The mass of NT-3 released 
from all scaffold types was not significantly different (p>0.05). The majority of this 
release occurred within the first day, and a substantial portion of the total loss occurred 
during the crosslinking, coating and wash steps. At the 8 week mark, 0.07 ±  0.01 ng/ml, 
0.061 ± 0.003 ng/ml, and 0.092 ± 0.003 ng/ml was still being released from SAC, SCC, 
and SDI respectively, with a total of 84.7 ± 3.7% (SAC), 68.1 ± 2.8% (SCC), and 85.2 ± 
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4.1% (SDI) of the total loaded still remaining within the scaffolds. This low release of 
NT-3 seen from all scaffolds was not expected, as previous investigators have described 
the rapid release of proteins from hydrogels through diffusion [202]. It was also expected 
that significantly different release profiles would be observed for the different scaffold 
types. However, the lack of a large hydrogel mesh size in our C/A scaffolds would limit 
the rapid escape of NT-3 via diffusion, confining the neurotrophin to the scaffold interior 
until sufficient scaffold erosion has taken place. Relying on scaffold erosion/degradation 
for neurotrophin release would likely lead to no significant difference in release rates 
when comparing the different scaffolds, since each scaffold base is identical and would 
therefore erode in a similar manner.  
The use of a polycation such as PLO to coat alginate microspheres has been 
shown to act as a perm-selective size exclusion membrane, regulating the passage of 
biomolecules into and out of a hydrogel [119]. In order to determine if the PLO and/or 
laminin coat influenced NT-3 release from the C/A scaffolds, in vitro release profiles 
were also determined for the uncoated and PLO-coated scaffolds. These release profiles 
are shown below in Figure 4.39, comparing the uncoated, PLO-coated, and PLO + 
laminin-coated scaffolds for SAC, SCC, and SDI separately.  
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Figure 4.39: Comparison of cumulative NT-3 release from uncoated scaffolds, PLO-
coated scaffolds, and PLO + Laminin coated scaffolds. A) Scaffold + alginate capsules 
(SAC); B) Scaffold +chitosan capsules (SCC); C) Scaffold with direct incorporation of 
NT-3 (SDI). ● = uncoated scaffold; ■ = PLO-coated scaffold; ▲ = PLO and laminin-
coated scaffold. 
 
 
 
There was no significant difference in NT-3 release for any of the scaffold types 
when comparing the effects of scaffold surface coatings (uncoated vs. PLO coated vs. 
PLO and laminin coated) (p>0.05). Since no significant effects on NT-3 release were 
observed with different scaffold surface coatings, we can conclude that the presence or 
absence of a perm-selective membrane on the scaffold wall is not the parameter primarily 
affecting the release of NT-3. This strengthens the position that the hydrogel mesh size is 
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likely the main barrier to rapid biomolecule release, leaving the bulk of the loaded NT-3 
entrapped until sufficient scaffold erosion has taken place. 
 
4.4.2 Controlled Release of BDNF from C/A Scaffolds 
 The in vitro release profiles of BDNF released from PLO and laminin-coated 
SAC, SCC, and SDI are shown in Figure 4.40. During the combined crosslinking, 
coating, and wash steps, a total of 110 ± 38.2 ng, 199 ± 27.8 ng and 170 ± 19.1 ng were 
released from SAC, SCC, and SDI respectively. As with NT-3, the greatest loss was at 
the crosslinking stage; with 44.7 ± 20.0 ng, 97.5 ± 21.1 ng, and 87.6 ± 23.0 ng released 
from SAC, SCC, and SDI respectively. BDNF release from SAC during crosslinking was 
significantly lower than SCC or SDI (p<0.001), but release from each scaffold type 
during the subsequent wash and coating steps was not significantly different (p>0.05).  
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Figure 4.40: Release of BDNF per C/A scaffolds at various stages in preparation and into 
release buffer. A) Noncumulative release from crosslinking, coating, and wash steps; B) 
Cumulative release into 1M trehalose after crosslinking, coating, and wash steps. SAC = 
Scaffold + alginate capsules; SCC = Scaffold + chitosan capsules; SDI = Scaffold with 
direct incorporation of BDNF.  
 
 
 
As shown in Figure 4.40B, all scaffold variations displayed an in vitro release 
profile shape similar to that of the NT-3 loaded scaffolds, with regards to a minimal burst 
release followed by low steady state release. Release from PLO/laminin coated scaffolds 
over the first three days represents a small percentage of the total encapsulated BDNF in 
all cases: 2.50 ± 0.258%, 1.69 ± 0.334%, and 1.53 ± 0.116% for SAC, SCC, and SDI 
respectively. After 8 weeks of supernatant collection, a total of 4.34 ± 0.246%, 2.29 ± 
0.469%, and 2.06 ± 0.163% of BDNF were released from SAC, SCC, and SDI 
respectively. There was no significant difference between the amount of BDNF released 
from SCC and SDI, however SAC released significantly more than these other two 
scaffold variations (p<0.001). At the 8 week mark, 0.05 ±  0.01 ng/ml, 0.07 ± 0.02 ng/ml, 
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and 0.14 ± 0.17 ng/ml was still being released from SAC,SCC, and SDI respectively, 
with a total of 84.6 ± 4.1% (SAC), 77.8 ± 2.7% (SCC), and 81.0 ± 2.0% (SDI) of the total 
loaded still remaining within the scaffolds. Similar to the release of NT-3, the majority of 
BDNF release occurred during the crosslinking, coating and wash steps. Release profiles 
of BDNF from uncoated and PLO-coated scaffolds were also determined, shown below 
in Figure 4.41.  
 
 
 
 
Figure 4.41: Comparison of cumulative BDNF release from uncoated scaffolds, PLO-
coated scaffolds, and PLO + Laminin coated scaffolds. A) Scaffold + alginate capsules 
(SAC); B) Scaffold +chitosan capsules (SCC); C) Scaffold with direct incorporation of 
BDNF (SDI). ● = uncoated scaffold; ■ = PLO-coated scaffold; ▲ = PLO and laminin-
coated scaffold. 
 
 
126 
 
 
For BDNF-loaded SCC and SDI, the PLO and laminin-coated scaffolds released 
the lowest amount of neurotrophin (SCC: p<0.001 compared to uncoated scaffolds; SDI: 
p<0.001 compared to uncoated or PLO-coated scaffolds). In contrast, SAC with a PLO 
and laminin coat released significantly more BDNF than uncoated or PLO-coated 
scaffolds (p<0.001). This is likely due to laminin binding to the positively charged PLO, 
which would result in a looser perm-selective membrane and therefore higher BDNF 
release. This looser perm-selective membrane did not increase BDNF release within SCC 
or SDI, and the reason for this difference in release is unclear. 
 
4.4.3 Comparison of NT-3 and BDNF Release from C/A Scaffolds 
Significantly more BDNF compared to NT-3 was released from SDI during the 
crosslinking, coating, and wash steps (p<0.01) though no significant difference was seen 
between NT-3 and BDNF release during these steps for SAC or SCC (p>0.05) (Figure 
4.42A). Examining neurotrophin release from the scaffolds after the 
crosslinking/coating/wash steps indicated that significantly more NT-3 was released 
compared to BDNF for SCC (p<0.01) and SDI (p<0.001), with no significant difference 
in neurotrophin release for SAC after 8 weeks (p>0.05) (Figure 4.42B).  
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Figure 4.42: Comparison of NT-3 and BDNF release from C/A scaffolds. A) 
Noncumulative release from crosslinking, coating, and wash steps; B) Cumulative release 
into 1M trehalose after crosslinking, coating, and wash steps. SAC = Scaffold + alginate 
capsules; SCC = Scaffold + chitosan capsules; SDI = Scaffold with direct incorporation 
of neurotrophin. 
 
 
 
These differences in release are due to slight variations in structure and charge 
distribution between these two related neurotrophins. When analyzed by native gel 
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electrophoresis, the BDNF homodimer migrates as a slightly lower band than the NT-3 
homodimer, due to its more compact hydrodynamic size [204]. As the slightly smaller 
biomolecule, BDNF diffuses out of the IPN matrix of the scaffold wall more easily than 
NT-3 during these preliminary crosslinking/coating/wash steps when no microcapsules 
are present. During cation exchange chromatography at pH 8.5, NT-3 elutes at a lower 
NaCl concentration than BDNF, indicating that BDNF binds more strongly to a 
negatively charged support such as alginate present in the C/A scaffold [204]. NT-3 is 
also eluted earlier during reverse phase chromatography, which demonstrates that NT-3 is 
more hydrophilic than BDNF and therefore able to migrate more easily through the C/A 
hydrogel scaffold, although the difference in size may negate this advantage in migration 
[204]. These differences in charge and polarity signify that BDNF binds more strongly to 
alginate in the C/A scaffold, hindering its release until sufficient scaffold 
breakdown/degradation has occurred. 
The high water content and large macropores of most hydrogels usually lead to a 
large burst release of encapsulated proteins and rapid diffusion-mediated protein release 
on the order of hours to days [184]. In contrast, neurotrophins incorporated within C/A 
scaffolds were able to be released in vitro in a sustained manner over several weeks. 
Although sustained delivery was achieved, large amounts of the neurotrophins remained 
entrapped within the scaffold walls. The scaffold walls do not have large interconnected 
pores visible through phase contrast microscopy or SEM, but instead are tightly 
compacted matrices of chitosan, alginate and chitosan-alginate PECs. This lack of an 
interconnected porous wall structure prevents the rapid diffusion of neurotrophins out of 
the scaffold, as the network mesh size is close to the hydrodynamic radius of the 
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encapsulated proteins. Degradation/erosion of the scaffold facilitates the release of the 
remaining entrapped proteins.  
The inability to completely release proteins from hydrogel systems has been 
previously reported by several investigators [155, 205, 206]. Pfister et al. used chitosan-
alginate nerve conduits coated with layers of PLGA for the controlled release of NGF 
[155]. Their “first generation” nerve conduits released only 1.5-7.5% of the initial NGF 
loaded (approximately 800 ng per conduit) over 15 days, with the lowest release seen 
when NGF was directly embedded into the alginate/chitosan matrix support structure. 
Their “second generation” nerve conduits, incorporating NGF so that it was not exposed 
to the environment at the ends of the conduit, only increased release to 12.5-25% over 15 
days. The limited release seen in their study and also from our C/A scaffolds can be 
explained by neurotrophin binding to alginate via electrostatic interactions and also by 
the formation of aggregates which would remain trapped in the scaffold until degradation 
has progressed far enough to release these larger aggregates [155]. NGF tends to 
aggregate over time, and since NT-3 and BDNF are also members of the neurotrophin 
family, it is likely that these proteins also form aggregates [207].  
Despite low total percentages of neurotrophin release from the scaffolds, the 
amounts released are in the low nanogram range, which meet specifications for daily 
therapeutic doses administered at the site of injury [155, 208]. Additionally, release of 
neurotrophins is expected to be higher in vivo, due to faster degradation rates. Cell 
ingrowth into the scaffolds and corresponding deposition of ECM, along with the 
production of free radicals, acidic byproducts, or enzymes produced contribute to the 
increased rate of scaffold degradation in vivo [209]. The presence of activated microglia 
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and macrophages in the spinal cord lesion cavity also leads to increased expression of 
lysozyme at the site of injury [210]. This enzyme degrades chitosan which will lead to an 
increased rate of C/A scaffold degradation, and thereby neurotrophin release, in vivo. 
 
4.4.4 Controlled Release of chABC from C/A Scaffolds 
A specific ELISA does not exist for the quantification of chABC and the 
fluorescent protein quantification assays used to calculate the microcapsule loading 
efficiency were not sensitive enough to detect the release of chABC from the scaffolds. 
The in vitro release profile of chABC was therefore determined by measuring its activity 
through the degradation of CSPGs. In order to maintain the enzymatic functionality of 
chABC in solution and thereby accurately quantify total protein released from the 
scaffolds, all release experiments were performed in 1M trehalose. Three assays were 
used in order to determine the release of chABC, a dimethylmethylene blue assay, a 
kinetic assay measuring A232nm of product formation, and SDS-PAGE. 
The DMMB assay quantifies GAGs based on a metachromatic shift in absorption 
maximum which occurs when the cationic dye 1,9-dimethylmethylene blue binds to 
sulfate or carboxyl groups present in GAGs [211]. A drawback of using this assay in the 
presence of alginate is that the carboxyl groups of alginate bind with the DMMB dye, 
interfering with the detection of the sulfated GAG. Enobakhare et al. developed a 
modified DMMB assay to detect sulfated GAGs in the presence of alginate [182]. In this 
modified assay the pH of the dye is lowered to 1.5, where only sulfated GAGs will 
complex with the dye rather than carboxyl groups, since sulfate groups have a lower pKa 
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[182]. This modified DMMB assay was used to quantify the amount of GAGs remaining 
after digestion of chondroitin sulfate C with chABC.  
The DMMB assay has limitations on the concentrations of GAG that can be 
quantified within a linear range. At a ratio of 200 µl DMMB dye to 8 µg chondroitin 
sulfate C, the standard curve is linear from 0-4 µg (serial dilution 1:2). At a GAG mass 
higher than this point, the standard curve flattens out and can no longer be fitted with a 
straight line. This signifies that there is a maximum limit to how much GAG can be 
detected at this dye:substrate ratio. At this limit, the chABC released from the scaffolds at 
day 1-2 degrades all of the substrate present, indicating that the GAG substrate is the 
limiting reagent. This lead to inaccuracies in comparing the activity of chABC released at 
various time points. Adjusting the dye:substrate ratio to 1000 µl dye:20 µg chondroitin 
sulfate increased the amount of GAG that could be detected within a linear range (up to 
20 µg) and a graph of the activity of chABC released from the scaffolds at various time 
points was plotted (Figure 4.43). However, chABC released at day 1 still degraded all of 
the chondroitin sulfate C substrate. In order to more accurately compare the release of 
chABC at different time points, another quantitative assay was used in which the amount 
of substrate was not the limiting reagent. 
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Figure 4.43: Quantification of GAG degradation after digestion of chondroitin sulfate C 
with chABC released from C/A scaffolds as determined by DMMB assay. 
 
 
 
An alternative method of quantifying chABC activity was by measuring the 
absorbance at 232nm of unsaturated disaccharides formed through the chABC-mediated 
degradation of chondroitin sulfate C [212, 213]. One unit of chABC hydrolyzes 
chondroitin sulfate C to produce 1 µmole of 2-acetamido-2-deoxy-3-O-(β-D-gluc-4-ene-
pyranosyluronic acid)-6-O-sulfo-D-galactose per minute at pH 8.0 at 37°C [212, 213]. 
The concentration of product formed per minute was used to calculate the amount of 
chABC released from the C/A scaffolds. Since this was a kinetic assay performed by 
measuring the change in absorbance over time, there was no saturation of the product, 
allowing this assay to quantify chABC release more accurately than the DMMB assay. 
Also, because the enzymatic functionality of released chABC was maintained in the 
presence of 1M trehalose, activity could be directly correlated to the mass of chABC 
released, producing an accurate profile of in vitro release. Figure 4.44 shows the amount 
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of chABC released from the C/A scaffolds during the crosslinking, coating, and wash 
steps and also during collection at designated time points. 
 
 
 
 
 
Figure 4.44: Quantification of scaffold-released chABC bioactivity through measurement 
of product formation at A232nm. A) chABC released during crosslinking, coating, and 
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wash steps; B) chABC released into 1M trehalose after crosslinking, coating, and wash 
steps. 
 
 
 
 As shown in figure 4.44B, the general trend of noncumulative chABC release 
from the scaffolds is similar to the release seen in Figure 4.43 as determined by the 
DMMB assay. A sharp drop in the amount of chABC release was seen after 24 hours, and 
significantly more chABC is released at this time point as compared to all other time 
points (p<0.001). The release at day 1 amounts to only 3.49 ± 0.136% (SAC), 3.58 ± 
0.708% (SCC), and 2.93 ± 0.360% (SDI) of the total amount of chABC loaded into the 
scaffolds, and release during the crosslinking, coating, and wash steps was approximately 
14.6 ± 1.58% (SAC), 10.6 ± 0.395% (SCC), and 8.75 ± 1.95% (SDI) of the total amount 
loaded. The cumulative total of 18.5 ± 1.63% (SAC), 14.6 ± 1.17% (SCC), and 12.0 ± 
1.56% (SDI) released after 14 days indicates that most of the chABC is not being 
released from the C/A scaffolds. 
 The molecular weight and therefore hydrodynamic volume of chABC is much 
larger than those of the neurotrophic factors, which causes a greater proportion of the 
loaded protein to be retained within the scaffold. The burst release seen at day one, and 
also during the crosslinking, coating, and wash steps, is due to diffusion of chABC 
located near the surface of the scaffold wall. Remaining chABC entrapped within the 
scaffold walls and/or microcapsules is too large to exit the scaffold pores via diffusion, 
and will therefore be released via degradation-mediated delivery. 
 SDS-PAGE was used to determine if chABC continued to be released from the 
scaffolds at levels undetectable by the DMMB or A232nm assays. After approximately 3 
days, amounts of chABC released from these scaffolds could not be distinguished from 
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background seen in the controls for these two quantitative assays. The degradation of 
decorin, a small CSPG, was evaluated after a 4 hour incubation period with release media 
collected from the scaffolds. This longer incubation provided more time for chABC to 
degrade the CSPGs and silver staining after SDS-PAGE was sensitive enough to detect 
the degradation of 5 µg of decorin. Decorin is composed of one chondroitin or dermatan 
sulfate GAG chain with a molecular weight of approximately 50 kDa attached to a core 
protein of approximately 40-45 kDa. This CSPG appears as a broad smear at ~100 kDa 
on a SDS-PAGE gel, while the core protein of degraded decorin appears at ~45 kDa. 
Figure 4.45 shows images of SDS-PAGE gels that illustrate the degradation of decorin by 
chABC released from the C/A scaffolds containing alginate microcapsules, chitosan 
microcapsules, and no capsules respectively.  
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Figure 4.45: SDS-PAGE of decorin degradation by scaffold-released chABC. A) Scaffold 
+ alginate capsules (SAC); B) Scaffold + chitosan capsules (SCC); C) Scaffold with 
direct incorporation of chABC (SDI). MW marker: 3.5-260 kDa. Lane 1: intact decorin; 
Lane 2: day 1 chABC; Lane 3: day 1 chABC + decorin; Lane 4: day 7 chABC + decorin; 
Lane 5: day 10 chABC + decorin; Lane 6: day 14 chABC + decorin; Lane 7: day 21 
chABC + decorin; Lane 8: day 28 chABC + decorin; Lane 9: day 35 chABC + decorin; 
Lane 10: day 42 chABC + decorin; Lane 11: blank day 1 + decorin. 
 
 
 
For all of the gels displayed, lanes 2 and 3 contain chABC released at day 1, 
without and with decorin. ChABC appears as a sharp band at approximately 100 kDa, 
with fainter bands seen nearby since the enzyme (Sigma) is unpurified. This band is not 
seen in any of the other lanes since the amount of chABC released was below the range 
detectable by silver staining, which also fits with the chABC release profiles shown in 
Figures 4.43 and 4.44. Even though the presence of chABC cannot be visualized within 
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these gels, the amount of this enzyme released was sufficient to digest CSPGs, as 
evidenced by the presence of bands of degraded decorin at ~45 kDa. Degradation of 
decorin can be seen for all scaffold types up to day 21, with chABC released from SAC 
and SCC degrading decorin up to day 28 and day 35 respectively.  
 Lee et al. report that the use of a hydrogel delivery vehicle consisting of lipid 
microtubes encapsulated in agarose was able to provide the sustained release of chABC 
in vitro for up to 15 days, using trehalose for enzyme stabilization [87]. Other 
investigators report the sustained release of bioactive chABC from collagen nanofibers 
for at least 32 days, using a DMMB assay for quantification [214]. However, this 
particular assay involved sampling small amounts of supernatant at various time points 
without removing and replacing the entire volume of supernatant in order to create sink 
conditions outside the nanofibers. Although performing the assay in this manner 
quantified the activity of chABC in the supernatant over time, this did not produce a true 
profile of the amount of chABC being released from the nanofibers in vitro. Although 
chABC was not released from our C/A scaffolds in a sustained manner, collecting the 
released protein in complete sink conditions demonstrated that chABC was released for 
up to 35 days, as displayed by the degradation of CSPGs in vitro. 
 
4.5 In vitro Evaluation of the Multi-Functional Scaffolds 
4.5.1 Bioactivity of NT-3 and BDNF Released from C/A Scaffolds  
 The bioactivity of NT-3 and BDNF released from the C/A scaffolds was 
evaluated with an in vitro DRG bioassay. DRG explants were cultured in conditioned 
release media collected from the scaffolds. Since the stimulation of axon growth at the 
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injury site is the most important during the first 10-15 days of repair, bioactivity of NT-3 
and BDNF released from the scaffolds was assayed at days 1, 7, and 14 [155]. The 
average neurite length was quantified and compared to controls of fresh 1 ng/ml 
neurotrophin or media without exogenous neurotrophin added. 
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Figure 4.46: Quantification of bioactivity of scaffold-released neurotrophins. A) Average 
DRG neurite length stimulated by NT-3 released from scaffolds; B) Average DRG 
neurite length stimulated by BDNF released from scaffolds, C) Average DRG neurite 
length stimulated by blank scaffolds. SAC = Scaffold + alginate capsules; SCC = 
Scaffold + chitosan capsules; SDI = scaffold with directly incorporated neurotrophin. 
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Negative control indicates no exogenous neurotrophins were added to the culture 
medium. 
 
 
 
For both NT-3 and BDNF-loaded scaffolds, conditioned media collected at day 1 
did not promote significantly more growth than the negative controls, although the results 
of the ELISA show that release was highest at this point. This lack of growth was caused 
by the higher concentration of trehalose present in the culture media at day 1, due to 
diffusion out of the scaffold. This higher trehalose concentration increased the osmolality 
of the culture media, which has been shown to reduce neurite outgrowth in vitro [215]. 
Although hyperosmotic conditions cause a decrease in neurite growth rates, others have 
found that lowering the osmolality of the culture media causes growth cones to 
reestablish their normal appearance and resume growth, indicating that hyperosmolarity 
does not have permanent effects on neurite growth [216]. Implanting a trehalose-loaded 
scaffold into the injured spinal cord should therefore have no long term negative effects 
on axon regeneration due to initial changes in osmolality. Lee et al. successfully 
implanted delivery vehicles containing chABC and NT-3, along with trehalose for 
enzyme stabilization, in the injured rat spinal cord, with no adverse effects on axonal 
growth [87].  
Regarding the NT-3-loaded scaffolds, conditioned media collected at day 7 and 
14 stimulated neurite growth that was not significantly different (p>0.05) compared to 
added NT-3 (1 ng/ml), indicating that NT-3 released from the scaffolds retains its 
bioactivity. For BDNF-loaded scaffolds, conditioned media collected at day 7 and 14 also 
stimulated neurite growth that was not significantly different from the positive control of 
added BDNF (1 ng/ml). However, this neurite growth was also not significantly different 
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from the negative control of culture medium without added neurotrophins, due to large 
standard deviations in average neurite length. Control scaffolds without loaded 
neurotrophins did not stimulate neurite growth that was significantly different from the 
negative controls of culture medium without added neurotrophins (p>0.05). Figure 4.46 
shows representative phase contrast images of DRG explants cultured in conditioned 
media taken from the C/A scaffolds at day 14, illustrating the length of neurites 
comparable to the positive controls of 1ng/ml NT-3 or BDNF. 
 
 
 
 
Figure 4.47: Representative images of neurite growth from DRG explants stimulated by 
neurotrophins released from C/A scaffolds at day 14. A) negative control (no exogenous 
neurotrophin added); B) 1 ng/ml exogenous NT-3 added; C) 1 ng/ml exogenous BDNF 
added; D) SAC NT-3 (0.76 ± 0.03 ng/ml); E) SCC NT-3 (0.71 ± 0.18 ng/ml); F) SDI NT-
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3 (2.53 ± 1.57 ng/ml); G) SAC BDNF (1.88 ± 0.14 ng/ml); H) SCC BDNF (0.36 ± 0.09 
ng/ml); I) SDI BDNF (0.28 ± 0.03 ng/ml). Concentrations of neurotrophin released from 
scaffolds as determined by ELISA. Scale bar = 200 µm. 
 
 
 
4.5.2 Effects of Scaffold-Released Biomolecules on DRG Neurite Growth Through 
an In vitro CSPG Barrier 
Although the assay described in Section 4.5.1 demonstrated that scaffold-
incorporated neurotrophins can promote the growth of DRG neurites, this assay did not 
evaluate the potential effects that the multi-functional scaffold would have on neurite 
growth through a growth-inhibiting glial scar. The multi-functional scaffolds were 
composed of C/A scaffolds with incorporated chABC and neurotrophins. The selection of 
biomolecule incorporation method was based on their respective in vitro release profiles. 
ChABC was incorporated within the multi-functional scaffold by loading within chitosan 
microcapsules, since release from this scaffold type was shown to degrade CSPGs over 
the longest time period. BDNF was incorporated within the multi-functional scaffold by 
loading within alginate microcapsules, since this scaffold type displayed significantly 
higher release. NT-3 was directly incorporated into the multi-functional scaffold, since 
there was no significant difference seen in release with or without the addition of 
microcapsules.  
The effects of the multi-functional scaffolds on DRG neurite growth were 
evaluated by culturing dissociated DRG neurons in the presence of these scaffolds using 
an in vitro glial scar model, or laminin/CSPG stripe assay. This in vitro glial scar was 
formed by adsorbing stripes of CSPGs and TRITC (in the form of CSPG/TRITC-soaked 
filter paper) onto a nitrocellulose-coated coverslip and then coating the entire surface 
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with laminin. Laminin promoted the attachment and growth of DRG neurites, while the 
stripe of CSPG acted as a barrier to neurite growth. C/A scaffolds with various 
combinations of incorporated biomolecules were suspended above the DRG neurons 
growing on the coverslip surface in a Netwell insert, a permeable 440 µm polyester mesh. 
The use of this insert allowed us to evaluate the growth of DRG neurites across a CSPG 
barrier under the influence of biomolecules actively being released from the C/A 
scaffolds, rather than adding conditioned media to the cells which would effectively be a 
bolus application of chABC and/or neurotrophic factors. Neurite density on laminin and 
CSPG + laminin areas was compared in order to quantify the ability of scaffold-released 
biomolecules to promote growth through this barrier. Graphs comparing neurite density 
within these two areas and representative fluorescent images of DRG neurons grown on 
these substrates are shown below. 
 
 
 
144 
 
 
Figure 4.48: Quantification of neurite density on Laminin/CSPG stripes after 48 hours in 
culture. Black = neurite density on laminin stripes; white = neurite density on CSPG + 
laminin stripes. *** indicates p<0.001. 
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Figure 4.49: DRG neurite growth on Laminin/CSPG stripes after 48 hours of culture. A) 
Unloaded scaffolds; B) BDNF-loaded scaffolds; C) NT-3 loaded scaffolds; D) BDNF and 
NT-3-loaded scaffolds. Red stripes indicate CSPG + laminin (TRITC labeled), black 
areas indicate laminin alone. DRG neurites are fluorescently labeled green (neurofilament 
200; Alexa Fluor 488) Scale bar = 100 µm.  
 
 
 
There was significantly greater neurite density on laminin (black) compared to the 
CSPG + laminin stripes (red) for DRGs grown in the presence of C/A scaffolds loaded 
with BDNF, NT-3, a combination of BDNF + NT-3, and unloaded scaffolds (p<0.001) 
(Figure 4.48). This indicated that neurotrophic factors released from the scaffold alone or 
in combination did not have a significant effect on the penetration of neurites into the 
growth inhibitory area. This result was expected since chABC was necessary in order to 
sufficiently degrade the CSPGs to permit neurite growth within this area. Also, when 
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examining neurite density on the laminin area alone, the combination of BDNF + NT-3 
released from the scaffolds promoted significantly more neurite growth compared to 
BDNF alone (p<0.01), though this density was not significantly different from the DRGs 
cultured with NT-3 loaded scaffolds (p>0.05). The normalized CSPG/laminin neurite 
density ratios were not significantly different when compared to positive controls of 
exogenous neurotrophins added at similar concentrations (p>0.05). 
 
 
 
 
Figure 4.50: Quantification of neurite density on Laminin/CSPG stripes after 48 hours in 
culture. Black = neurite density on laminin stripes; white = neurite density on CSPG + 
laminin stripes. * indicates p<0.05, *** indicates p<0.001. 
 
 
 
147 
 
 
Figure 4.51: DRG neurite growth on Laminin/CSPG stripes after 48 hours in culture. A) 
chABC-loaded scaffolds; B) chABC + BDNF-loaded scaffolds; C) chABC + NT-3 
loaded scaffolds; D) chABC + BDNF + NT-3-loaded scaffolds. Red stripes indicate 
CSPG + laminin (TRITC labeled), black areas indicate laminin alone. DRG neurites are 
fluorescently labeled green (neurofilament 200; Alexa Fluor 488) Scale bar = 100 µm.  
 
 
 
ChABC released from the C/A scaffolds alone or in combination with 
neurotrophic factors promoted the growth of DRG neurites through the barrier of CSPGs, 
as evidenced by neurite densities that were not significantly different on laminin 
compared to the CSPG + laminin stripes (p>0.05 for chABC, chABC + NT -3, chABC + 
NT-3 + BDNF; p<0.05 for chABC + BDNF). Although the amount of released chABC 
was quite low, as described in Section 4.4.4, the chABC that was released from the 
scaffolds was able to promote significantly more growth through a CSPG barrier than 
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scaffolds that were not loaded with this enzyme (p<0.01). The normalized CSPG/laminin 
neurite density ratios were not significantly different when compared to positive controls 
of exogenous chABC and/or neurotrophins added at similar concentrations (p>0.05). 
 A synergistic effect on neurite growth through a CSPG barrier was not observed 
using the combination of chABC and neurotrophic factors. Tropea et al. observed a 
synergistic effect on the growth of retinal axons in vivo after treatment with chABC and 
BDNF, however, the amounts of these proteins administered were much higher than that 
released from the C/A scaffolds (two injections of 1 µl of 10 µg/µl BDNF and 750 nl of 
48 U/ml chABC were made 3 days apart, compared to C/A scaffolds loaded with a total 
of 1 µg neurotrophin and 2 U chABC) [66].  
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5. CONCLUSIONS AND CONTRIBUTIONS TO SCIENCE 
 The overall goal of this work was to create and develop a multi-functional 
chitosan-alginate scaffold in order to provide a combination of strategies for spinal cord 
repair. This novel scaffold, fabricated by freeze casting, was evaluated in vitro to 
determine its suitability for use as a biomaterial support for regenerating axons and as a 
therapeutic biomolecule delivery vehicle. The following conclusions can be drawn from 
the results presented here: 
 Freeze casting can be successfully used to fabricate a novel C/A scaffold at 
physiological pH with longitudinally aligned channels extending from end to end. This is 
the first report of such a linearly aligned scaffold fabricated from C/A PECs. These 
scaffolds, crosslinked with calcium chloride to minimize swelling, had a compressive 
strength comparable to spinal cord tissue, indicating that there will be no mechanical 
mismatch to impede axon extension across the scaffold-tissue interface in vivo. The 
scaffolds were able to support the viability, attachment, and directionally oriented growth 
of DRG neurites in vitro, with surface adsorptions of a polycation and laminin promoting 
the maximum amount of neurite growth. The characteristics of these scaffolds and their 
ability to promote directionally oriented neurite growth suggest that this scaffold is a 
promising candidate for use as a physical guidance channel for the growth of 
regenerating axons across a spinal cord lesion.  
 Spray drying can be used to fabricate alginate and chitosan microcapsules in order 
to incorporate bioactive molecules into the C/A scaffolds for sustained release. Both the 
biomolecule-laden alginate and chitosan microcapsules were able to be incorporated into 
the scaffolds without affecting the structure. Sustained release of the neurotrophins NT-3 
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and BDNF was achieved, with a burst of less than 5% of the total protein loaded and 
release observed for 8 weeks. However, over the time course of the release experiment, 
the majority of the neurotrophins remained entrapped within the scaffold walls, as their 
diffusion was limited by the hydrogel mesh size. In vivo scaffold erosion with time is 
expected, releasing the remaining agents. Although DMMB and kinetic A232nm analysis of 
chABC release showed a burst release over 24 hours followed by release that was not 
detectable over background levels, SDS-PAGE analysis indicated that chABC was still 
released from the scaffolds for up to 35 days. Similar to the neurotrophins, most of the 
incorporated chABC remained within the scaffold walls, with the potential to be released 
through erosion and/or degradation. The data demonstrate that the C/A scaffolds are 
capable of providing the sustained release of incorporated biomolecules as hypothesized, 
though their sustained release abilities proved to be too effective, leaving most of the 
biomolecules entrapped within the walls. Taking into account the results of these in vitro 
studies and also future in vivo studies, the selection of scaffold type with different 
incorporated microcapsules will give a choice of biomolecule release profile, potentially 
tailoring the desired release to the specific incorporated biomolecule. 
 An in vitro assay using DRG explants revealed that the neurotrophins released 
from the scaffolds retained bioactivity, promoting similar neurite growth to the positive 
controls. The multi-functional scaffolds were able to promote the growth of DRG 
neurites through an in vitro barrier of CSPGs, demonstrating their potential for promoting 
axonal regeneration through the growth-inhibiting glial scar via the release of chABC 
and/or neurotrophins. Although limited amounts of biomolecule release were observed in 
vitro, higher release amounts are predicted in vivo due to cell ingrowth, ECM deposition, 
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and scaffold erosion/degradation.  Overall, these multi-functional scaffolds are suitable 
for use and future testing in vivo as a combination strategy for spinal cord repair due to 
their ability to promote the directionally oriented growth of neurites and their ability to 
release therapeutic biomolecules in a sustained manner. 
 
Contributions to Science 
 This thesis represents an incremental advance in the field of neural tissue 
engineering, describing the production, development and characterization of a chitosan-
alginate scaffold for use as a nerve guidance scaffold. Future in vivo work is expected to 
confirm the in vitro findings of this scaffold’s suitability as a substrate for axon 
regeneration and as a vehicle for the prolonged delivery of therapeutic biomolecules to 
the injured spinal cord. Also included within Appendix C is a description of the 
successful bioconjugation of chABC to alginate. Although this bioconjugation did not 
enhance the activity of chABC, it demonstrated that covalent attachment of this enzyme 
to a potential scaffold was possible while maintaining its ability to degrade CSPGs. This 
bioconjugation procedure may benefit future researchers investigating alternative 
methods of incorporating chABC within neural tissue engineering scaffolds. 
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6. RECOMMENDATIONS 
This work has demonstrated that a multi-functional chitosan-alginate scaffold is 
suitable for use as a scaffold for spinal cord repair, supporting the viability and 
directional growth of DRG neurites in vitro and providing the sustained release of 
biomolecules beneficial for axonal regeneration. Further studies are recommended to 
expand research in this area, presented below: 
 To evaluate different methods of scaffold sterilization and their effects on the 
release and bioactivity of encapsulated biomolecules. Various methods of scaffold 
sterilization such as UV sterilization may speed scaffold degradation, leading to 
faster/higher released amounts of biomolecules. However, sterilization methods 
may also have deleterious effects on the bioactivity of these encapsulated 
molecules. The efficacy of sterilization methods as well as their overall effects on 
the multi-functional scaffold should be evaluated in preparation for in vivo work. 
 To seed the C/A scaffolds with various neural stem cell populations, such as 
neural progenitor cells. Various investigators, including our group, have 
implanted biomaterial scaffolds seeded with neural stem cells into the injured 
spinal cord with positive effects on axon regeneration and functional recovery. 
The C/A scaffolds can be evaluated for their ability to support the viability and 
differentiation of these cell populations for transplantation into the injured spinal 
cord.  
 To develop C/A scaffolds with strategically placed microcapsules containing 
neurotrophins in order to investigate the effects of a neurotrophin gradient on 
axonal growth within the scaffold 
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 To study the effects of the C/A scaffolds on neural regeneration in an in vivo rat 
spinal cord injury model. Scaffolds with and without incorporated biomolecules 
should be implanted into a rat spinal cord injury model in order to evaluate their 
effects on inflammatory response, axonal ingrowth, glial scar tissue formation, 
and functional recovery.  
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Appendix A: List of Nomenclature and Symbols 
 
 
 
 
BDNF: Brain-derived neurotrophic factor 
β-gal: β-galactosidase 
C/A: Chitosan-alginate 
ChABC: Chondroitinase ABC 
CNS: Central Nervous System 
CSF: Cerebrospinal fluid 
CSPG: Chondroitin sulfate proteoglycan 
DI water: Deionized water 
DRG: Dorsal root ganglia 
DMEM: Dulbecco’s Modified Eagle Medium 
DMMB: Dimethylmethylene blue 
ECM: Extracellular matrix 
ELISA: Enzyme-linked immunosorbent assay 
FBS: Fetal bovine serum 
GAG: Glycosaminoglycan 
HBSS: Hank’s Buffered Salt Solution 
HEPES: 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid sodium salt 
IPN: Interpenetrating network 
MW: Molecular weight 
NGF: Nerve growth factor 
NT-3: Neurotrophin-3 
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PBS: Phosphate buffered saline 
PEC: Polyelectrolyte complex 
PEG: Polyethylene glycol 
PLL: Poly-L-lysine 
PLO: Poly-L-ornithine 
PTFE: polytetrafluoroethylene 
SAC: Scaffold containing alginate microcapsules 
SCC: Scaffold containing chitosan microcapsules 
SCI: Spinal cord injury 
SDI: Scaffold with direct incorporation of biomolecules 
SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM: Scanning electron microscopy 
TRITC: tetramethylrhodamine-5-(and-6)-isothiocyanate mixed isomers 
ξ: Hydrogel network mesh size 
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Appendix B: Larger Images of C/A Scaffolds 
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Figure AB1: Larger images of Figure 4.3. Light micrographs of C/A scaffolds produced 
by mixing chitosan and alginate in different ratios; and 100% alginate scaffold. A) 90:10, 
B) 75:25, C) 50:50 chitosan:alginate ratio; D) 100% alginate scaffold. All scaffolds had 
2.4% w/v total polymer content and were freeze cast at 6oC/min. Scale bar = 500 µm. 
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Appendix C: Bioconjugation of chABC to Alginate 
 
 
 
 
1. Specific Aims 
 Previous work in this laboratory involved the use of alginate hydrogels containing 
encapsulated fibroblasts that were genetically engineered to produce neurotrophins 
(BDNF or NT-3). Bioconjugation chemistry was used to covalently link the glial scar-
degrading enzyme chABC to alginate, in order to incorporate it into the hydrogel 
scaffold. Specifically the aims were:  
 
1) To investigate methods of stabilizing chABC in order to enhance the breakdown and 
prevention of glial scar tissue formation 
a) To stabilize chABC through the use of bioconjugation chemistry 
 Various bioconjugation techniques will be investigated in attempts to stabilize 
chABC. 
 The bioconjugated chABC should retain the ability to degrade chondroitin sulfate 
proteoglycans (CSPGs) and should be physically accessible to the location of the 
nascent glial scar. 
Hypothesis: The short half-life of chABC is due to thermal destabilization of the protein, 
leading to destruction of the active site. ChABC stabilized through bioconjugation will 
provide prolonged enzyme activity and stability as compared to unmodified chABC due 
to covalent modification preserving the active site.  
 
b) To evaluate the efficacy of the stabilized chABC in vitro  
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 The most active form of stabilized chABC will be evaluated for its ability to 
degrade CSPGs in vitro using dorsal root ganglia (DRGs) and an in vitro glial scar 
model. 
Hypothesis: Neurite growth is impeded when the nerve growth cone encounters a barrier 
of CSPGs. The bioconjugated chABC will retain its ability to successfully degrade 
CSPGs in vitro and allow neurite growth to proceed through these degraded CSPGs, due 
to enzymatic depolymerization of the barrier.  
 
2. Materials and Methods 
Various bioconjugation techniques were employed in order to find the best 
method of stabilizing chABC in order to prolong its activity and glial scar-degrading 
effects. Of the techniques used, the one that produced the most active conjugate was the 
formation of chABC-PEG-alginate.  
Chondroitinase ABC was covalently linked to thiolated alginate (thiol groups 
added in a separate, previous procedure) using a heterobifunctional polyethylene glycol 
(PEG) crosslinker with N-hydroxysuccinimide (NHS) ester and maleimide groups that 
allowed the covalent conjugation of molecules containing amine and sulfhydryl (thiol) 
groups. This chABC-PEG-alginate conjugate was intended to be employed as a final coat 
for our laboratory’s currently existing alginate scaffold, used in the treatment of spinal 
cord injury. The fabrication of this chABC-PEG-alginate conjugate is described below. 
 
Alginate thiolation 
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Alginate was thiolated (i.e. SH groups added) through the following procedure, 
modified from Bernkop-Schnurch et al. [217]: 
A 1% (w/v) solution of alginate was prepared in 100 mL deionized water. 98.83 
mg of N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) is added 
and the solution stirred for 45 minutes at room temperature to activate 10% of the 
carboxyl groups in the alginate solution. 50 mg of L-cysteine hydrochloride monohydrate 
was added to the activated alginate, the pH was adjusted to 4.0, and the solution was 
stirred for 2 hours at room temperature. The pH was raised to 6.0 and the solution stirred 
for an additional hour at room temperature. The alginate-cysteine conjugate was then 
dialyzed at 4oC against 1 mM HCl, followed by two more dialysis steps against 1 mM 
HCl + 1% NaCl, and then exhaustively against 1 mM HCl. The thiolated alginate was 
lyophilized and stored at -20oC until needed. 
 
Chondroitinase ABC-PEG-Alginate conjugation 
ChABC was covalently linked to thiolated alginate via a heterobifunctional 
polyethylene glycol (PEG) spacer arm[218]. The procedure is as follows: 
ChABC was dissolved in cold PBS pH 7.4 (4oC). The crosslinker (NHS-PEG6-
Maleimide) was added to the solution in a 10-fold molar excess. The reaction mixture 
was stirred for 2 hours at 4oC. The excess crosslinker was removed using a Pierce 
desalting column equilibrated with PBS pH 7.4. The desalted chABC-PEG was mixed 
with the thiolated alginate and this mixture was stirred for 2 hours at 4oC. The chABC-
PEG-alginate conjugate was then lyophilized for at least 24 hours and stored at -20oC 
until needed. 
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In order to compare the activity of unmodified chABC and modified chABC 
conjugates, the following assay was used:  
Chondroitinase ABC activity assay 
A manufacturers’ enzyme assay protocol (Sigma-Aldrich) was followed (based on 
Saito et al., 1968 and Yamagata et al., 1968)[212, 213]: 
The following solutions were prepared: 0.5% solution of chondroitin-6-sulfate 
was prepared in a Tris-sodium acetate buffer (250 mM Tris HCl, 300 mM Sodium 
Acetate, 0.05% (w/v) BSA, pH 8.0); 50 mM potassium chloride solution, pH 1.8. 
Immediately before beginning the assay, a solution containing approximately 0.06 – 0.10 
unit/ml chABC was prepared in cold HEPES buffer pH 7.4 containing no salt. 0.8 ml of 
the enzyme solution was pipetted into a tube containing 0.2 ml of the chondroitin-6-
sulfate solution, mixing by inversion. The tube was incubated in a 37oC water bath for 21 
minutes. Every 3 minutes starting at t=0, 0.1 ml of the mixture was transferred to a 
separate tube containing 0.9 ml of the potassium chloride solution. These tubes were 
centrifuged for 10 minutes at 10,800 x g, and the absorbance at 232 nm was recorded for 
each tube. The ΔA232nm/min was determined from a linear portion of the graph and this 
was used to calculate the activity of the chABC. 
 
In order to determine if chABC was attached to the alginate via NHS-PEG-
Maleimide, SDS-PAGE and size exclusion HPLC were both used. These techniques 
separate compounds by molecular weight, allowing us to compare differences in the 
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molecular weight of the unmodified chABC and the chABC-PEG-alginate conjugate, and 
therefore show that the enzyme is attached to the alginate. 
 
SDS-PAGE 
Invitrogen reagents were used to perform SDS-PAGE. 
Analysis of chABC-PEG-alginate samples 
Fifteen µl of sample was mixed with 5 µl NuPAGE LDS Sample Buffer 
(containing β-mercaptoethanol: 1 µl in 500 µl Sample buffer) and heated at 70oC for 10 
minutes. A 3-8% Tris-Acetate gradient gel (1.0 mm) was placed in an electrophoresis 
chamber and filled with NuPAGE Tris-Acetate SDS Running Buffer. 20 µl of the sample 
(10 µl protein standard, HiMark Pre-Stained High Molecular Weight Protein Standard) 
was loaded into each lane, and the gel was run at 75V for approximately 2.5 hours. The 
gel was stained for approximately 1.5 hours in Coomassie blue stain, and destained in 
10% acetic acid/10% methanol solution overnight.  
 
Comparison of chABC-PEG-alginate samples and trehalose-stabilized chABC 
In order to compare our samples with the trehalose-stabilized chABC of Lee et 
al., dilutions of chABC were made with PBS to obtain the same mass listed in their paper 
[87]. 
250 ng of chABC (or chABC-PEG-alginate) was mixed with 0.5 ml PBS, or 0.5 ml 1M 
trehalose in PBS. Separate tubes of these mixtures were pre-incubated for up to 1 week at 
37oC. After pre-incubation, 10 µl of 0.5 mg/ml decorin was added and the mixture was 
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incubated in a 37oC water bath for 4 hours. Samples were then removed and stored at -
80oC until ready for SDS-PAGE analysis. 
Fifteen µl of sample was mixed with 5 µl NuPAGE LDS Sample Buffer 
(containing β-mercaptoethanol: 1 µl in 500 µl Sample buffer) and heated at 70oC for 10 
minutes. 5 µl Novex Sharp Unstained Protein Standard was mixed with 45 µl Sample 
Buffer without heating. A 4-12% Bis-Tris gradient gel (1.0 mm) was placed in an 
electrophoresis chamber and filled with NuPAGE MOPS SDS Running Buffer. 20 µl of 
the sample (5 µl protein standard) was loaded into each lane, and the gel was run at 200V 
for 50 minutes. Silver staining was performed using a Pierce Silver Stain Kit. 
  
High Performance Liquid Chromatography 
HPLC was performed using a TSK-GEL Bioassist G3000SWXLSize Exclusion 
Column (Tosoh Bioscience) and Waters HPLC instrument (1525 Binary HPLC Pump, 
2414 Refractive Index Detector, 2484 Dual λ Absorbance Detector, 717plus 
Autosampler). chABC-PEG-alginate samples were made as described above, diluted to 
0.08-0.8 mg/ml with PBS, and filtered with a 0.45 µm syringe filter. The eluent for the 
column was 0.1M phosphate buffer solution containing 0.2 M NaCl (pH 7.4) and the 
flow rate was set at 0.5 ml/min. 20 µl of each sample was analyzed in the HPLC machine 
using a detection wavelength of 280 nm. 
 
b) To test the efficacy of the stabilized chABC in vitro  
After determining that the chABC was indeed linked to the alginate, it was 
necessary to test the efficacy of the chABC-PEG-alginate conjugate. This was done by 
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evaluating the growth of DRG neurites through an in vitro glial scar model, comparing 
the CSPG-degrading effects of our chABC-PEG-alginate with the effects of unmodified 
chABC (positive control) and the absence of chABC (negative control). The in vitro glial 
scar was produced by the following methods: 
 
Laminin/CSPG striped substrate [16, 185, 186]  
A “glial scar” was fabricated on a flat culture surface by generating a striped 
pattern of adsorbed proteins: 
Coverslips were baked at 150oC for 3 hours before using silicone aquarium 
sealant to glue the coverslips to the underside of holes formed in the bottom of a tissue 
culture dish. The wells formed by this procedure were coated with a solution of 
nitrocellulose (20 cm2 dissolved in 24 mL reagent grade methanol) and the surfaces were 
then air dried and UV sterilized. Filter paper was cut into strips and then soaked in a 
solution of CSPGs (50 µg/mL) and TRITC (4.4 µg/mL). The soaked filter paper strips 
were laid onto the nitrocellulose substrate, air dried, and then removed, resulting in the 
transfer of CSPGs and TRITC to the nitrocellulose substrate. Laminin (25 µg/mL) was 
then spread evenly over the entire dish to create alternating stripes of laminin and 
CSPG+laminin.  
 
Chick embryo DRGs were used to evaluate the glial scar-degrading effects of the 
chABC-incorporated construct. The DRGs were extracted using the following methods 
and were grown on the laminin/CSPG striped substrate to monitor and measure neurite 
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growth through the CSPG barriers in the presence/absence of the alginate-immobilized 
chABC:  
 
Dorsal Root Ganglia (DRG) Collection and Dissociation 
 Fertilized white Leghorn eggs (Charles River Laboratories, Wilmington, MA) 
were kept in an egg incubator at 37oC with an automatic egg turner for 9-11 days before 
being removed for dissection. Eggs were sprayed with alcohol and then cracked open to 
remove the chick embryo. The heads of the embryos were removed and the bodies placed 
in sterile culture dishes to dissect under a dissecting microscope. The thoracic cavity of 
the embryo was opened and the organs removed to expose the spine and DRGs. The 
DRGs were removed with dissecting forceps and placed in a 12-well culture dish with 
Ham’s F-12 medium.  
 DRGs were dissociated by incubating the whole DRG explants in PBS for 10 
minutes at 37oC, then briefly centrifuging to pellet the cells, followed by a 12 minute 
incubation in 0.25% trypsin-EDTA at 37oC. The DRGs were briefly centrifuged again 
and then triturated in 2 ml of DMEM + 10% FBS using a flame polished glass Pasteur 
pipette. The dissociated DRGs were plated in a tissue culture plate for up to 2 hours in 
order to allow non-neuronal cells to attach. The neuronal cells were then harvested from 
the tissue culture plate and plated on the laminin/CSPG striped substrate. 
 
3. Results and Discussion 
3.1 Stability of unmodified chondroitinase ABC 
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Before attempting to stabilize chondroitinase ABC (chABC), it was first 
necessary to determine the stability of unmodified chABC at 37oC. The stability of 
chABC was assayed over 96 hours in HEPES buffered saline pH 7.4, by measuring the 
absorbance (232nm) of unsaturated disaccharides formed through the chABC-mediated 
degradation of chondroitin-6-sulfate [212, 213].  
 
 
 
 
Figure AC.1: Stability of chondroitinase ABC at 37oC 
 
 
 
As can be seen in Figure AC.1, chABC loses much of its activity during the first 
24 hours at 37oC. Using an initial starting activity of 0.1 Units/ml, the enzyme half-life 
was approximately 3 hours. It would therefore be beneficial to increase the stability of 
chABC for prolonged enzymatic activity. Many attempts at stabilization were made, 
briefly detailed in the following sections. 
 
3.2 Attempts to stabilize chABC through cross-linked aggregates 
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The first stabilization method attempted was to form crosslinked enzyme 
aggregates (CLEAs) of chABC. This procedure consists of precipitating an enzyme with 
ammonium sulfate or acetone and then covalently crosslinking the precipitated 
aggregates with glutaraldehyde to produce a highly active and stable biocatalyst[219, 
220]. None of the stabilization attempts made with the CLEA procedure produced active 
chABC. This loss of activity could be attributed to several possible causes, such as the 
glutaraldehyde itself. A crosslinker such as glutaraldehyde could render chABC inactive 
due to its high reactivity and small size, which allows it to penetrate into the active site of 
chABC, affecting the amino acids involved in its catalytic activity [221]. Loss of activity 
could have also been caused by high ionic strength of the solution, due to the high 
concentration of ammonium sulfate necessary for enzyme precipitation. Increasing ionic 
strength was found to have negative effects on the activity of chABC.  We found that the 
activity of chABC was at a peak when the enzyme was reconstituted in a buffer with an 
ionic strength of 0.1 M and declined with increasing ionic strength. Using acetone as a 
precipitant to avoid the effects of high ionic strength did not increase the activity of the 
chABC CLEAs. Even simply precipitating the enzyme with acetone and omitting the 
glutaraldehyde cross-linking step caused a loss of chABC activity of 97.3%.  
To avoid the loss of activity seen with the preparation of CLEAs of chABC, we 
attempted to crosslink chABC with dextran aldehyde, a larger crosslinker that would be 
less likely to interfere with the enzyme active site. Dextran is a naturally occurring 
polysaccharide synthesized in yeast and bacteria. Its use in the modification of 
macromolecules has been shown to increase in vivo circulation half-life, decrease 
immunogenicity and increase the metabolic stability of a drug or enzyme [222]. The 
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initial activity level was still less than that of the unmodified enzyme, but the chABC-
dextran aldehyde conjugate did retain enough activity (retained 33.7% of the original 
unmodified chABC activity) in order to perform a stability assay and compare its activity 
over time to that of unmodified chABC.  
 
 
 
 
Figure AC.2: Stability of chABC-dextran aldehyde conjugate compared to unmodified 
chABC. 
 
 
 
 As can be seen from Figure AC.2, though we expected the chABC-dextran 
aldehyde conjugate to retain more stability as compared to the unmodified enzyme, this is 
not the case. The half-life remained approximately 3 hours, but chABC activity continued 
to drop off sharply after that time point. The original intention was to stabilize chABC 
and encapsulate it within our previously used alginate construct for prolonged release into 
the site of injury in the spinal cord. Since none of the previous attempts to stabilize the 
chABC were very successful, the plan for incorporating chABC into our alginate 
construct was altered. Instead of encapsulating chABC, we would covalently attach the 
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enzyme to the alginate itself. A final coat of the construct with this chABC-modified 
alginate would provide the enzyme proximity to the CSPGs present in the glial scar for 
degradation. 
 
3.3 Heterobifunctional conjugation using a PEG spacer arm 
Polyethylene glycol (PEG) has been widely used to modify proteins and enzymes 
to improve their stability [218, 223]. Using a PEG spacer arm with functional end groups 
would hypothetically have the advantages of simultaneously stabilizing chABC while 
linking it to the alginate. A heterobifunctional PEG (MW: 601.60 Da) was chosen in 
order to avoid cross-linking between enzyme units, rather than to the alginate. The 
functional reactive groups chosen were an N-hydroxysuccinimide (NHS) ester, to react 
with amines in the enzyme, and maleimide, to react with sulfhydryl groups that would be 
present after covalent introduction into the alginate in a separate procedure[217]. The 
NHS ester end of the PEG was first linked to the chABC, since this functional group is 
easily susceptible to hydrolysis, and the maleimide end of the PEG was then linked to the 
thiolated (-SH group added) alginate. 
Initial activity of the chABC-PEG-alginate conjugate was much less than the 
unmodified chABC, retaining only 25.14 ± 8.53% of the original unmodified chABC 
activity, due to the immobilization of the enzyme. A stability assay was performed on this 
conjugate and the results are shown below in Figure 3. 
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Figure AC.3: Stability of chABC-PEG-alginate conjugate compared to the chABC-
dextran aldehyde conjugate and unmodified chABC. 
 
 
 
 Figure AC.3 shows that the even with the large drop in initial activity, the 
chABC-PEG-alginate conjugate retained similar stability to the unmodified enzyme. 
Using a larger amount of chABC-PEG-alginate (in order to make up for the loss in initial 
activity) led to prolonged enzyme activity with a half-life of approximately 20 hours, 
shown below in Figure AC.4. 
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Figure AC.4: Stability comparison of unmodified and modified chABC with varying 
amount of chABC-PEG-alginate. 
 
 
 
3.4 SDS-PAGE and HPLC 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis(SDS-PAGE) and high 
performance liquid chromatography (HPLC) were performed on the chABC-PEG-
alginate samples in order to determine if the chABC was attached to the thiolated alginate 
via NHS-PEG-Maleimide, since both of these methods separate compounds by molecular 
weight, and changes in molecular weight due to the immobilization process could 
therefore be assessed. For SDS-PAGE analysis, samples were fabricated with varying 
amounts of thiolated alginate, electrophoresed on a gradient gel and visualized with 
Coomassie blue staining, using a molecular weight size marker ranging from 4-250 kDa. 
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Figure AC.5: SDS-PAGE analysis of chABC-PEG-alginate. MW Ladder: 4-250kDa 
range. Lane A: unmodified ChABC; Lane B: ChABC + PEG (no alginate); Lane C: 
ChABC + PEG + 50 µl alginate; Lane D: ChABC + PEG + 100 µl alginate; Lane E: 
ChABC + PEG + 250 µl alginate; Lane F: ChABC + PEG + 0.5 ml alginate; Lane G: 
ChABC + PEG + 1 ml alginate. 
 
 
 
 Since Protanal LF 200M alginate has a molecular weight range from 270-325 
kDa, a band for the chABC-PEG-alginate conjugate cannot be seen in the gel using 
Coomassie blue stain, though a large smear is seen much higher in the gel when using the 
much more sensitive silver stain (results not shown). The bands appearing in Figure 5 are 
that of unlinked chondroitinase ABC (~120kDa). As increasing amounts of thiolated 
alginate are used for sample fabrication, the unlinked chABC band density decreases, due 
to the fact that much of it has now been linked, and the effective molecular weight of the 
chABC-PEG-alginate is much higher than that of the chABC alone (or chABC linked to 
just PEG). Using higher amounts of thiolated alginate for sample fabrication leads to a 
higher percentage of chABC being covalently linked to the alginate since there are more 
thiol groups available for crosslinking, therefore leading to a decrease in band density of 
the unlinked enzyme. Quantification of band density is shown below, illustrating a 
definite decrease in free chABC as the amount of thiolated alginate used increases. 
 
 
 
A B C D E F G 
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Figure AC.6: Quantification of SDS-PAGE band density. Density for the unmodified 
chABC band set at 100% in order to compare the relative band density for other lanes. 
 
 
 
 Size exclusion HPLC was also performed on chABC-PEG-alginate samples as a 
second method of demonstrating attachment between the chABC and thiolated alginate 
via heterobifunctional PEG. Samples were fabricated and run through a size exclusion 
column to determine changes in molecular weight. As shown below in Figure AC.7, a 
peak for unmodified chABC (red line) is detected at approximately 19 minutes. In 
comparison, a peak for chABC-PEG-alginate (black line) is detected at approximately 11 
minutes. Since compounds of larger molecular weight exit a size exclusion column faster 
than smaller molecular weight compounds, this indicates that the chABC is covalently 
attached to thiolated alginate via the heterobifunctional PEG based on its larger molecular 
weight and earlier peak detection time as compared to unmodified chABC. 
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Figure AC.7: HPLC analysis of chABC and chABC-PEG-alginate. Red: unmodified 
chABC. Black: chABC-PEG-alginate.  
 
 
 
3.5 ChABC-PEG-alginate degradation of an in vitro glial scar 
DRGs were grown on laminin and CSPG stripes formed in culture wells in order 
to evaluate the ability of the chABC-PEG-alginate to promote neurite growth by 
degrading an in vitro glial scar. This in vitro glial scar was formed by adsorbing stripes of 
CSPGs (in the form of CSPG-soaked filter paper) onto a nitrocellulose-coated coverslip 
(shown in red in the pictures below) and then coating the entire surface with laminin [16, 
185, 186]. DRG neurons (labeled in green in the pictures below) are then seeded on the 
surface of the CSPG/laminin striped coverslip. Laminin promotes the attachment and 
growth of DRG neurites, while the stripe of CSPG acts as a barrier to neurite growth. 
Culture media containing no chABC (negative control) or containing unmodified chABC 
(positive control) were compared to media containing our reconstituted chABC-PEG-
alginate. 
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(a)  
(b)  
(c)  
Figure AC.8: DRG neurite growth on Laminin/CSPG stripes with (a) Negative control: 
no chABC present; (b) Positive control: unmodified chABC in culture medium; (c) 
chABC-PEG-alginate reconstituted in culture medium. The entire surface is coated in 
laminin; red stripes are fluorescently labeled CSPGs (in vitro glial scar); neurites 
fluorescently labeled in green.  
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 As shown in the fluorescent micrographs above, DRG neurites in the negative 
control group (a) do not penetrate the stripe of CSPG + laminin but flourish on the 
laminin substrate. In contrast, the DRG neurites in the positive control group (b) and 
chABC-PEG-alginate group (c) penetrate and show extensive growth through the CSPG 
+ laminin stripe. The density of DRG neurite growth in these experimental groups was 
quantified using Scion Image, results shown below. 
 
 
 
 
Figure AC.9: Quantification of neurite density on Laminin/CSPG stripes. Black = neurite 
density on laminin stripes; white = neurite density on CSPG + laminin stripes. Negative 
control = no chABC present; Positive control = unmodified chABC. 
 
 
 
 Comparing neurite density within each group: for the negative control (no chABC 
present), there was significantly greater neurite density on the laminin stripes than the 
CSPG + laminin stripes (p<0.01).  For both the positive control (unmodified chABC) and 
chABC-PEG-alginate groups, neurite density on the laminin stripes and CSPG + laminin 
197 
 
stripes was not significantly different (p >0.05 for both groups). This indicates that the 
chABC-PEG-alginate is able to promote in vitro neurite growth through the degradation 
of CSPGs as well as unmodified chABC.  
 
3.6 Comparison of ChABC-PEG-alginate and trehalose-stabilized chABC 
Recently, Lee et al. reported on the use of trehalose for the thermostabilization of 
chABC at 37oC for up to 4 weeks [87]. The methods displayed in this paper to assay 
enzymatic activity were used to confirm their findings and compare the stability of our 
chABC-PEG-alginate samples and their trehalose-stabilized chABC. Unmodified 
chABC, chABC mixed with trehalose (1M), and chABC-PEG-alginate were pre-
incubated for varying amounts of time at 37oC before incubating with decorin, a CSPG, 
and analyzing the degradation products using SDS-PAGE and silver staining, with a 
molecular weight marker ranging from 3.5-260 kDa. 
 
 
 
198 
 
 
Figure AC.10: SDS-PAGE of chABC sample enzymatic activity after 37oC pre-
incubation for 1 day and 1 week; silver stained. Lane 1: Molecular Weight marker: 3.5-
260 kDa; Lane 2: intact decorin; Lane 3: fresh chABC; Lane 4: fresh chABC + decorin; 
Lane 5: 1 day pre-incubated chABC + decorin; Lane 6: 1 day pre-incubated 
chABC/trehalose + decorin; Lane 7: 1 day pre-incubated chABC-PEG-alginate; Lane 8: 1 
week pre-incubated chABC + decorin; Lane 9: 1 week pre-incubated chABC/trehalose + 
decorin; Lane 10: 1 week pre-incubated chABC-PEG-alginate + decorin. 
 
 
 
 Intact decorin appears as a broad smear at ~100 kDa on a SDS-PAGE gel, while 
degraded decorin appears as a tighter band at ~45 kDa. A band for chABC appears at 
~120 kDa. It is shown above that mixing trehalose with chABC does preserve the 
enzymatic activity; the chABC/trehalose mixture is still stable after 1 week, compared to 
the unmodified chABC which shows no decorin degradation products after 1 week pre-
incubation. Also, our chABC-PEG-alginate samples show no decorin degradation 
products, even after 1 day. This can be explained by the loss in initial activity when the 
enzyme is immobilized onto our alginate support. We can conclude that the chABC-
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PEG-alginate samples are nowhere near comparable with the stability and prolonged 
enzyme activity of the trehalose-stabilized chABC, which has been shown to still retain 
activity after 4 weeks of 37oC pre-incubation. Trehalose has been shown to be an 
excellent stabilizer of proteins and enzymes, achieved through increasing the transition 
temperature (ΔTm) of proteins. The presence of trehalose reduces the entropy of the 
denatured state of proteins, which increases the relative stability of the native protein 
state [224]. Conversely, immobilization can sometimes worsen the performance of 
enzymes, due to enzymatic structural changes introduced through the immobilization 
procedure [225, 226]. This can result in lower activity and a higher Michaelis-Menten 
constant when compared to the unmodified enzyme. We have found this to be true for the 
immobilization of chABC to alginate through the use of NHS-PEG-Maleimide. To move 
further, we investigated incorporating chABC into a chitosan-alginate scaffold in the 
presence of trehalose for stabilization, described in the main body of this thesis. 
 
  
200 
 
Vita 
 
 
 
 
Nicola Louise Francis was born on June 11, 1982 in Bermuda. She received a 
B.S.E. in Bioengineering from the University of Pennsylvania in 2004, conducting senior 
design research in PLGA microsphere fabrication and scaffold construction for bone 
tissue engineering. During the summers of her undergraduate and Master’s education, she 
returned home to work at the Bermuda Institute of Ocean Sciences, gaining experience in 
the area of marine molecular biology. After completing her undergraduate education, she 
pursued a Master’s degree in Biomedical Engineering at Drexel University, joining the 
laboratory of Dr. Margaret Wheatley to study the effects of alginate-encapsulated 
fibroblasts genetically engineered to produce neurotrophic factors on the in vitro growth 
of dorsal root ganglia neurites. 
After finishing her Master’s degree in 2006, she continued to work towards her 
Ph.D. in Dr. Wheatley’s lab, developing and characterizing multi-functional biopolymer 
scaffolds for neural tissue engineering. During her time at Drexel, she co-authored 
several publications (“Fabrication of an ice-templated, linearly aligned chitosan-alginate 
scaffold for neural tissue engineering”, “Ice-Templated Scaffolds with Micro-Ridged 
Pores Direct DRG Neurite Growth”, “Influence of alginate cross-linking method on 
neurite response to microencapsulated neurotrophin-producing fibroblasts”, “Neural 
Progenitor Cells Grown on Hydrogel Surfaces Respond to the Product of the Transgene 
of Encapsulated Genetically Engineered Fibroblasts”, and “Lack of age-associated 
telomere shortening in long- and short-lived species of sea urchins”) and won several 
awards for presenting her research.
 
 
 
 
 
 
